CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
HCV | Abstract Library
Abstract Library
 
The summaries are free for public use. The Chronic Liver Disease Foundation will continue to add and archive summaries of articles deemed relevant to CLDF by the Board of Trustees and its Advisors.
  1. Revolutionizing treatment outcomes in hepatitis C: managed care implications and considerations-diagnosis and management
    Shah M1, Younossi ZM. Am J Manag Care. 2015 Mar;21(5 Suppl):s86-96.


  2. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-label Study of Patients With Genotype 1b Chronic Hepatitis C Virus, With and Without Cirrhosis
    Lawitz E1, Makara M2, Akarca US3, Thuluvath PJ4, Preotescu LL5, Varunok P6, Morillas RM7, Hall C8, Mobashery N8, Redman R8, Pilot-Matias T8, Vilchez RA8, Hézode C9. Gastroenterology. 2015 Jul 10. pii: S0016-5085(15)00936-1. doi: 10.1053/j.gastro.2015.07.001. [Epub ahead of print]


  3. Revolutionizing treatment outcomes in hepatitis c: managed care implications and considerations-the new and evolving standards of care
    Owens GM1. Am J Manag Care. 2015 Mar;21(5 Suppl):s97-s105.


  4. Revolutionizing treatment outcomes in hepatitis c: managed care implications and considerations-a clinical overview
    Shah M1, Younossi ZM, Opsha Y. Am J Manag Care. 2015 Mar;21(5 Suppl):s76-85.


  5. Increase in nonhepatic diagnoses among persons with hepatitis C hospitalized for any cause, United States, 2004-2011
    Tong X1, Spradling PR. J Viral Hepat. 2015 Apr 20. doi: 10.1111/jvh.12414. [Epub ahead of print]


  6. Treating Fibrosing Cholestatic Hepatitis C with Sofosbuvir and Ribavirin: A Matched Analysis
    Saab S1,2, Jimenez M3, Bau S2, Goo T1, Zhao D3, Durazo F1,2, Han S1,2, El Kabany M1,2, Kaldas F2, Tong MJ2,4, Busuttil RW2. Clin Transplant. 2015 Jul 4. doi: 10.1111/ctr.12584. [Epub ahead of print]


  7. Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection
    Signorovitch JE1, Betts KA1, Song Y1, Sorg RA2, Li J1, Behl AS3, Kalsekar A3. J Comp Eff Res. 2015 Jul 10:1-13. [Epub ahead of print]


  8. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis
    Bailly F1, Pradat P, Virlogeux V, Zoulim F. Dig Dis. 2015;33(4):613-23. doi: 10.1159/000375359. Epub 2015 Jul 6.


  9. Modelling hepatitis C therapy-predicting effects of treatment
    Perelson AS1, Guedj J2. Nat Rev Gastroenterol Hepatol. 2015 Jun 30. doi: 10.1038/nrgastro.2015.97. [Epub ahead of print]


  10. The promise of treatment as prevention for hepatitis C: Meeting the needs of people who inject drugs?
    Harris M1, Albers E2, Swan T3. Int J Drug Policy. 2015 Jun 4. pii: S0955-3959(15)00138-3. doi: 10.1016/j.drugpo.2015.05.005. [Epub ahead of print]


  11. Cost-effectiveness of strategies for testing current hepatitis C virus infection
    Chapko MK1, Dufour DR2, Hatia R3, Drobeniuc J3, Ward JW3, Teo CG3. Hepatology. 2015 Jun 30. doi: 10.1002/hep.27966. [Epub ahead of print]


  12. The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study
    Fortier E1, Alavi M2, Micallef M2, Dunlop AJ3, Balcomb AC4, Day CA5, Treloar C6, Bath N7, Haber PS8, Dore GJ2, Bruneau J9, Grebely J10; ETHOS Study Group. Int J Drug Policy. 2015 Jun 11. pii: S0955-3959(15)00181-4. doi: 10.1016/j.drugpo.2015.06.001. [Epub ahead of print]


  13. A phase II, randomized, controlled trial of S-adenosylmethionine in reducing serum alpha-fetoprotein (AFP) in patients with hepatitis C cirrhosis and elevated AFP
    Morgan TR1, Osann K2, Bottiglieri T3, Pimstone N4, Hoefs JC5, Hu KQ6, Hassanein T7, Boyer T8, Kong L9, Chen WP10, Richmond E11, Gonzalez R12, Rodriguez LM13, Meyskens FL14. Cancer Prev Res (Phila). 2015 Jun 30. pii: canprevres.0029.2015. [Epub ahead of print]


  14. Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States
    Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Ann Intern Med. 2015 Jun 30. doi: 10.7326/M15-0406. [Epub ahead of print]


  15. Assessment of Drug-Drug Interactions Between Daclatasvir and Methadone or Buprenorphine/Naloxone
    Garimella T1, Wang R2, Luo WL2, Wastall P2, Kandoussi H2, DeMicco M3, Bruce RD4, Hwang C2, Bertz R2, Bifano M2. Antimicrob Agents Chemother. 2015 Jun 29. pii: AAC.00478-15. [Epub ahead of print]


  16. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans
    Backus LI1,2, Belperio PS1, Shahoumian TA1, Loomis TP1, Mole LA1. Aliment Pharmacol Ther. 2015 Jun 26. doi: 10.1111/apt.13300. [Epub ahead of print]


  17. Underascertainment of Acute Hepatitis C Virus Infections in the U.S. Surveillance System: A Case Series and Chart Review
    Onofrey S, Aneja J, Haney GA, Nagami EH, Jr AD, Lauer GM, Hills-Evans K, Barton K, Kulaga S, Bowen MJ, Cocoros N, McGovern BH, Church DR, Kim AY. Ann Intern Med. 2015 Jun 30. doi: 10.7326/M14-2939. [Epub ahead of print]


  18. Pharmacokinetics and Safety of Coadministered Paritaprevir plus Ritonavir
    (Paritaprevir), Ombitasvir, and Dasabuvir in Hepatic Impairment.


  19. The common sense model applied to hepatitis C: a qualitative analysis of the impact of disease comparison and witnessed death on hepatitis C illness perception
    Safo SA1, Batchelder A2,3, Peyser D4,5, Litwin AH6.


  20. Interferon-free, direct-acting antiviral therapy for chronic hepatitis C
    Gutierrez JA1, Lawitz EJ1, Poordad F1. J Viral Hepat. 2015 Jun 17. doi: 10.1111/jvh.12422. [Epub ahead of print]


  21. HIV, Hepatitis C, and Abstinence from Alcohol Among Injection and Non-injection Drug Users
    Elliott JC1, Hasin DS, Stohl M, Des Jarlais DC. AIDS Behav. 2015 Jun 17. [Epub ahead of print]


  22. Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum
    Meyer JP1, Moghimi Y2, Marcus R3, Lim JK4, Litwin AH5, Altice FL6. Int J Drug Policy. 2015 May 17. pii: S0955-3959(15)00135-8. doi: 10.1016/j.drugpo.2015.05.002. [Epub ahead of print]


  23. Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013
    Jordan AE1, Des Jarlais DC2, Arasteh K2, McKnight C2, Nash D3, Perlman DC4. Drug Alcohol Depend. 2015 Apr 13. pii: S0376-8716(15)00195-7. doi: 10.1016/j.drugalcdep.2015.03.039. [Epub ahead of print]


  24. Grazoprevir/Elbasvir plus Ribavirin For Chronic HCV Genotype-1 Infection After Failure of Combination Therapy Containing a Direct-Acting Antiviral Agent
    Forns X1, Gordon SC2, Zuckerman E3, Lawitz E4, Calleja JL5, Hofer H6, Gilbert C7, Palcza J7, Howe AY7, DiNubile MJ7, Robertson MN7, Wahl J7, Barr E7, Buti M8. J Hepatol. 2015 Apr 17. pii: S0168-8278(15)00291-3. doi: 10.1016/j.jhep.2015.04.009. [Epub ahead of print]


  25. Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-?-induced protein 10 levels in HBV/HCV-coinfected patients
    Wiegand SB1, Jaroszewicz J2, Potthoff A3, Höner Zu Siederdissen C3, Maasoumy B3, Deterding K3, Manns MP1, Wedemeyer H1, Cornberg M4. Clin Microbiol Infect. 2015 Apr 13. pii: S1198-743X(15)00367-5. doi: 10.1016/j.cmi.2015.03.003. [Epub ahead of print]


  26. Hepatitis C virus reinfection and spontaneous clearance of reinfection - the InC3 study
    Sacks-Davis R1, Grebely J2, Dore GJ2, Osburn W3, Cox AL3, Rice TM4, Spelman T1, Bruneau J5, Prins M6, Kim AY7, McGovern BH8, Shoukry NH5, Schinkel J9, Allen TM7, Morris M4, Hajarizadeh B2, Maher L2, Lloyd AR10, Page K4, Hellard M1; InC3 study grou J Infect Dis. 2015 Apr 15. pii: jiv220. [Epub ahead of print]


  27. Treatment of hepatitis C in difficult-to-treat patients
    Ferenci P1. Nat Rev Gastroenterol Hepatol. 2015 Apr 21. doi: 10.1038/nrgastro.2015.53. [Epub ahead of print]


  28. Perception of Effort During Activity in Patients With Chronic Hepatitis C and Nonalcoholic Fatty Liver Disease
    Weinstein AA1, Escheik C2, Oe B2, Price JK2, Gerber L3, Younossi Z2. PM R. 2015 Jun 11. pii: S1934-1482(15)00287-7. doi: 10.1016/j.pmrj.2015.06.001. [Epub ahead of print]


  29. The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life
    Younossi ZM1,2, Stepanova M1,2, Nader F1,2, Lam B1,2, Hunt S1,2. Aliment Pharmacol Ther. 2015 Jun 9. doi: 10.1111/apt.13269. [Epub ahead of print]


  30. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study
    Younossi ZM1,2, Stepanova M1,2, Pol S3, Bronowicki JP4, Carrieri MP5,6,7, Bourlière M8. Liver Int. 2015 Jun 9. doi: 10.1111/liv.12886. [Epub ahead of print]


  31. Hepatitis C virus in Mexican Americans: a population-based study reveals relatively high prevalence and negative association with diabetes
    Watt GP1, Vatcheva KP1, Beretta L2, Pan JJ3, Fallon MB3, McCORMICK JB1, Fisher-Hoch SP1. Epidemiol Infect. 2015 Jun 19:1-9. [Epub ahead of print]


  32. The corrected donor age for hepatitis C virus infected liver transplant recipients
    Dirchwolf M1, Dodge JL2, Gralla J3, Bambha KM3, Nydam T3, Hung KW3, Rosen HR3, Feng S2, Terrault NA2, Biggins SW3. Liver Transpl. 2015 Jun 13. doi: 10.1002/lt.24194. [Epub ahead of print]


  33. Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C
    Fazel Y1, Lam B, Golabi P, Younossi Z. Expert Opin Drug Saf. 2015 Jun 4:1-10. [Epub ahead of print]


  34. Factors Influencing Uptake of Rapid HIV and Hepatitis C Screening Among Drug Misusing Adult Emergency Department Patients: Implications for Future HIV/HCV Screening Interventions
    Merchant RC1, DeLong AK, Liu T, Baird JR. AIDS Behav. 2015 Jun 3. [Epub ahead of print]


  35. Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013
    Wandeler G1, Schlauri M2, Jaquier ME2, Rohrbach J2, Metzner KJ3, Fehr J3, Ambrosioni J4, Cavassini M5, Stöckle M6, Schmid P7, Bernasconi E8, Keiser O9, Salazar-Vizcaya L9, Furrer H2, Rauch A2; Swiss HIV Cohort Study, Aubert V, Battegay M, Bernasconi E, Böni J, Bucher HC, Burton-Jeangros C, Calmy A, Cavassini M, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, Gorgievski M, Günthard H, Haerry D, Hasse B, Hirsch HH, Hoffmann M, Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos R, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Metzner K, Müller N, Nadal D, Nicca D, Pantaleo G, Rauch A, Regenass S, Rickenbach M, Rudin C, Schöni-Affolter F, Schmid P, Schüpbach J, Speck R, Tarr P, Telenti A, Trkola A, Vernazza P, Weber R, Yerly S. Open Forum Infect Dis. 2015 Mar 25;2(1):ofv026. doi: 10.1093/ofid/ofv026. eCollection


  36. Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens
    Chen TY1, Jain MK1. AIDS Patient Care STDS. 2015 Jun;29(6):329-37. doi: 10.1089/apc.2014.0247.


  37. Ribavirin Reduces Absolute Lymphocyte Counts in Hepatitis C Virus-Infected Patients Treated With Interferon-Free, Direct-Acting Antiviral Regimens
    Harrington PR1, Fleischer R1, Connelly SM1, Lewis LL1, Murray J1. Clin Infect Dis. 2015 May 28. pii: civ419. [Epub ahead of print]


  38. A Clinician's Guide to Drug-Drug Interactions with Direct Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection
    Dick TB1, Lindberg LS1, Ramirez DD1, Charlton MR2. Hepatology. 2015 May 29. doi: 10.1002/hep.27920. [Epub ahead of print]


  39. Hepatitis C Virus Disease Progression in People Who Inject Drugs: Protocol for a Systematic Review and Meta-Analysis
    Combellick J1, Smith DJ, Jordan AE, Hagan H. JMIR Res Protoc. 2015 Jun 8;4(2):e68. doi: 10.2196/resprot.4518.


  40. Is antenatal screening for hepatitis C virus cost effective? A decade's experience at a London centre
    Selvapatt N1, Ward T2, Bailey H3, Bennett H2, Thorne C3, See LM4, Tudor-Williams G5, Thursz M6, McEwan P7, Brown A8. J Hepatol. 2015 May 26. pii: S0168-8278(15)00342-6. doi: 10.1016/j.jhep.2015.05.015. [Epub ahead of print]


  41. Hepatitis C Infection in the Elderly
    Saab S1, Rheem J, Sundaram V. Dig Dis Sci. 2015 May 26. [Epub ahead of print]


  42. Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection
    Yang HJ1, Ryoo JY, Yoo BK. Int J Clin Pharm. 2015 Jun 6. [Epub ahead of print]


  43. Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection
    Bunchorntavakul C1,2, Reddy KR2. Aliment Pharmacol Ther. 2015 May 27. doi: 10.1111/apt.13264. [Epub ahead of print]


  44. Beyond viral response: A prospective evaluation of a community-based, multi-disciplinary, peer-driven model of HCV treatment and support
    Mason K1, Dodd Z1, Sockalingam S2, Altenberg J1, Meaney C3, Millson P4, Powis J5. Int J Drug Policy. 2015 Apr 29. pii: S0955-3959(15)00123-1. doi: 10.1016/j.drugpo.2015.04.012. [Epub ahead of print]


  45. Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant
    Herzer K1, Papadopoulos-Köhn A, Walker A, Achterfeld A, Paul A, Canbay A, Timm J, Gerken G. Digestion. 2015 May 19;91(4):326-333. [Epub ahead of print]


  46. Inosine triphosphate pyrophosphohydrolase activity: more accurate predictor for ribavirin-induced anemia in hepatitis C infected patients than ITPA genotype
    Peltenburg NC, Bakker JA, Vroemen WH, de Knegt RJ, Leers MP, Bierau J, Verbon A. Clin Chem Lab Med. 2015 May 13. pii: /j/cclm.ahead-of-print/cclm-2015-0057/cclm-2015-0057.xml. doi: 10.1515/cclm-2015-0057. [Epub ahead of print]


  47. Therapy for hepatitis C genotype 3: moving forward
    Buti M1,2, Llaneras J1, Riveiro-Barciela M1, Esteban R1,2. J Viral Hepat. 2015 May 13. doi: 10.1111/jvh.12419. [Epub ahead of print]


  48. Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin
    Rower JE1, Meissner EG2, Jimmerson LC1, Osinusi A3, Sims Z2, Petersen T2, Bushman LR1, Wolfe P4, McHutchison JG5, Kottilil S2, Kiser JJ6. J Antimicrob Chemother. 2015 May 13. pii: dkv122. [Epub ahead of print]


  49. Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study
    Yeung MW, Young J, Moodie E, Rollet-Kurhajec KC, Schwartzman K, Greenaway C, Cooper C, Cox J, Gill J, Hull M, Walmsley S, Klein MB. HIV Clin Trials. 2015 May-Jun;16(3):100-10. doi: 10.1179/501100000024. Epub 2015 May 14.


  50. Hepatitis C in Arkansas: updates on epidemiology, testing and treatment
    Beebe A, Quattlebaum T, Gicquelais RE, Zohoori N, Haselow DT, Smith NH. J Ark Med Soc. 2015 May;111(12):248-51.


  51. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease
    Charlton M1, Everson GT2, Flamm SL3, Kumar P4, Landis C5, Brown RS Jr6, Fried MW7, Terrault NA8, O'Leary JG9, Vargas HE10, Kuo A11, Schiff E12, Sulkowski MS13, Gilroy R14, Watt KD15, Brown K16, Kwo P17, Pungpapong S18, Korenblat KM19, Muir AJ20, Teperman L21, Fontana RJ22, Denning J23, Arterburn S23, Dvory-Sobol H23, Brandt-Sarif T23, Pang PS23, McHutchison JG23, Reddy KR24, Afdhal N25; SOLAR-1 Investigators. Gastroenterology. 2015 May 15. pii: S0016-5085(15)00682-4. doi: 10.1053/j.gastro.2015.05.010. [Epub ahead of print]


  52. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis
    Muir AJ1, Poordad F2, Lalezari J3, Everson G4, Dore GJ5, Herring R6, Sheikh A7, Kwo P8, Hézode C9, Pockros PJ10, Tran A11, Yozviak J12, Reau N13, Ramji A14, Stuart K15, Thompson AJ16, Vierling J17, Freilich B18, Cooper J19, Ghesquiere W20, Yang R21, McPhee F22, Hughes EA21, Swenson ES22, Yin PD22. JAMA. 2015 May 5;313(17):1736-44. doi: 10.1001/jama.2015.3868.


  53. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection
    Poordad F1, Sievert W2, Mollison L3, Bennett M4, Tse E5, Bräu N6, Levin J7, Sepe T8, Lee SS9, Angus P10, Conway B11, Pol S12, Boyer N13, Bronowicki JP14, Jacobson I15, Muir AJ16, Reddy KR17, Tam E18, Ortiz-Lasanta G19, de Lédinghen V20, Sulkowski M21, Boparai N22, McPhee F23, Hughes E22, Swenson ES23, Yin PD23; UNITY-1 Study Group. JAMA. 2015 May 5;313(17):1728-35. doi: 10.1001/jama.2015.3860.


  54. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hcv genotype 1 infection: Analysis of phase 3 ION trials
    Alqahtani SA1, Afdhal N2, Zeuzem S3, Gordon S4, Mangia A5, Kwo P6, Fried M7, Yang JC8, Ding X8, Pang PS8, McHutchison JG8, Pound D9, Reddy KR10, Marcellin P11, Kowdley KV12, Sulkowski M1. Hepatology. 2015 May 11. doi: 10.1002/hep.27890. [Epub ahead of print]


  55. Sorting out cirrhosis: Mechanisms of non-response to hepatitis C therapy
    Al Marzooqi SH1, Feld JJ. Liver Int. 2015 May 2. doi: 10.1111/liv.12861. [Epub ahead of print]


  56. Interferon-free therapy for hepatitis C: The hurdles amid a golden era
    Colombo M1. Dig Liver Dis. 2015 Apr 11. pii: S1590-8658(15)00276-5. doi: 10.1016/j.dld.2015.04.003. [Epub ahead of print]


  57. Increased Incidence of Cancer and Cancer-related Mortality Among Persons with Chronic Hepatitis C Infection, 2006-2010
    Allison RD1, Tong X2, Moorman AC2, Ly KN2, Rupp L3, Xu F2, Gordon SC3, Holmberg SD2; Chronic Hepatitis Cohort Study (CHeCS) Investigators. J Hepatol. 2015 Apr 30. pii: S0168-8278(15)00304-9. doi: 10.1016/j.jhep.2015.04.021. [Epub ahead of print]


  58. Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?
    Janardhan SV1, Reau NS1. Hepat Med. 2015 Apr 16;7:11-20. doi:


  59. Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients with Hepatitis C, Regardless of Response to Antiviral Therapy
    Lens S1, Rincón D2, García-Retortillo M3, Albillos A4, Calleja JL5, Bañares R2, González-Abraldes J6, Bosch J7, Sanchez-Tapias JM1, Forns X1, García-Pagán JC8. Clin Gastroenterol Hepatol. 2015 Apr 22. pii: S1542-3565(15)00415-2. doi: 10.1016/j.cgh.2015.04.013. [Epub ahead of print]


  60. Systematic review of the pharmacological treatment of alcohol use disorders in individuals infected with hepatitis C
    Thibault A1,2, Brissette S3,4, Jutras-Aswad D5,6. Addict Sci Clin Pract. 2015 Feb 24;10(1):6. [Epub ahead of print]


  61. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic HCV Genotype 1, 4, or 6 Infection: A Randomized Trial
    Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR. Ann Intern Med. 2015 Apr 24. doi: 10.7326/M15-0785. [Epub ahead of print]


  62. Implementing Updated Recommendations on Hepatitis C Virus Screening: Translating Federal Guidance Into State Practice
    Martin EG1, Norcott AM, Khalid H, O?Connell DA. J Public Health Manag Pract. 2015 Apr 22. [Epub ahead of print]


  63. Impact of all oral anti-hepatitis C virus therapy: A meta-analysis
    Bansal S1, Singal AK1, McGuire BM1, Anand BS1. World J Hepatol. 2015 Apr 18;7(5):806-13. doi: 10.4254/wjh.v7.i5.806.


  64. From non-A, non-B hepatitis to hepatitis C virus cure
    Pawlotsky JM1, Feld JJ2, Zeuzem S3, Hoofnagle JH4. J Hepatol. 2015 Apr;62(1S):S87-S99. doi: 10.1016/j.jhep.2015.02.006.


  65. Telaprevir- and Boceprevir-Based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study
    Verna EC1, Saxena V, Burton JR Jr, O'Leary JG, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS Jr, Terrault NA; for the CRUSH-C Consortium. Transplantation. 2015 Feb 24. [Epub ahead of print]


  66. A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection
    Park H1, Adeyemi A, Henry L, Stepanova M, Younossi Z. J Viral Hepat. 2015 Apr 22. doi: 10.1111/jvh.12413. [Epub ahead of print]


  67. Acquiring hepatitis C in prison: the social organisation of injecting risk
    Treloar C1, McCredie L2, Lloyd AR3; HITS-p investigators. Harm Reduct J. 2015 Apr 24;12(1):10. doi: 10.1186/s12954-015-0045-2.


  68. Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade
    Barth H1. World J Hepatol. 2015 Apr 18;7(5):725-37. doi: 10.4254/wjh.v7.i5.725.


  69. Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013
    Jordan AE1, Des Jarlais DC2, Arasteh K2, McKnight C2, Nash D3, Perlman DC4. Drug Alcohol Depend. 2015 Apr 13. pii: S0376-8716(15)00195-7. doi: 10.1016/j.drugalcdep.2015.03.039. [Epub ahead of print]


  70. Grazoprevir/Elbasvir plus Ribavirin For Chronic HCV Genotype-1 Infection After Failure of Combination Therapy Containing a Direct-Acting Antiviral Agent
    Forns X1, Gordon SC2, Zuckerman E3, Lawitz E4, Calleja JL5, Hofer H6, Gilbert C7, Palcza J7, Howe AY7, DiNubile MJ7, Robertson MN7, Wahl J7, Barr E7, Buti M8. J Hepatol. 2015 Apr 17. pii: S0168-8278(15)00291-3. doi: 10.1016/j.jhep.2015.04.009. [Epub ahead of print]


  71. Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-?-induced protein 10 levels in HBV/HCV-coinfected patients
    Wiegand SB1, Jaroszewicz J2, Potthoff A3, Höner Zu Siederdissen C3, Maasoumy B3, Deterding K3, Manns MP1, Wedemeyer H1, Cornberg M4. Clin Microbiol Infect. 2015 Apr 13. pii: S1198-743X(15)00367-5. doi: 10.1016/j.cmi.2015.03.003. [Epub ahead of print]


  72. Hepatitis C virus reinfection and spontaneous clearance of reinfection - the InC3 study
    Sacks-Davis R1, Grebely J2, Dore GJ2, Osburn W3, Cox AL3, Rice TM4, Spelman T1, Bruneau J5, Prins M6, Kim AY7, McGovern BH8, Shoukry NH5, Schinkel J9, Allen TM7, Morris M4, Hajarizadeh B2, Maher L2, Lloyd AR10, Page K4, Hellard M1; InC3 study grou J Infect Dis. 2015 Apr 15. pii: jiv220. [Epub ahead of print]


  73. Treatment of hepatitis C in difficult-to-treat patients
    Ferenci P1. Nat Rev Gastroenterol Hepatol. 2015 Apr 21. doi: 10.1038/nrgastro.2015.53. [Epub ahead of print]


  74. Ledipasvir/Sofosbuvir: A Review of Its Use in Chronic Hepatitis C
    Keating GM1. Drugs. 2015 Apr 3. [Epub ahead of print]


  75. Acceptability and yield of birth-cohort screening for hepatitis C virus in a Canadian population being screened for colorectal cancer: a cross-sectional study
    Myers RP1, Crotty P2, Town S3, English J3, Fonseca K4, Tellier R4, Swain MG2, McGregor SE3, Heitman SJ3, Hilsden RJ5.


  76. HIV and HCV Medications in End-Stage Renal Disease
    Greenberg KI1, Perazella MA, Atta MG. Semin Dial. 2015 Apr 6. doi: 10.1111/sdi.12367. [Epub ahead of print]


  77. Sofosbuvir for treatment of chronic hepatitis C
    Kattakuzhy S1, Levy R, Kottilil S. Hepatol Int. 2015 Jan 28. [Epub ahead of print]


  78. Chronic hepatitis C - what do the new drugs offer and who should get them first?
    Ryder SD1. Clin Med. 2015 Apr;15(2):197-200. doi: 10.7861/clinmedicine.15-2-197.


  79. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir
    Kirby BJ1, Symonds WT, Kearney BP, Mathias AA. Clin Pharmacokinet. 2015 Mar 31. [Epub ahead of print]


  80. Comparison of Risk-Based Hepatitis C Screening and the True Seroprevalence in an Urban Prison System
    Kuncio DE1, Newbern EC, Fernandez-Viña MH, Herdman B, Johnson CC, Viner KM. J Urban Health. 2015 Mar 21. [Epub ahead of print]


  81. Post-Liver Transplant Hepatitis C Therapy
    Rahimi RS1, O'Leary JG. Curr Treat Options Gastroenterol. 2015 Mar 27. [Epub ahead of print]


  82. New Medical Treatment Strategies for Nonalcoholic Steatohepatitis
    Fuchs M1. Curr Treat Options Gastroenterol. 2015 Mar 21. [Epub ahead of print]


  83. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir
    Younossi ZM1, Stepanova M2, Afdhal N3, Kowdley KV4, Zeuzem S5, Henry L6, Hunt SL7, Marcellin P8. J Hepatol. 2015 Mar 17. pii: S0168-8278(15)00192-0. doi: 10.1016/j.jhep.2015.03.014. [Epub ahead of print]


  84. Most patients with HCV-associated lymphoma present with mild liver disease: A call to revise antiviral treatment prioritization
    Torres HA1, Mahale P. Liver Int. 2015 Mar 16. doi: 10.1111/liv.12825. [Epub ahead of print]


  85. A comparative study of patients' knowledge about hepatitis C in the United States and in urban and rural China
    Wu E1, Chen X, Guan Z, Cao C, Rao H, Feng B, Chan M, Fu S, Lin A, Wei L, Lok AS. Hepatol Int. 2015 Jan;9(1):58-66. doi: 10.1007/s12072-014-9559-z. Epub 2014 Jul 31.


  86. Expanding capacity for hepatitis C treatment in the United States: team-based care and use of nonphysician providers
    Kwong J1, Epstein R2. J Int Assoc Provid AIDS Care. 2015 Mar;14(2):112-5. doi: 10.1177/2325957414560065.


  87. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States
    Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Ann Intern Med. 2015 Mar 17;162(6):397-406. doi: 10.7326/M14-1336.



  88. Sep 9;10(3):164-71. doi: 10.1108/IJPH-11-2013-0051.


  89. The Cost-effectiveness, Health Benefits, and Financial Costs of New Antiviral
    Rein DB1, Wittenborn JS1, Smith BD2, Liffmann DK1, Ward JW2. Clin Infect Dis. 2015 Mar 16. pii: civ220. [Epub ahead of print]


  90. Meal ingestion markedly increases liver stiffness suggesting the need for liver stiffness determination in fasting conditions
    Alvarez D1, Orozco F2, Mella JM2, Anders M2, Antinucci F2, Mastai R3. Gastroenterol Hepatol. 2015 Mar 10. pii: S0210-5705(15)00029-1. doi: 10.1016/j.gastrohep.2015.01.009. [Epub ahead of print]


  91. A Review of Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients
    Burgess S1, Partovi N2, Yoshida EM2, Erb SR2, Azalgara VM2, Hussaini T3. Ann Pharmacother. 2015 Mar 13. pii: 1060028015576180. [Epub ahead of print]


  92. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus
    Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, Avorn J, Choudhry NK. Ann Intern Med. 2015 Mar 17;162(6):407-19. doi: 10.7326/M14-1152.


  93. A Nationwide Reporting System to Satisfy the Ethical Obligation to Prevent Drug Diversion-Related Transmission of Hepatitis C in Healthcare Facilities
    Lahey T1, Nelson WA2. Clin Infect Dis. 2015 Mar 12. pii: civ203. [Epub ahead of print]


  94. Hepatitis C virus therapeutic development: in pursuit of perfectovir
    Dore GJ1, Feld JJ2. Clin Infect Dis. 2015 Mar 11. pii: civ197. [Epub ahead of print]


  95. Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start?
    Sengupta S1, Wroblewski K, Aronsohn A, Reau N, Reddy KG, Jensen D, Te H. Dig Dis Sci. 2015 Mar 6. [Epub ahead of print]


  96. Hepatitis C virus treatment in the 'real-world': how well do 'real' patients respond?
    Deborah Friedman N1, Green JH2, Weber HM2, Stephen S2, Lane SE3, Ting AY4, Watson JP5. J Clin Exp Hepatol. 2014 Sep;4(3):214-20. doi: 10.1016/j.jceh.2014.07.003. Epub 2014 Jul 25.


  97. Comparison of Rates of Death Having any Death-Certificate Mention of Heart, Kidney, or Liver Disease Among Persons Diagnosed with HIV Infection with those in the General US Population, 2009-2011
    Whiteside YO1, Selik R1, An Q1, Huang T2, Karch D1, Hernandez AL1, Hall HI1. Open AIDS J. 2015 Feb 27;9:14-22. doi: 10.2174/1874613601509010014. eCollection 2015.


  98. An update on the association of vitamin D deficiency with common infectious diseases
    Watkins RR1, Lemonovich TL, Salata RA. Can J Physiol Pharmacol. 2015 Jan 26:1-6. [Epub ahead of print]


  99. Integrated Care Increases Treatment and Improves Outcomes of Patients with Chronic HCV Infection and Psychiatric Illness or Substance Abuse
    Ho SB1, Bräu N2, Cheung R3, Liu L4, Sanchez C5, Sklar M4, Phelps TE6, Marcus SG7, Wasil MM5, Tisi A7, Huynh L6, Robinson SK4, Gifford A8, Asch SM3, Groessl EJ4. Clin Gastroenterol Hepatol. 2015 Feb 24. pii: S1542-3565(15)00161-5. doi: 10.1016/j.cgh.2015.02.022. [Epub ahead of print]


  100. Protease inhibitors block multiple functions of the NS3/4A protease-helicase during the hepatitis C virus life cycle
    McGivern DR1, Masaki T2, Lovell W2, Hamlett C3, Saalau-Bethell S3, Graham B3. J Virol. 2015 Mar 4. pii: JVI.03188-14. [Epub ahead of print]


  101. A pilot study of rapid hepatitis C virus testing in the Rhode Island Department of Corrections
    Beckwith CG1, Kurth AE2, Bazerman LB3, Patry EJ3, Cates A4, Tran L3, Noska A1, Kuo I4. J Public Health (Oxf). 2015 Mar 2. pii: fdv023. [Epub ahead of print]


  102. Perspectives of fixed daily dose of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C
    Floreani A1. Expert Opin Pharmacother. 2015 Mar 1:1-4. [Epub ahead of print]


  103. Retrospective cohort study of liver transplantation in the United Kingdom between 1994 and 2010: the impact of hepatitis C infection
    Edeghere O1, Verlander NQ2, Aboulhab J3, Costella A4, Harris HE4, Balogun MA4, Ramsay ME4. Public Health. 2015 Feb 25. pii: S0033-3506(15)00043-8. doi: 10.1016/j.puhe.2015.01.024. [Epub ahead of print]


  104. Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection
    Osinusi A1, Townsend K2, Kohli A3, Nelson A4, Seamon C5, Meissner EG6, Bon D7, Silk R8, Gross C8, Price A8, Sajadi M9, Sidharthan S5, Sims Z5, Herrmann E7, Hogan J10, Teferi G10, Talwani R9, Proschan M11, Jenkins V12, Kleiner DE13, Wood BJ14, Subramanian GM15, Pang PS15, McHutchison JG15, Polis MA2, Fauci AS2, Masur H5, Kottilil S4. JAMA. 2015 Feb 23. doi: 10.1001/jama.2015.1373. [Epub ahead of print]


  105. Discovery and Development of Hepatitis C Virus Inhibitors Targeting the NS5A Protein
    Yu Z, Zhao L, You QD1. Mini Rev Med Chem. 2015 Feb 26. [Epub ahead of print]


  106. A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients
    Patel N1, Nasiri M, Koroglu A, Bliss S, Davis M, McNutt LA, Miller C. Infect Dis Ther. 2015 Jan 28. [Epub ahead of print]


  107. Ledipasvir/sofosbuvir regimens for chronic hepatits c (chc) infection: insights from a work productivity economic model from the United States
    Younossi Z1, Jiang Y, Smith NJ, Stepanova M, Beckerman R. Hepatology. 2015 Feb 23. doi: 10.1002/hep.27757. [Epub ahead of print]


  108. The hepatitis C genotype 1 paradox: Cost per treatment is increasing, but cost per cure is decreasing
    Shafran SD. Can J Gastroenterol Hepatol. 2015 Jan-Feb;29(1):46-8.


  109. Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia
    Treloar C1, Rance J1, Bath N2, Everingham H2, Micallef M3, Day C4, Hazelwood S5, Grebely J3, Dore GJ3. Int J Drug Policy. 2015 Jan 24. pii: S0955-3959(15)00008-0. doi: 10.1016/j.drugpo.2015.01.005. [Epub ahead of print]


  110. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders
    Jensen D1, Sherman KE2, Hézode C3, Pol S4, Zeuzem S5, Ledinghen V6, Tran A7, Elkhashab M8, Younes ZH9, Kugelmas M10, Mauss S11, Everson G12, Luketic V13, Vierling J14, Serfaty L15, Brunetto M16, Heo J17, Bernstein D18, McPhee F19, Hennicken D20, Mendez P21, Hughes E21, Noviello S21; on behalf of the HALLMARK-QUAD Study Team. J Hepatol. 2015 Feb 19. pii: S0168-8278(15)00125-7. doi: 10.1016/j.jhep.2015.02.018. [Epub ahead of print]


  111. "Test, Listen, Cure" (TLC) Hepatitis C Community Awareness Campaign
    Coughlin SS1. JMIR Res Protoc. 2015 Feb 6;4(1):e13. doi: 10.2196/resprot.3822.


  112. Hepatitis C virus-associated B-cell non-Hodgkin lymphomas
    Vannata B1, Zucca E1. Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):590-8. doi: 10.1182/asheducation-2014.1.590. Epub 2014 Nov 18.


  113. ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients
    Gamal N1, Vitale G, Andreone P. Expert Rev Anti Infect Ther. 2015 Jan 12:1-10. [Epub ahead of print]


  114. Improvement of predictive models of risk of disease progression in chronic hepatitis C by incorporating longitudinal data
    Konerman MA1, Zhang Y, Zhu J, Higgins PD, Lok AS, Waljee AK. Hepatology. 2015 Feb 12. doi: 10.1002/hep.27750. [Epub ahead of print]


  115. Viruses in cancer cell plasticity: the role of hepatitis C virus in hepatocellular carcinoma
    Hibner U1, Grégoire D1.Author information Contemp Oncol (Pozn). 2015;19(1A):A62-7. doi: 10.5114/wo.2014.47132.


  116. Findings from Integrated Behavioral and Biologic Survey among Males Who Inject Drugs (MWID) - Vietnam, 2009-2010: Evidence of the Need for an Integrated Response to HIV, Hepatitis B Virus, and Hepatitis C Virus
    Nadol P1, O'connor S2, Duong H3, Le LV3, Thang PH4, Tram TH4, Ha HT4, Mcconnell MS3, Partridge J5, Kaldor J6, Law M6, Nguyen TA4. PLoS One. 2015 Feb 18;10(2):e0118304. doi: 10.1371/journal.pone.0118304. eCollection 2015.


  117. Hepatitis C
    Webster DP1, Klenerman P2, Dusheiko GM3. Lancet. 2015 Feb 13. pii: S0140-6736(14)62401-6. doi: 10.1016/S0140-6736(14)62401-6. [Epub ahead of print]


  118. Risk of infections during interferon-based treatment in patients with chronic HCV infection and advanced hepatic fibrosis
    Maan R1, van der Meer AJ, Hansen BE, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Manns MP, Zeuzem S, Janssen HL, de Knegt RJ, Veldt BJ. J Gastroenterol Hepatol. 2015 Feb 13. doi: 10.1111/jgh.12929. [Epub ahead of print]


  119. What psychiatric screening and monitoring might be needed with the new generation of hepatitis C treatments?
    Rowan PJ1. World J Virol. 2015 Feb 12;4(1):13-6. doi: 10.5501/wjv.v4.i1.13.


  120. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease
    Leidner AJ1, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD. Hepatology. 2015 Feb 11. doi: 10.1002/hep.27736. [Epub ahead of print]


  121. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study
    Molina JM1, Orkin C2, Iser DM3, Zamora FX4, Nelson M5, Stephan C6, Massetto B7, Gaggar A7, Ni L7, Svarovskaia E7, Brainard D7, Subramanian GM7, McHutchison JG7, Puoti M8, Rockstroh JK9; for the PHOTON-2 study team. Lancet. 2015 Feb 3. pii: S0140-6736(14)62483-1. doi: 10.1016/S0140-6736(14)62483-1. [Epub ahead of print]


  122. Drug-drug Interaction Profile of the All-Oral Anti-Hepatitis C Virus Regimen of Paritaprevir/Ritonavir, Ombitasvir and Dasabuvir
    Menon R1, Badri P2, Wang T2, Polepally A2, Zha J2, Khatri A2, Wang H2, Hu B2, Coakley E2, Podsadecki T2, Awni W2, Dutta S2. J Hepatol. 2015 Jan 31. pii: S0168-8278(15)00057-4. doi: 10.1016/j.jhep.2015.01.026. [Epub ahead of print]


  123. Systematic review: patient-reported outcomes in chronic hepatitis C - the impact of liver disease and new treatment regimens
    Younossi Z1, Henry L. Aliment Pharmacol Ther. 2015 Jan 23. doi: 10.1111/apt.13090. [Epub ahead of print]


  124. Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: A retrospective clinical-pathological study
    K-Kutala B1, Bedossa P2, Guedj J3, Asselah T4, Martinot-Peignoux M5, Duval X3, Marcellin P4. Dig Liver Dis. 2014 Dec 25. pii: S1590-8658(14)00842-1. doi: 10.1016/j.dld.2014.12.010. [Epub ahead of print]


  125. Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C
    McEwan P1, Ward T1, Bennett H2, Kalsekar A3, Webster S2, Brenner M4, Yuan Y3. PLoS One. 2015 Jan 30;10(1):e0117334. doi: 10.1371/journal.pone.0117334. eCollection 2015.


  126. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection
    Younossi ZM1, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Aliment Pharmacol Ther. 2015 Jan 26. doi: 10.1111/apt.13081. [Epub ahead of print]


  127. All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase 3 Study
    Nelson DR1, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, Bennett M, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA; on behalf of the ALLY-3 Study Team. Hepatology. 2015 Jan 23. doi: 10.1002/hep.27726. [Epub ahead of print]


  128. Hepatitis C Virus treatment as prevention among injecting drug users: who should we cure first?
    de Vos AS1, Prins M, Kretzschmar ME. Addiction. 2015 Jan 13. doi: 10.1111/add.12842. [Epub ahead of print]


  129. Chronic Hepatitis C Infection as a Risk Factor for Renal Cell Carcinoma
    Gonzalez HC1, Lamerato L, Rogers CG, Gordon SC. Dig Dis Sci. 2015 Jan 17. [Epub ahead of print]


  130. Meta-Analysis: Superior Treatment Response in Asian Patients with Hepatitis C Virus Genotype 6 versus Genotype 1 with Pegylated Interferon and Ribavirin
    Nguyen NH1, McCormack SA, Vutien P, Yee BE, Devaki P, Jencks D, Nguyen MH. Intervirology. 2015 Jan 10;58(1):27-34. [Epub ahead of print]


  131. Hepatitis C Virus (HCV) Antibody Positivity and Predictors among Previously Undiagnosed Adult Primary Care Outpatients: Cross-Sectional Analysis of a Multi-Site Retrospective Cohort Study
    Smith BD1, Yartel AK2, Krauskopf K3, Massoud OI4, Brown KA5, Fallon MB6, Rein DB7. Clin Infect Dis. 2015 Jan 16. pii: civ002. [Epub ahead of print]


  132. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study
    Kohli A1, Osinusi A2, Sims Z3, Nelson A4, Meissner EG4, Barrett LL5, Bon D6, Marti MM4, Silk R7, Kotb C7, Gross C7, Jolley TA4, Sidharthan S3, Petersen T3, Townsend K4, Egerson D7, Kapoor R7, Spurlin E4, Sneller M4, Proschan M8, Herrmann E6, Kwan R4, Teferi G9, Talwani R10, Diaz G11, Kleiner DE12, Wood BJ13, Chavez J9, Abbott S9, Symonds WT14, Subramanian GM14, Pang PS14, McHutchison J14, Polis MA4, Fauci AS4, Masur H3, Kottilil S15. Lancet. 2015 Jan 12. pii: S0140-6736(14)61228-9. doi: 10.1016/S0140-6736(14)61228-9. [Epub ahead of print]


  133. Study of pruritus in chronic hepatitis C patients
    Suzuki K1, Tamano M1, Katayama Y1, Kuniyoshi T1, Kagawa K1, Takada H1, Suzuki K1. World J Gastroenterol. 2014 Dec 21;20(47):17877-82. doi: 10.3748/wjg.v20.i47.17877.


  134. Normocaloric low cholesterol diet modulates th17/treg balance in patients with chronic hepatitis C virus infection
    Maggio R1, Viscomi C2, Andreozzi P3, D'Ettorre G4, Viscogliosi G3, Barbaro B2, Gori M2, Vullo V4, Balsano C1. PLoS One. 2014 Dec 22;9(12):e112346. doi: 10.1371/journal.pone.0112346. eCollection 2014.


  135. Influence of Hepatitis C Virus and IL28B Genotypes on Liver Stiffness
    Lundbo LF1, Clausen LN1, Weis N2, Schønning K3, Rosenørn L4, Benfield T1, Christensen PB5. PLoS One. 2014 Dec 29;9(12):e115882. doi: 10.1371/journal.pone.0115882. eCollection 2014.


  136. Finally sofosbuvir: an oral anti-HCV drug with wide performance capability
    Kayali Z1, Schmidt WN2. Pharmgenomics Pers Med. 2014 Dec 8;7:387-98. doi: 10.2147/PGPM.S52629. eCollection 2014.


  137. Low risk of liver decompensation among human immunodeficiency virus/hepatitis c virus-coinfected patients with mild fibrosis in the short-term
    Macías J1, Mancebo M, Márquez M, Merino D, Téllez F, Rivero A, von Wichmann MA, López-Cortés LF, Merchante N, Santos J, Raffo M, Pérez-Pérez M, Camacho Á, Iribarren JA, Pineda JA. Hepatology. 2014 Dec 24. doi: 10.1002/hep.27674. [Epub ahead of print]


  138. Association of hepatitis C virus infection with incidence and progression of chronic kidney disease in a large cohort of US veterans
    Molnar MZ1, Alhourani HM, Wall BM, Lu JL, Streja E, Kalantar-Zadeh K, Kovesdy CP. Hepatology. 2014 Dec 20. doi: 10.1002/hep.27664. [Epub ahead of print]


  139. Ethical assessment of hepatitis C virus treatment: The lesson from first generation protease inhibitors
    Sacchini D1, Craxì L2, Refolo P3, Minacori R3, Cicchetti A4, Gasbarrini A5, Cammà C6, Spagnolo AG3; on behalf of the WEF Study Group. Dig Liver Dis. 2014 Nov 24. pii: S1590-8658(14)00805-6. doi: 10.1016/j.dld.2014.11.011. [Epub ahead of print]


  140. Metabolic Phenotyping for Enhanced Mechanistic Stratification of Chronic Hepatitis C-Induced Liver Fibrosis
    Sands CJ1, Guha IN2, Kyriakides M1, Wright M3, Beckonert O1, Holmes E1, Rosenberg WM4, Coen M1. Am J Gastroenterol. 2014 Dec 23. doi: 10.1038/ajg.2014.370. [Epub ahead of print]


  141. Cure of HCV related liver disease
    Shiffman ML1, Benhamou Y. Liver Int. 2015 Jan;35 Suppl 1:71-7. doi: 10.1111/liv.12734.


  142. Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients
    Peter J1, Nelson DR. Liver Int. 2015 Jan;35 Suppl 1:65-70. doi: 10.1111/liv.12718.


  143. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C
    Welch NM1, Jensen DM. Liver Int. 2015 Jan;35 Suppl 1:11-7. doi: 10.1111/liv.12715.


  144. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C
    Younossi Z1, Henry L2. Dig Liver Dis. 2014 Dec 15;46S5:S186-S196. doi: 10.1016/j.dld.2014.09.025. Epub 2014 Nov 10.


  145. Sofosbuvir as backbone of interferon free treatments
    Bourlière M1, Oules V2, Ansaldi C2, Adhoute X2, Castellani P2. Dig Liver Dis. 2014 Dec 15;46S5:S212-S220. doi: 10.1016/j.dld.2014.09.024. Epub 2014 Nov 6.


  146. Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C
    Kumar S1, Jacobson IM2. J Hepatol. 2014 Nov;61(1S):S91-S97. doi: 10.1016/j.jhep.2014.09.006. Epub 2014 Nov 3.


  147. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies
    Lenz O1, Verbinnen T2, Fevery B2, Tambuyzer L2, Vijgen L2, Peeters M2, Buelens A2, Ceulemans H2, Beumont M2, Picchio G3, Meyer SD2. J Hepatol. 2014 Nov 28. pii: S0168-8278(14)00881-2. doi: 10.1016/j.jhep.2014.11.032. [Epub ahead of print]


  148. Extrahepatic manifestations of chronic hepatitis C virus infection
    Cacoub P1, Gragnani L2, Comarmond C3, Zignego AL2. Dig Liver Dis. 2014 Dec 15;46S5:S165-S173. doi: 10.1016/j.dld.2014.10.005. Epub 2014 Nov 8.


  149. Resolute efforts to cure hepatitis C: Understanding patients' reasons for completing antiviral treatment
    Clark JA1, Gifford AL2. Health (London). 2014 Nov 5. pii: 1363459314555237. [Epub ahead of print]


  150. Outcomes in Liver Transplantation: Does Sex Matter?
    Sarkar M1, Watt KD2, Terrault N3, Berenguer M4. J Hepatol. 2014 Nov 26. pii: S0168-8278(14)00872-1. doi: 10.1016/j.jhep.2014.11.023. [Epub ahead of print]


  151. Liver Stiffness Measurement among Patients with Chronic Hepatitis B and C: Results from a 5-Year Prospective Study
    Christiansen KM, Mössner BK, Hansen JF, Jarnbjer EF, Pedersen C, Christensen PB. PLoS One. 2014 Nov 4;9(11):e111912. doi: 10.1371/journal.pone.0111912. eCollection 2014.


  152. An Interferon-free Antiviral Regimen for HCV after Liver Transplantation
    Kwo PY1, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R, Gordon F, Levitsky J, Terrault NA, Burton JR, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X N Engl J Med. 2014 Nov 11. [Epub ahead of print]


  153. A prophylactic hepatitis C virus vaccine: A distant peak still worth climbing
    Baumert TF1, Fauvelle C2, Chen DY3, Lauer GM4. J Hepatol. 2014 Nov;61(1S):S34-S44. doi: 10.1016/j.jhep.2014.09.009. Epub 2014 Nov 3.


  154. Are selective serotonin reuptake inhibitors associated with hepatocellular carcinoma in patients with hepatitis C?
    Pocha C1, Knott A, Rector TS, Dieperink E. J Clin Psychiatry. 2014 Oct;75(10):e1122-6. doi: 10.4088/JCP.13m08877.


  155. The association of hepatitis C virus infection and post-liver transplant diabetes: data from 17 000 HCV-infected transplant recipients
    Younossi Z1, Stepanova M, Saab S, Trimble G, Mishra A, Henry L. Aliment Pharmacol Ther. 2014 Nov 21. doi: 10.1111/apt.13027. [Epub ahead of print]


  156. Accuracy of real-time tissue elastography for the evaluation of hepatic fibrosis in patients with chronic hepatitis B: a prospective multicenter study
    Wu T1, Ren J, Cong SZ, Meng FK, Yang H, Luo Y, Lin HJ, Sun Y, Wang XY, Pei SF, Zheng Y, He Y, Chen Y, Hu Y, Yang N, Li P, Kudo M, Zheng RQ. Dig Dis. 2014;32(6):791-9. doi: 10.1159/000368024. Epub 2014 Oct 29.


  157. Long-term prognosis of patients with hepatitis B infection: causes of death and utility of nucleos(t)ide analogue therapy
    Tada T1, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabtake S, Ito T. J Gastroenterol. 2014 Nov 7. [Epub ahead of print]


  158. Chronic Hepatitis B and Liver Cancer Risks among Asian Immigrants in New York City: Results from a Large, Community-Based Screening, Evaluation, and Treatment Program
    Pollack HJ1, Kwon SC2, Wang SH3, Wyatt LC2, Trinh-Shevrin C2; AAHBP Coalition. Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2229-39. doi: 10.1158/1055-9965.EPI-14-0491.


  159. Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation
    Charlton M1, Gane E2, Manns MP3, Brown RS Jr4, Curry MP5, Kwo PY6, Fontana RJ7, Gilroy R8, Teperman L9, Muir AJ10, McHutchison JG11, Symonds WT11, Brainard D11, Kirby B11, Dvory-Sobol H11, Denning J11, Arterburn S11, Samuel D12, Forns X13, Terrault NA14. Gastroenterology. 2014 Oct 7. pii: S0016-5085(14)01194-9. doi: 10.1053/j.gastro.2014.10.001. [Epub ahead of print]


  160. Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies
    Manns MP1, Fried MW, Zeuzem S, Jacobson IM, Forns X, Poordad F, Peeters M, Fu M, Lenz O, Ouwerkerk-Mahadevan S, Jessner W, Scott JA, Kalmeijer R, De La Rosa G, Sinha R, Beumont-Mauviel M. J Viral Hepat. 2014 Nov 3. doi: 10.1111/jvh.12346. [Epub ahead of print]


  161. Concordance of Sustained Virologic Response 4, 12, and 24 Weeks Post-Treatment With Sofosbuvir-Containing Regimens for Hepatitis C Virus
    Yoshida EM1, Sulkowski MS, Gane EJ, Herring RW Jr, Ratziu V, Ding X, Wang J, Chuang SM, Ma J, McNally J, Stamm LM, Brainard DM, Symonds WT, McHutchison JG, Beavers KL, Jacobson IM, Reddy KR, Lawitz E. Hepatology. 2014 Oct 14. doi: 10.1002/hep.27366. [Epub ahead


  162. Hepatic Decompensation Likely Attributable to Simeprevir in Patients with Advanced Cirrhosis
    Stine JG1, Intagliata N, Shah NL, Argo CK, Caldwell SH, Lewis JH, Northup PG. Dig Dis Sci. 2014 Nov 6. [Epub ahead of print]


  163. Low Relapse Rate Leads to High Concordance of Sustained Virologic Response (SVR) at 12 Weeks With SVR at 24 Weeks After Treatment With ABT-450/Ritonavir, Ombitasvir, and Dasabuvir Plus Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection in the AVIATOR Study
    Poordad F1, Agarwal K2, Younes Z3, Cohen D4, Xie W4, Podsadecki T4. Clin Infect Dis. 2014 Nov 2. pii: ciu865. [Epub ahead of print]


  164. Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C
    Stirnimann G. Expert Opin Pharmacother. 2014 Dec;15(17):2609-22. doi: 10.1517/14656566.2014.972364. Epub 2014 Oct 27.


  165. The continuum of hepatitis C testing and care
    Viner K1, Kuncio D, Newbern EC, Johnson CC. Hepatology. 2014 Oct 28. doi: 10.1002/hep.27584. [Epub ahead of print]


  166. Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies
    Manns MP1, Fried MW, Zeuzem S, Jacobson IM, Forns X, Poordad F, Peeters M, Fu M, Lenz O, Ouwerkerk-Mahadevan S, Jessner W, Scott JA, Kalmeijer R, De La Rosa G, Sinha R, Beumont-Mauviel M. J Viral Hepat. 2014 Nov 3. doi: 10.1111/jvh.12346. [Epub ahead of print]


  167. Pharmacokinetics, safety, and tolerability of faldaprevir in patients with renal impairment
    Huang F1, Moschetti V2, Lang B3, Halabi A4, Petersen-Sylla M4, Yong CL5, Elgadi M6. Antimicrob Agents Chemother. 2014 Oct 27. pii: AAC.03359-14. [Epub ahead of print]


  168. Cirrhosis in hepatitis C virus-infected patients: a review for practitioners new to hepatitis C care
    Muir AJ. Top Antivir Med. 2014 Sep-Oct;22(4):685-9.


  169. Chemotherapy-related reactivation of hepatitis B infection: Updates in 2013
    Kim HY, Kim W. World J Gastroenterol. 2014 Oct 28;20(40):14581-14588.


  170. Infrequent Development of Resistance in Genotype 1-6 Hepatitis C Virus-Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials
    Svarovskaia ES1, Dvory-Sobol H1, Parkin N2, Hebner C1, Gontcharova V1, Martin R1, Ouyang W1, Han B1, Xu S1, Ku K1, Chiu S1, Gane E3, Jacobson IM4, Nelson DR5, Lawitz E6, Wyles DL7, Bekele N1, Brainard D1, Symonds WT1, McHutchison JG1, Miller MD1, Mo H1. Clin Infect Dis. 2014 Sep 28. pii: ciu697. [Epub ahead of print]


  171. Association between serum vitamin D and severity of liver fibrosis in chronic hepatitis C patients: a systematic meta-analysis
    Luo YQ1, Wu XX, Ling ZX, Cheng YW, Yuan L, Xiang C. J Zhejiang Univ Sci B. 2014 Oct;15(10):900-6. doi: 10.1631/jzus.B1400073.


  172. Evaluating a hepatitis c quality gap: missed opportunities for HCV-related cares
    Liu Y, Lawrence RH, Falck-Ytter Y, Watts B, Hirsch AA1. Am J Manag Care. 2014 Jul 1;20(7):e257-64.


  173. Cost-effectiveness of rapid HCV testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs
    Schackman BR1, Leff JA, Barter DM, DiLorenzo MA, Feaster DJ, Metsch LR, Freedberg KA, Linas BP. Addiction. 2014 Oct 8. doi: 10.1111/add.12754. [Epub ahead of print]


  174. Hepatitis C core antigen testing: a reliable, quick and potentially cost-effective alternative to Hepatitis C polymerase chain reaction in diagnosing acute hepatitis C virus infection
    Cresswell FV1, Fisher M2, Hughes DJ1, Shaw SG1, Homer G3, Hassan-Ibrahim MO3. Clin Infect Dis. 2014 Oct 9. pii: ciu782. [Epub ahead of print]


  175. Hepatitis B knowledge and preventive practices of Chinese American immigrants in Southern California
    Zhao X1, Edwards QT, Patel N, Hicks RW. J Am Assoc Nurse Pract. 2014 Oct 6. doi: 10.1002/2327-6924.12173. [Epub ahead of print]


  176. A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection
    Zuo SR1, Zuo XC, Wang CJ, Ma YT, Zhang HY, Li ZJ, Song LY, Deng ZZ, Liu SK. J Clin Pharmacol. 2014 Oct 7. doi: 10.1002/jcph.409. [Epub ahead of print]


  177. Sofosbuvir (Sovaldi) for the treatment of hepatitis C
    Lam B1, Henry L, Younossi Z. Expert Rev Clin Pharmacol. 2014 Sep;7(5):555-66. doi: 10.1586/17512433.2014.928196. Epub 2014 Jun 11.


  178. What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?
    McDonald SA1, Innes HA2, Hayes PC3, Dillon JF4, Mills PR5, Goldberg DJ6, Barclay S7, Allen S8, Fox R5, Fraser A9, Kennedy N10, Bhattacharyya D11, Hutchinson SJ2. J Hepatol. 2014 Sep 4. pii: S0168-8278(14)00635-7. doi: 10.1016/j.jhep.2014.08.046. [Epub ahead of print]


  179. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic HCV, genotype-1 infected patients
    Meissner EG1, Lee YJ, Osinusi A, Sims Z, Qin J, Sturdevant D, McHutchison J, Subramanian M, Sampson M, Naggie S, Patel K, Remaley AT, Masur H, Kottilil S. Hepatology. 2014 Sep 9. doi: 10.1002/hep.27424. [Epub ahead of print]


  180. Simeprevir (TMC435) with Peginterferon/Ribavirin in Patients Coinfected with HCV Genotype-1 and HIV-1: A Phase III Study
    Dieterich D1, Rockstroh JK2, Orkin C3, Gutiérrez F4, Klein MB5, Reynes J6, Shukla U7, Jenkins A8, Lenz O9, Ouwerkerk-Mahadevan S10, Peeters M9, De La Rosa G7, Tambuyzer L9, Jessner W9. Clin Infect Dis. 2014 Sep 5. pii: ciu675. [Epub ahead of print]


  181. Hepatitis C drugs: The end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: A concise review
    Yau AH, Yoshida EM. Can J Gastroenterol Hepatol. 2014 Sep;28(8):445-51.


  182. Triple therapy for hepatitis C improves viral response but also increases the risk of severe infections and anaemia: a frequentist meta-analysis approach
    Lanini S1, Mammone A, Puro V, Girardi E, Bruzzi P, Ippolito G. New Microbiol. 2014 Jul;37(3):263-76. Epub 2014 Jul 1.


  183. Disease characteristics and treatment patterns in veterans with rheumatoid arthritis and concomitant hepatitis C infection
    Patel R1, Mikuls T, Richards JS, Kerr G, Cannon G, Baker JF. Arthritis Care Res (Hoboken). 2014 Sep 3. doi: 10.1002/acr.22463. [Epub ahead of print]


  184. Current Practices of Screening for Incident Hepatitis C Virus Infection among HIV- Infected, HCV-Uninfected Individuals in Primary Care
    Freiman JM1, Huang W1, White L2, Geng EH3, Hurt CB4, Taylor LE5, Overton ET6, Cachay ER7, Kitahata MM8, Moore RD9, Rodriguez B10, Mayer KH11, Linas BP12. Clin Infect Dis. 2014 Sep 3. pii: ciu698. [Epub ahead of print]


  185. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C
    Younossi ZM1, Stepanova M2, Henry L3, Gane E4, Jacobson IM5, Lawitz E6, Nelson D7, Gerber L2, Nader F8, Hunt S2. Clin Gastroenterol Hepatol. 2014 Aug;12(8):1349-59.e13. doi: 10.1016/j.cgh.2013.11.032. Epub 2013 Dec 6.


  186. Prevalence and correlates of hepatitis C virus infection among inmates at two New York State correctional facilities
    Alvarez KJ1, Befus M2, Herzig CT3, Larson E3. J Infect Public Health. 2014 Aug 30. pii: S1876-0341(14)00118-X. doi: 10.1016/j.jiph.2014.07.018. [Epub ahead of print]


  187. Is hepatitis C associated with atherosclerotic burden? A systematic review and meta-analysis
    Huang H, Kang R, Zhao Z. PLoS One. 2014 Sep 3;9(9):e106376. doi: 10.1371/journal.pone.0106376. eCollection 2014.


  188. Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus
    Summers BB1, Beavers JW, Klibanov OM. J Pharm Pharmacol. 2014 Aug 31. doi: 10.1111/jphp.12294. [Epub ahead of print]


  189. Management of hepatitis C virus and human immunodeficiency virus coinfection
    O'neil CR1, Coffin CS. Minerva Gastroenterol Dietol. 2014 Sep;60(3):165-75.


  190. Follow-up testing for hepatitis C virus infection: an analysis of massachusetts surveillance data, 2007-2010
    Barton K, Church D, Onofrey S, Cocoros N, DeMaria A Jr. Public Health Rep. 2014 Sep;129(5):403-7.


  191. BMI, male sex and IL28B genotype associated with persistently high hepatitis C virus RNA levels among chronically infected drug users up to 23 years following seroconversion
    Grady BP1, Prins M, Rebers S, Molenkamp R, Geskus RB, Schinkel J. J Viral Hepat. 2014 Sep 1. doi: 10.1111/jvh.12303. [Epub ahead of print]


  192. Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department
    Galbraith JW1, Franco RA, Donnelly JP, Rodgers JB, Morgan JM, Viles AF, Overton ET, Saag MS, Wang HE. Hepatology. 2014 Sep 1. doi: 10.1002/hep.27410. [Epub ahead of print]


  193. Systematic review: identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring-predictors and predictive models of disease progression
    Konerman MA1, Yapali S, Lok AS. Aliment Pharmacol Ther. 2014 Aug 28. doi: 10.1111/apt.12921. [Epub ahead of print]


  194. Marijuana use in hepatitis C infection does not affect liver biopsy histology or treatment outcomes
    Liu T, Howell GT, Turner L, Corace K, Garber G, Cooper C. Can J Gastroenterol Hepatol. 2014 Jul-Aug;28(7):381-4.


  195. A Pilot Study Examining the Safety and Tolerability of Valacyclovir in Veterans With Hepatitis C Virus/Herpes Simplex Virus Type 2 Coinfection
    Burton MJ1, Penman A, Sunesara I, McGuire BM, Hook EW 3rd. Am J Med Sci. 2014 Aug 26. [Epub ahead of print]


  196. Liver inflammation is a Risk Factor for Prediabetes in At-Risk Latinos with and without Hepatitis C Infection
    Burman BE1, Bacchetti P, Ayala CE, Gelman N, Melgar J, Khalili M. Liver Int. 2014 Aug 23. doi: 10.1111/liv.12676. [Epub ahead of print]


  197. Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection
    Flanagan S1, Crawford-Jones A, Orkin C. Expert Rev Clin Pharmacol. 2014 Sep 11:1-14. [Epub ahead of print]


  198. Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection
    Scott J1, Rosa K, Fu M, Cerri K, Peeters M, Beumont M, Zeuzem S, Evon DM, Gilles L.


  199. Treating hepatitis C in the elderly: the future is near?
    Conti F1, Vitale G, Andreone P. Expert Opin Pharmacother. 2014 Oct;15(14):2019-28. doi: 10.1517/14656566.2014.945422. Epub 2014 Aug 26.


  200. An update on the treatment of genotype-1 chronic hepatitis C infection: lessons from recent clinical trials
    Wendt A1, Bourlière M2. Ther Adv Infect Dis. 2013 Dec;1(6):191-208. doi: 10.1177/2049936113502647.


  201. Lack of Clinically Significant Pharmacokinetic Interaction Between the Thrombopoietin Receptor Agonist Eltrombopag and Hepatitis C Virus Protease Inhibitors Boceprevir and Telaprevir
    Wire MB1, Fang L2, Hussaini A3, Kleha JF4, Theodore D4. Antimicrob Agents Chemother. 2014 Aug 25. pii: AAC.03091-14. [Epub ahead of print]


  202. Systematic review: identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring-predictors and predictive models of disease progression
    Konerman MA1, Yapali S, Lok AS. Aliment Pharmacol Ther. 2014 Aug 28. doi: 10.1111/apt.12921. [Epub ahead of print]


  203. The frequency and determinants of liver stiffness measurement failure: a retrospective study of
    Ji D1, Shao Q1, Han P2, Li F1, Li B1, Zang H3, Niu X1, Li Z1, Xin S3, Chen G1. PLoS One. 2014 Aug 14;9(8):e105183. doi: 10.1371/journal.pone.0105183. eCollection 2014.


  204. Distinct Patterns of the Lipid Alterations between Genotype 1 and 2 Chronic Hepatitis C Patients after Viral Clearance
    Chang ML1, Tsou YK2, Hu TH3, Lin CH2, Lin WR2, Sung CM2, Chen TH2, Cheng ML4, Chang KC3, Chiu CT2, Yeh CT2, Pang JH5, Shiao MS4. PLoS One. 2014 Aug 14;9(8):e104783. doi: 10.1371/journal.pone.0104783. eCollection 2014.


  205. Daclatasvir + Asunaprevir: first global approval
    Poole RM. Drugs. 2014 Sep;74(13):1559-71. doi: 10.1007/s40265-014-0279-4.


  206. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for Sofosbuvir
    Donaldson EF1, Harrington PR, O'Rear JJ, Naeger LK. Hepatology. 2014 Aug 14. doi: 10.1002/hep.27375. [Epub ahead of print]


  207. Pegylated interferon pharmacokinetics and self-reported depressive symptoms during antiviral treatment for chronic hepatitis C
    Evon DM1, Esserman DE2, Howell MA3, Ruffin RA1. Pharmacopsychiatry. 2014 Sep;47(6):195-201. doi: 10.1055/s-0034-1385929. Epub 2014 Aug 14.


  208. Hepatitis C in African Americans
    Saab S1, Jackson Md Facg C2, Nieto DO Facg Facp J3, Francois Md MSc Facg F4. Am J Gastroenterol. 2014 Sep 2. doi: 10.1038/ajg.2014.243. [Epub ahead of print]


  209. Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study
    Hayashi N1, Mobashery N, Izumi N. J Gastroenterol. 2014 Aug 13. [Epub ahead of print]


  210. Safety, pharmacokinetics and pharmacodynamics of the oral Toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C
    Lawitz E1, Gruener D, Marbury T, Hill J, Webster L, Hassman D, Nguyen AH, Pflanz S, Mogalian E, Gaggar A, Massetto B, Subramanian GM, McHutchison JG, Jacobson IM, Freilich B, Rodriguez-Torres M. Antivir Ther. 2014 Aug 8. doi: 10.3851/IMP2845. [Epub ahead of print]


  211. The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis c virus
    Eley T1, Sevinsky H, Huang SP, He B, Zhu K, Kandoussi H, Gardiner D, Grasela DM, Bertz R, Bifano M. Clin Drug Investig. 2014 Sep;34(9):661-71. doi: 10.1007/s40261-014-0219-9.


  212. Treatment of hepatitis C: a systematic review
    Kohli A1, Shaffer A2, Sherman A2, Kottilil S2. JAMA. 2014 Aug 13;312(6):631-40. doi: 10.1001/jama.2014.7085.


  213. Ending hepatitis C in the United States: the role of screening
    Coffin PO1, Reynolds A2. Hepat Med. 2014 Jul 3;6:79-87. doi: 10.2147/HMER.S40940. eCollection 2014.


  214. Effectiveness of Telaprevir and Boceprevir Triple Therapy for Patients with Hepatitis C Virus Infection in a Large Integrated Care Setting
    Price JC1, Murphy RC, Shvachko VA, Pauly MP, Manos MM. Dig Dis Sci. 2014 Aug 8. [Epub ahead of print]


  215. Pegylated-IFN?2a for HIV/hepatitis C virus coinfected patients: out with the old, in with the new
    Bichoupan K1, Dieterich DT. Expert Opin Biol Ther. 2014 Sep;14(9):1369-78. doi: 10.1517/14712598.2014.943180.


  216. Modeling viral evolutionary dynamics after telaprevir-based treatment
    Haseltine EL1, De Meyer S2, Dierynck I2, Bartels DJ1, Ghys A2, Davis A1, Zhang EZ1, Tigges AM1, Spanks J1, Picchio G3, Kieffer TL1, Sullivan JC1. PLoS Comput Biol. 2014 Aug 7;10(8):e1003772. doi: 10.1371/journal.pcbi.1003772. eCollection 2014.


  217. Performance Comparison of the Versant HCV Genotype 2.0 Assay (LiPA) and the Abbott Realtime HCV Genotype II for Detecting Hepatitis C Virus Genotype 6
    Yang R1, Cong X1, Du S1, Fei R1, Rao H1, Wei L2. J Clin Microbiol. 2014 Aug 6. pii: JCM.00882-14. [Epub ahead of print]


  218. The role played by gender in viral hepatitis
    Bernabucci V1, Villa E. Scand J Clin Lab Invest Suppl. 2014;74(244):90-4. doi: 10.3109/00365513.2014.936695.


  219. Global epidemiology and genotype distribution of the hepatitis C virus infection
    Gower E1, Estes C C1, Hindman S1, Razavi-Shearer K1, Razavi H2. J Hepatol. 2014 Jul 30. pii: S0168-8278(14)00526-1. doi: 10.1016/j.jhep.2014.07.027. [Epub ahead of print]


  220. The changing burden of hepatitis C virus infection in the United States: model-based predictions
    Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. Ann Intern Med. 2014 Aug 5;161(3):170-80. doi: 10.7326/M14-0095.


  221. Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz and tenofovir
    Sabo JP1, Kort J1, Ballow C2, Haschke M3, Battegay M3, Fuhr R4, Girlich B5, Schobelock M6, Feifel U7, Lang B8, Li Y1, Elgadi M9. Clin Infect Dis. 2014 Aug 4. pii: ciu616. [Epub ahead of print]


  222. Clinical outcomes of compensated and decompensated cirrhosis: A long term study
    Samonakis DN, Koulentaki M, Coucoutsi C, Augoustaki A, Baritaki C, Digenakis E, Papiamonis N, Fragaki M, Matrella E, Tzardi M, Kouroumalis EA. World J Hepatol. 2014 Jul 27;6(7):504-12. doi: 10.4254/wjh.v6.i7.504.


  223. Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C
    Petta S1, Cabibbo G1, Enea M2, Macaluso FS1, Plaia A2, Bruno R3, Gasbarrini A4, Bruno S5, Craxì A1, Cammà C6; on behalf of the WEF study group. Dig Liver Dis. 2014 Jul 22. pii: S1590-8658(14)00422-8. doi: 10.1016/j.dld.2014.06.009. [Epub ahead of print]


  224. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
    Lawitz E1, Sulkowski MS2, Ghalib R3, Rodriguez-Torres M4, Younossi ZM5, Corregidor A6, DeJesus E7, Pearlman B8, Rabinovitz M9, Gitlin N10, Lim JK11, Pockros PJ12, Scott JD13, Fevery B14, Lambrecht T15, Ouwerkerk-Mahadevan S14, Callewaert K14, Symonds WT16, Picchio G17, Lindsay KL17, Beumont M14, Jacobson IM18. Lancet. 2014 Jul 26. pii: S0140-6736(14)61036-9. doi: 10.1016/S0140-6736(14)61036-9. [Epub ahead of print]


  225. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
    Manns M1, Pol S2, Jacobson IM3, Marcellin P4, Gordon SC5, Peng CY6, Chang TT7, Everson GT8, Heo J9, Gerken G10, Yoffe B11, Towner WJ12, Bourliere M13, Metivier S14, Chu CJ15, Sievert W16, Bronowicki JP17, Thabut D18, Lee YJ19, Kao JH20, McPhee F21, Kopit J21, Mendez P22, Linaberry M22, Hughes E22, Noviello S22; on behalf of the HALLMARK-DUAL Study Team. Lancet. 2014 Jul 26. pii: S0140-6736(14)61059-X. doi: 10.1016/S0140-6736(14)61059-X. [Epub ahead of print]


  226. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection
    Saab S1, Gordon SC, Park H, Sulkowski M, Ahmed A, Younossi Z. Aliment Pharmacol Ther. 2014 Jul 28. doi: 10.1111/apt.12871. [Epub ahead of print]


  227. Severity of liver disease among chronic hepatitis C patients: an observational study of 4594 patients in 5 EU countries
    Marcellin P1, Grotzinger K, Theodore D, Demuth D, Manns M, Bañares Cañizares R, Pike J, Forssen UM. J Gastroenterol Hepatol. 2014 Aug 4. doi: 10.1111/jgh.12698. [Epub ahead of print]


  228. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study
    Hézode C1, Hirschfield GM2, Ghesquiere W3, Sievert W4, Rodriguez-Torres M5, Shafran SD6, Thuluvath PJ7, Tatum HA8, Waked I9, Esmat G10, Lawitz EJ11, Rustgi VK12, Pol S13, Weis N14, Pockros PJ15, Bourlière M16, Serfaty L17, Vierling JM18, Fried MW19, Weiland O20, Brunetto MR21, Everson GT22, Zeuzem S23, Kwo PY24, Sulkowski M25, Bräu N26, Hernandez D27, McPhee F27, Wind-Rotolo M28, Liu Z29, Noviello S28, Hughes EA28, Yin PD27, Schnittman S27. Gut. 2014 Jul 30. pii: gutjnl-2014-307498. doi: 10.1136/gutjnl-2014-307498. [Epub ahead of print]


  229. New Therapies for Hepatitis C: Considerations in Patients with Renal Impairment
    Zimner-Rapuch S1, Janus N, Deray G, Launay-Vacher V. Drugs. 2014 Jul 25. [Epub ahead of print]


  230. Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: Multicenter prospective observational study (REPENTINA 3)
    Loras C1, Gisbert JP2, Saro MC3, Piqueras M4, Sánchez-Montes C5, Barrio J6, Ordás I7, Montserrat A8, Ferreiro R9, Zabana Y1, Chaparro M2, Fernández-Bañares F1, Esteve M10; for the REPENTINA study, GETECCU group (Grupo Español de trabajo de Enfermedades de Crohn y Colitis Ulcerosa). J Crohns Colitis. 2014 Jul 19. pii: S1873-9946(14)00206-2. doi: 10.1016/j.crohns.2014.06.009. [Epub ahead of print]


  231. Costs of Telaprevir-based Triple Therapy for Hepatitis C: $189,000 per Sustained Virologic Response
    Bichoupan K1, Martel-Laferriere V, Sachs D, Ng M, Schonfeld EA, Pappas A, Crismale J, Stivala A, Khaitova V, Gardenier D, Linderman M, Perumalswami PV, Schiano TD, Odin JA, Liu L, Moskowitz AJ, Dieterich DT, Branch AD. Hepatology. 2014 Jul 28. doi: 10.1002/hep.27340. [Epub ahead of print]


  232. Delivery of treatment for hepatitis C virus infection in the primary care setting
    Baker D1, Alavi M, Erratt A, Hill S, Balcomb A, Hallinan R, Siriragavan S, Richmond D, Smart J, Keats J, Doong N, Marks P, Grebely J, Dore GJ. Eur J Gastroenterol Hepatol. 2014 Sep;26(9):1003-9. doi: 10.1097/MEG.0000000000000150.


  233. Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection
    Gentile I1, Buonomo AR1, Zappulo E1, Minei G1, Morisco F2, Borrelli F1, Coppola N3, Borgia G1. Ther Clin Risk Manag. 2014 Jun 26;10:493-504. doi: 10.2147/TCRM.S66731. eCollection 2014.


  234. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection
    Sulkowski MS1, Naggie S2, Lalezari J3, Fessel WJ4, Mounzer K5, Shuhart M6, Luetkemeyer AF7, Asmuth D8, Gaggar A9, Ni L9, Svarovskaia E9, Brainard DM9, Symonds WT9, Subramanian GM9, McHutchison JG9, Rodriguez-Torres M10, Dieterich D11; PHOTON-1 Investigators. JAMA. 2014 Jul 23-30;312(4):353-61. doi: 10.1001/jama.2014.7734.


  235. Assessment of Hepatitis C Risk Factors and Infection Prevalence in a Jail Population
    Wenger PJ1, Rottnek F, Crippin JS, Parker T. Am J Public Health. 2014 Jul 17:e1-e6. [Epub ahead of print]


  236. The Effect of HIV-Hepatitis C Co-Infection on Bone Mineral Density and Fracture: A Meta-Analysis
    O'Neill TJ1, Rivera L1, Struchkov V2, Zaheen A3, Thein HH4. PLoS One. 2014 Jul 17;9(7):e101493. doi: 10.1371/journal.pone.0101493. eCollection 2014.


  237. Efficacy and safety of sofosbuvir-based therapy for the treatment of chronic hepatitis C in treatment-naïve and treatment-experienced patients
    Liu X1, Wang Y2, Zhang G1, Li N3, Zhu Q3, Chang H1, Han Q3, Lv Y4, Liu Z5. Int J Antimicrob Agents. 2014 Jun 10. pii: S0924-8579(14)00163-0. doi: 10.1016/j.ijantimicag.2014.04.018. [Epub ahead of print]


  238. Concordance of risk behavior reporting within HCV serodiscordant injecting partnerships of young injection drug users in San Francisco, CA
    Evans JL1, Morris MD2, Yu M2, Page K2, Hahn JA2. Drug Alcohol Depend. 2014 Jul 4. pii: S0376-8716(14)00955-7. doi: 10.1016/j.drugalcdep.2014.06.028. [Epub ahead of print]


  239. Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C
    Bronowicki JP1, Ratziu V2, Gadano A3, Thuluvath PJ4, Bessone F5, Martorell CT6, Pol S7, Terg R8, Younes Z9, He B10, Eley T10, Cohen D11, Yu F11, Hernandez D11, McPhee F11, Mendez P10, Hughes E10. J Hepatol. 2014 Jul 16. pii: S0168-8278(14)00480-2. doi: 10.1016/j.jhep.2014.07.011. [Epub ahead of print]


  240. Hepatitis C virus screening practices and seropositivity among US veterans born during 1945 - 1965
    Cartwright EJ1, Rentsch C, Rimland D. BMC Res Notes. 2014 Jul 14;7(1):449. doi: 10.1186/1756-0500-7-449.


  241. Antiviral treatment of hepatitis C
    Feeney ER1, Chung RT2. BMJ. 2014 Jul 7;349:g3308. doi: 10.1136/bmj.g3308.


  242. MicroRNA and hepatitis C virus- challenges in investigation and translation: a review of the literature
    Waldron PR1, Holodniy M2. Diagn Microbiol Infect Dis. 2014 Jun 5. pii: S0732-8893(14)00243-0. doi: 10.1016/j.diagmicrobio.2014.05.024. [Epub ahead of print]


  243. An overview of hepatitis C vaccines
    Garcia A, Fernandez S, Toro F, De Sanctis JB1. Recent Pat Inflamm Allergy Drug Discov. 2014;8(2):85-91.


  244. Hepatic Retransplant: What Have We Learned?
    Kitchens WH1, Yeh H2, Markmann JF3. Clin Liver Dis. 2014 Aug;18(3):731-751. doi: 10.1016/j.cld.2014.05.010.


  245. Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential
    Lauffenburger JC1, Mayer CL, Hawke RL, Brouwer KL, Fried MW, Farley JF. Eur J Gastroenterol Hepatol. 2014 Jul 10. [Epub ahead of print]


  246. Oral manifestations of hepatitis C virus infection
    Carrozzo M, Scally K. World J Gastroenterol. 2014 Jun 28;20(24):7534-7543.


  247. Association between chronic hepatitis C virus infection and low muscle mass in US adults
    Gowda C1, Compher C, Amorosa VK, Lo Re V 3rd. J Viral Hepat. 2014 Jul 2. doi: 10.1111/jvh.12273. [Epub ahead of print]


  248. Estimating the true prevalence of hepatitis C in rhode island
    Kinnard EN1, Taylor LE2, Galárraga O3, Marshall BD4. R I Med J (2013). 2014 Jul 1;96(7):19-24.


  249. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis
    Yehia BR1, Schranz AJ2, Umscheid CA3, Lo Re V 3rd4. PLoS One. 2014 Jul 2;9(7):e101554. doi: 10.1371/journal.pone.0101554. eCollection 2014.


  250. Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: A meta-analysis
    García-Álvarez M1, Pineda-Tenor D, Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, Resino S. Hepatology. 2014 Jun 27. doi: 10.1002/hep.27281. [Epub ahead of print]


  251. Viral kinetic modeling: state of the art
    Canini L1, Perelson AS. J Pharmacokinet Pharmacodyn. 2014 Jun 25. [Epub ahead of print]


  252. Preference, acceptability and implications of the rapid hepatitis C screening test among high-risk young people who inject drugs
    Hayes B, Briceno A, Asher A, Yu M, Evans JL, Hahn JA, Page K. BMC Public Health. 2014 Jun 25;14(1):645. [Epub ahead of print]


  253. Emerging therapeutic options for the management of hepatitis C infection
    Thompson JR. World J Gastroenterol. 2014 Jun 21;20(23):7079-7088.


  254. Simeprevir (TMC435) once daily with peginterferon ?-2b and ribavirin in patients with genotype-1 hepatitis-C virus infection: the CONCERTO-4 study
    Kumada H1, Hayashi N, Izumi N, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Rito K, Komada Y, Seto C, Goto S. Hepatol Res. 2014 Jun 24. doi: 10.1111/hepr.12375. [Epub ahead of print]


  255. Risk of hepatitis C virus exposure in orthopedic surgery: is universal screening needed?
    DelSole EM, Mercuri JJ, Stachel A, Phillips MS, Zuckerman JD1. Am J Orthop (Belle Mead NJ). 2014 Jun;43(6):E117-23.


  256. Sustained Virological Response with Telaprevir in 1078 Patients With Advanced Hepatitis C: The International Telaprevir Access Program
    Colombo M1, Strasser SI2, Moreno C3, Ferreira PA4, Urbanek P5, Fernández I6, Abdurakmonov D7, Streinu-Cercel A8, Verheyen A9, Iraqi W10, DeMasi R11, Hill A12, Lonjon-Domanec I10, Wedemeyer H13. J Hepatol. 2014 Jun 16. pii: S0168-8278(14)00400-0. doi: 10.1016/j.jhep.2014.06.005. [Epub ahead of print]


  257. Natural history and management of hepatitis C: does sex play a role?
    Baden R1, Rockstroh JK2, Buti M3. Infect Dis. 2014 Jul 15;209 Suppl 3:S81-5. doi: 10.1093/infdis/jiu057.


  258. Restricting liver transplant recipients to younger donors does not increase wait-list time or drop-out rate: The hepatitis C experience
    Flemming JA1, Vagefi PA, Freise CE, Yao FY, Terrault NA. Liver Transpl. 2014 Jun 25. doi: 10.1002/lt.23937. [Epub ahead of print]


  259. Simeprevir (TMC435) once daily with peginterferon ?-2b and ribavirin in patients with genotype-1 hepatitis-C virus infection: the CONCERTO-4 study
    Kumada H1, Hayashi N, Izumi N, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Rito K, Komada Y, Seto C, Goto S. Hepatol Res. 2014 Jun 24. doi: 10.1111/hepr.12375. [Epub ahead of print]


  260. Risk of hepatitis C virus exposure in orthopedic surgery: is universal screening needed?
    DelSole EM, Mercuri JJ, Stachel A, Phillips MS, Zuckerman JD1. Am J Orthop (Belle Mead NJ). 2014 Jun;43(6):E117-23.


  261. Sustained Virological Response with Telaprevir in 1078 Patients With Advanced Hepatitis C: The International Telaprevir Access Program
    Colombo M1, Strasser SI2, Moreno C3, Ferreira PA4, Urbanek P5, Fernández I6, Abdurakmonov D7, Streinu-Cercel A8, Verheyen A9, Iraqi W10, DeMasi R11, Hill A12, Lonjon-Domanec I10, Wedemeyer H13. J Hepatol. 2014 Jun 16. pii: S0168-8278(14)00400-0. doi: 10.1016/j.jhep.2014.06.005. [Epub ahead of print]


  262. Natural history and management of hepatitis C: does sex play a role?
    Baden R1, Rockstroh JK2, Buti M3. Infect Dis. 2014 Jul 15;209 Suppl 3:S81-5. doi: 10.1093/infdis/jiu057.


  263. Restricting liver transplant recipients to younger donors does not increase wait-list time or drop-out rate: The hepatitis C experience
    Flemming JA1, Vagefi PA, Freise CE, Yao FY, Terrault NA. Liver Transpl. 2014 Jun 25. doi: 10.1002/lt.23937. [Epub ahead of print]


  264. Incidence and Management of Rash in Telaprevir-Treated Patients: Lessons for Simeprevir?
    Smith MA1, Johnson HJ2, Chopra KB2, Dunn MA2, Ulrich AM2, Mohammad RA3. Ann Pharmacother. 2014 Jun 17. pii: 1060028014539274. [Epub ahead of print]


  265. New insight into the enhanced effect of pegylated IFN-alpha
    Abe H1, Hayes CN, Chayama K. Hepatology. 2014 Jun 18. doi: 10.1002/hep.27269. [Epub ahead of print]


  266. Prevention of Disease Progression with Anti-Inflammatory Therapy in Patients with HCV-Related Cirrhosis: A Markov Model
    Ikeda K1, Kawamura Y, Kobayashi M, Fukushima T, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H. Oncology. 2014 Jun 7;86(5-6):295-302. [Epub ahead of print]


  267. High Post-Transplant Virologic Response in Hepatitis C Virus Infected Patients Treated with Pre-Transplant Protease Inhibitor-Based Triple Therapy
    Verna EC1, Shetty K, Lukose T, Terry N, Mentore K, Olsen SK, Fox AN, Dove LM, Brown RS. Liver Int. 2014 Jun 6. doi: 10.1111/liv.12616. [Epub ahead of print]


  268. Outbreaks of Infections Associated With Drug Diversion by US Health Care Personnel
    Schaefer MK1, Perz JF2. Mayo Clin Proc. 2014 May 30. pii: S0025-6196(14)00342-5. doi: 10.1016/j.mayocp.2014.04.007. [Epub ahead of print]


  269. Validation of the fatigue severity scale in chronic hepatitis C
    Rosa K, Fu M, Gilles L, Cerri K, Peeters M, Bubb J, Scott J. Health Qual Life Outcomes. 2014 Jun 11;12(1):90. [Epub ahead of print]


  270. IP-10 Kinetics in Treatment-Naïve Versus -Experienced Patients Receiving Interferon-Free Hepatitis C Virus Therapy: Implications for the Innate Immune Response
    Lin JC1, Habersetzer F2, Rodriguez-Torres M3, Afdhal N4, Lawitz EJ5, Paulson MS6, Zhu Y6, Subramanian GM6, McHutchison JG6, Sulkowski M7, Wyles DL1, Schooley RT1. J Infect Dis. 2014 Jun 6. pii: jiu325. [Epub ahead of print]


  271. Long term changes in liver histology following treatment of chronic hepatitis C virus
    Shiffman ML1, Sterling RK2, Contos M3, Hubbard S2, Long A1, Luketic VA2, Stravitz RT2, Fuchs M2, Sanyal AJ2. Ann Hepatol. 2014 Jul-Aug;13(4):340-9.


  272. Pushing to a cure by harnessing innate immunity against hepatitis C virus
    Ireton RC1, Gale M Jr2. Antiviral Res. 2014 Jun 4. pii: S0166-3542(14)00149-1. doi: 10.1016/j.antiviral.2014.05.012. [Epub ahead of print]


  273. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
    Manns M1, Marcellin P2, Poordad F3, de Araujo ES4, Buti M5, Horsmans Y6, Janczewska E7, Villamil F8, Scott J9, Peeters M10, Lenz O10, Ouwerkerk-Mahadevan S11, De La Rosa G12, Kalmeijer R12, Sinha R10, Beumont-Mauviel M10. Lancet. 2014 Jun 3. pii: S0140-6736(14)60538-9. doi: 10.1016/S0140-6736(14)60538-9. [Epub ahead of print]


  274. Higher risk of incident hepatitis C virus among young women who inject drugs compared with young men in association with sexual relationships: a prospective analysis from the UFO Study cohort
    Tracy D1, Hahn JA2, Fuller Lewis C1, Evans J3, Briceño A3, Morris MD3, Lum PJ4, Page K3. BMJ Open. 2014 May 29;4(5):e004988. doi: 10.1136/bmjopen-2014-004988.


  275. Hepatitis C in HIV-Infected Patients: Impact of Direct-Acting Antivirals
    Bichoupan K1, Dieterich DT. Drugs. 2014 May 28. [Epub ahead of print]


  276. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
    Jacobson IM1, Dore GJ2, Foster GR3, Fried MW4, Radu M5, Rafalsky VV6, Moroz L7, Craxi A8, Peeters M9, Lenz O9, Ouwerkerk-Mahadevan S10, De La Rosa G11, Kalmeijer R11, Scott J12, Sinha R9, Beumont-Mauviel M9. Lancet. 2014 Jun 3. pii: S0140-6736(14)60494-3. doi: 10.1016/S0140-6736(14)60494-3. [Epub ahead of print]


  277. Response-Guided Therapy for Hepatitis C Genotype 2 and 3 in Those with HIV Coinfection
    Win LL1, James P, Wong DK. Dig Dis Sci. 2014 May 21. [Epub ahead of print]


  278. The current state and future prospects of chronic hepatitis C virus infection treatment
    Moore C1, Levitsky J. Curr Infect Dis Rep. 2014 Aug;16(8):413. doi: 10.1007/s11908-014-0413-1.


  279. Response-Guided Therapy in Patients with Genotype 1 HCV: Current Status and Future Prospects
    Lawitz EJ1, Membreno FE. J Gastroenterol Hepatol. 2014 May 22. doi: 10.1111/jgh.12632. [Epub ahead of print]


  280. The hepatitis C cascade of care: identifying priorities to improve clinical outcomes
    Linas BP1, Barter DM2, Leff JA3, Assoumou SA2, Salomon JA4, Weinstein MC5, Kim AY6, Schackman BR3. PLoS One. 2014 May 19;9(5):e97317. doi: 10.1371/journal.pone.0097317. eCollection 2014.


  281. My Treatment Approach to Chronic Hepatitis C Virus
    Shiffman ML1, Long AG2, James A2, Alexander P2. Mayo Clin Proc. 2014 May 24. pii: S0025-6196(14)00372-3. doi: 10.1016/j.mayocp.2014.04.013. [Epub ahead of print]


  282. Resistance to hepatitis C virus protease inhibitors
    Kieffer TL1, George S2. Curr Opin Virol. 2014 May 19;8C:16-21. doi: 10.1016/j.coviro.2014.04.008. [Epub ahead of print]


  283. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C
    Elkrief L1, Chouinard P, Bendersky N, Hajage D, Larroque B, Babany G, Kutala B, Francoz C, Boyer N, Moreau R, Durand F, Marcellin P, Rautou PE, Valla D. Hepatology. 2014 May 20. doi: 10.1002/hep.27228. [Epub ahead of print]


  284. Advances in newly developing therapy for chronic hepatitis C virus infection
    Pockros PJ. Front Med. 2014 Jun;8(2):166-74. doi: 10.1007/s11684-014-0334-2. Epub 2014 May 29.


  285. Sustained Virologic Response Rates With Telaprevir-Based Therapy in Treatment-Naive Patients Evaluated by Race or Ethnicity
    Flamm SL1, Muir AJ, Fried MW, Reddy KR, Nelson DR, Bzowej NH, Sullivan JC, Bengtsson L, DeMasi R, Wright CI, Kieffer TL, George S, Adda N, Dusheiko GM. J Clin Gastroenterol. 2014 May 13. [Epub ahead of print]


  286. Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study
    Frimpong JA1, D'Aunno T, Jiang L. Am J Public Health. 2014 Jun;104(6):e75-82. doi: 10.2105/AJPH.2013.301827. Epub 2014 Apr 17.


  287. Is Screening Baby Boomers for HCV Enough? A Call to Screen for Hepatitis C Virus in Persons from Countries of High Endemicity
    Asselah T1, Perumalswami PV, Dieterich D. Liver Int. 2014 May 20. doi: 10.1111/liv.12599. [Epub ahead of print]


  288. Lower life expectancy among people with an HCV notification: a population-based linkage study
    Alavi M1, Law MG, Grebely J, Thein HH, Walter S, Amin J, Dore GJ. J Viral Hepat. 2014 Jun;21(6):e10-8. doi: 10.1111/jvh.12245.


  289. Epidemiology of hepatitis C virus in pennsylvania state prisons, 2004-2012: limitations of 1945-1965 birth cohort screening in correctional settings
    Larney S1, Mahowald MK, Scharff N, Flanigan TP, Beckwith CG, Zaller ND. Am J Public Health. 2014 Jun;104(6):e69-74. doi: 10.2105/AJPH.2014.301943. Epub 2014 Apr 17.


  290. Adherence During Antiviral Treatment Regimens for Chronic Hepatitis C: A Qualitative Study of Patient-reported Facilitators and Barriers
    Evon DM1, Golin CE, Bonner JE, Grodensky C, Velloza J. J Clin Gastroenterol. 2014 May 13. [Epub ahead of print]


  291. Predictors of donor follow-up after living donor liver transplantation
    Brown RS Jr1, Smith A, Dew MA, Gillespie BW, Hill-Callahan M, Ladner DP. Liver Transpl. 2014 May 13. doi: 10.1002/lt.23912. [Epub ahead of print]


  292. Multiplex Protein Analysis to determine Fibrosis Stage and Progression in Patients with Chronic Hepatitis C
    Patel K1, Remlinger KS2, Walker TG3, Leitner P4, Lucas JE5, Gardner SD2, McHutchison JG6, Irving W7, Guha IN7. Clin Gastroenterol Hepatol. 2014 May 7. pii: S1542-3565(14)00672-7. doi: 10.1016/j.cgh.2014.04.037. [Epub ahead of print]


  293. Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters
    van der Meer AJ1, Hansen BE, Fattovich G, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Manns MP, Ieluzzi D, Zeuzem S, Hofmann WP, de Knegt RJ, Veldt BJ, Janssen HL. Gut. 2014 May 9. doi: 10.1136/gutjnl-2013-305357. [Epub ahead of print]


  294. ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-experienced Patients with HCV Genotype 1b Infection
    Andreone P1, Colombo MG2, Enejosa JV3, Koksal I4, Ferenci P5, Maieron A6, Müllhaupt B7, Horsmans Y8, Weiland O9, Reesink HW10, Rodrigues L Jr3, Hu YB3, Podsadecki T3, Bernstein B3. Gastroenterology. 2014 May 9. pii: S0016-5085(14)00603-9. doi: 10.1053/j.gastro.2014.04.045. [Epub ahead of print]


  295. Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
    Zeuzem S1, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R; the VALENCE Investigators. N Engl J Med. 2014 May 4. [Epub ahead of print]


  296. Next generation sequencing sheds light on the natural history of hepatitis C infection in patients that fail treatment
    Abdelrahman T1, Hughes J, Main J, McLauchlan J, Thursz M, Thomson E. Hepatology. 2014 May 2. doi: 10.1002/hep.27192. [Epub ahead of print]


  297. Beyond sofosbuvir: What opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?
    Sofia MJ. Antiviral Res. 2014 May 2. pii: S0166-3542(14)00114-4. doi: 10.1016/j.antiviral.2014.04.008. [Epub ahead of print]


  298. A US Multicenter Study of Hepatitis C Treatment of Liver Transplant Recipients with Protease-Inhibitor Triple Therapy
    Burton JR Jr1, O'Leary JG2, Verna EC3, Saxena V4, Dodge JL4, Stravitz RT5, Levitsky J6, Trotter JF2, Everson GT1, Brown RS Jr3, Terrault NA7. J Hepatol. 2014 May 3. pii: S0168-8278(14)00300-6. doi: 10.1016/j.jhep.2014.04.037. [Epub ahead of print]


  299. Expanding primary care capacity to treat hepatitis C virus infection through an evidence-based care model - Arizona and utah, 2012-2014
    Mitruka K, Thornton K, Cusick S, Orme C, Moore A, Manch RA, Box T, Carroll C, Holtzman D, Ward JW; Division of Viral Hepatitis, National Center for National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC. MMWR Morb Mortal Wkly Rep. 2014 May 9;63(18):393-8.


  300. Frontiers in the treatment of hepatitis C virus infection
    Ahn J, Flamm SL. Gastroenterol Hepatol (N Y). 2014 Feb;10(2):90-100.


  301. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential
    Stedman C. Therap Adv Gastroenterol. 2014 May;7(3):131-140.


  302. All-Oral Combination of Ledipasvir, Vedroprevir, Tegobuvir, and Ribavirin in Treatment-Naive Patients with Genotype 1 HCV Infection
    Wyles DL1, Rodriguez-Torres M, Lawitz E, Shiffman ML, Pol S, Herring RW, Massetto B, Kanwar B, Trenkle JD, Pang PS, Zhu Y, Mo H, Brainard DM, Subramanian GM, McHutchison JG, Habersetzer F, Sulkowski MS. Hepatology. 2014 Feb 5. doi: 10.1002/hep.27053. [Epub ahead of print]


  303. Interferon-free strategies with a nucleoside/nucleotide analogue
    Feld JJ. Semin Liver Dis. 2014 Feb;34(1):37-46. doi: 10.1055/s-0034-1371009. Epub 2014 Apr 29.


  304. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 HCV in interferon ineligible/intolerant individuals
    Hagan LM1, Sulkowski MS, Schinazi RF. Hepatology. 2014 Mar 28. doi: 10.1002/hep.27151. [Epub ahead of print]


  305. ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type
    Matsuura K1, Tanaka Y, Watanabe T, Fujiwara K, Orito E, Kurosaki M, Izumi N, Sakamoto N, Enomoto N, Yatsuhashi H, Kusakabe A, Shinkai N, Nojiri S, Joh T, Mizokami M. J Viral Hepat. 2013 Sep 3. doi: 10.1111/jvh.12171. [Epub ahead of print]


  306. Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy
    Miller MH1, Agarwal K, Austin A, Brown A, Barclay ST, Dundas P, Dusheiko GM, Foster GR, Fox R, Hayes PC, Leen C, Millson C, Ryder SD, Tait J, Ustianowski A, Dillon JF. Aliment Pharmacol Ther. 2014 Apr 22. doi: 10.1111/apt.12764. [Epub ahead of print]


  307. The role of interferon in the new era of hepatitis C treatments
    Parekh PJ1, Shiffman ML. Expert Rev Gastroenterol Hepatol. 2014 Apr 23. [Epub ahead of print]


  308. Drugs Aging. 2014 May;31(5):339-47. doi: 10.1007/s40266-014-0170-8.
    Malnick S1, Maor Y, Melzer E, Tal S. Drugs Aging. 2014 May;31(5):339-47. doi: 10.1007/s40266-014-0170-8.


  309. CXCL10 levels identify individuals with rapid fibrosis at 12 months post-transplant for hepatitis C virus and predict treatment response
    Joshi D1, Carey I, Foxton M, Al-Freah M, Bruce M, Heaton N, Quaglia A, O'Grady J, Aluvihare V, Agarwal K. Clin Transplant. 2014 Apr 21. doi: 10.1111/ctr.12354. [Epub ahead of print]


  310. Combination of Racial/Ethnic and Etiology/Disease-Specific Factors are associated with Lower Survival following Liver Transplantation in African Americans: An Analysis from UNOS/OPTN Database
    Wong RJ1, Ahmed A. Clin Transplant. 2014 Apr 21. doi: 10.1111/ctr.12374. [Epub ahead of print]


  311. Patient-Reported Outcomes Assessment in Chronic Hepatitis C Treated with Sofosbuvir and Ribavirin: The VALENCE Study
    Younossi ZM1, Stepanova M2, Zeuzem S3, Dusheiko G4, Esteban R5, Hezode C6, Reesink HW7, Weiland O8, Nader F9, Hunt SL2. J Hepatol. 2014 Apr 5. pii: S0168-8278(14)00220-7. doi: 10.1016/j.jhep.2014.04.003. [Epub ahead of print]


  312. Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
    Afdhal N1, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P; the ION-1 Investigators. N Engl J Med. 2014 Apr 11. [Epub ahead of print]


  313. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens
    Younossi ZM1, Stepanova M, Nader F, Jacobson IM, Gane E, Nelson D, Lawitz E, Hunt SL. Hepatology. 2014 Apr 8. doi: 10.1002/hep.27161. [Epub ahead of print]


  314. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
    Afdhal N1, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P; ION-2 Investigators. N Engl J Med. 2014 Apr 17;370(16):1483-93. doi: 10.1056/NEJMoa1316366. Epub 2014 Apr 11.


  315. Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
    Kowdley KV1, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW; the ION-3 Investigators. N Engl J Med. 2014 Apr 10. [Epub ahead of print]


  316. The Rapid Evolution of Treatment Strategies for Hepatitis C
    Muir AJ. Am J Gastroenterol. 2014 Apr 15. doi: 10.1038/ajg.2014.66. [Epub ahead of print]


  317. Curing Chronic Hepatitis C - The Arc of a Medical Triumph
    Chung RT1, Baumert TF. N Engl J Med. 2014 Apr 10. [Epub ahead of print]


  318. How can we improve tracking of transplanted tissue in the United States?
    Mahajan R1, Kuehnert MJ. Cell Tissue Bank. 2013 Nov 27. [Epub ahead of print]


  319. Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study
    Barocas JA1, Brennan MB, Hull SJ, Stokes S, Fangman JJ, Westergaard RP. Harm Reduct J. 2014 Jan 14;11:1. doi: 10.1186/1477-7517-11-1.


  320. Hepatitis C virus maintains infectivity for weeks after drying on inanimate surfaces at room temperature: implications for risks of transmission
    Paintsil E1, Binka M, Patel A, Lindenbach BD, Heimer R. J Infect Dis. 2014 Apr;209(8):1205-11. doi: 10.1093/infdis/jit648. Epub 2013 Nov 23.


  321. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men
    Fierer DS1, Dieterich DT, Mullen MP, Branch AD, Uriel AJ, Carriero DC, van Seggelen WO, Hijdra RM, Cassagnol DG; New York Acute Hepatitis C Surveillance Network. Clin Infect Dis. 2014 Mar;58(6):873-9. doi: 10.1093/cid/cit799. Epub 2013 Dec 13.


  322. Maternal-fetal transmission of hepatitis C infection: what is so special about babies?
    Wen JW1, Haber BA. J Pediatr Gastroenterol Nutr. 2014 Mar;58(3):278-82. doi: 10.1097/MPG.0000000000000258.


  323. Impact of Provider Type on Hepatitis C Outcomes With Boceprevir-based and Telaprevir-based Regimens
    Backus LI1, Belperio PS, Shahoumian TA, Mole LA. J Clin Gastroenterol. 2014 Mar 24. [Epub ahead of print]


  324. Hepatitis C virus: a silent killer relevant to dentistry
    Carrozzo M. Oral Dis. 2014 Mar 26. doi: 10.1111/odi.12240. [Epub ahead of print]


  325. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 HCV in interferon ineligible/intolerant individuals
    Hagan LM1, Sulkowski MS, Schinazi RF. Hepatology. 2014 Mar 28. doi: 10.1002/hep.27151. [Epub ahead of print]


  326. Boceprevir In Liver Transplant Recipients
    Saab S1, Manne V, Bau S, Reynolds JA, Allen R, Goldstein L, Durazo F, El-Kabany M, Han S, Busuttil RW. Liver Int. 2014 Mar 26. doi: 10.1111/liv.12548. [Epub ahead of print]


  327. Second wave Anti-HCV Protease Inhibitors: Too little too late?
    De Nicola S1, Aghemo A. Liver Int. 2014 Mar 20. doi: 10.1111/liv.12543. [Epub ahead of print]


  328. The Effect of Mild to Moderate Renal Impairment on the Pharmacokinetics of the Nucleoside Analog Hepatitis C Virus Polymerase Inhibitor Mericitabine
    Haznedar J1, Moreira S, Marbury T, Robson R, Smith W, Kulkarni R, Munson ML, Thommes JA, Lemenuel-Diot A, Washington C, Smith P, Chen YC. Drug Dev Res. 2013 Dec 26. doi: 10.1002/ddr.21166. [Epub ahead of print]


  329. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 12188)
    Deuffic-Burban S1, Schwarzinger M2, Obach D3, Mallet V4, Pol S5, Pageaux GP6, Canva V7, Deltenre P8, Roudot-Thoraval F9, Larrey D10, Dhumeaux D11, Mathurin P12, Yazdanpanah Y13. J Hepatol. 2014 Mar 17. pii: S0168-8278(14)00155-X. doi: 10.1016/j.jhep.2014.03.011. [Epub ahead of print]


  330. Fracture risk in hepatitis C virus infected persons: results from the DANVIR cohort study
    Eg Hansen AB1, Haukali Omland L2, Krarup H3, Obel N2; on behalf of the DANVIR cohort study. J Hepatol. 2014 Mar 17. pii: S0168-8278(14)00151-2. doi: 10.1016/j.jhep.2014.03.007. [Epub ahead of print]


  331. Barriers to HCV treatment in the era of triple therapy: A prospective multi-centered study in clinical practice
    Crespo J1, Cabezas J, Sacristán B, Olcoz JL, Pérez R, de la Vega J, García R, García-Pajares F, Sáez-Royuela F, González JM, Jiménez F, Rodríguez S, Cuadrado A, López-Arias MJ, García I, Milla A, García-Riesco E, Muñoz M, Sánchez-Antolín G, Jorquera F. Liver Int. 2014 Mar 20. doi: 10.1111/liv.12536. [Epub ahead of print]


  332. Hepatitis C treatment: an incipient therapeutic revolution
    Delemos AS1, Chung RT2. Trends Mol Med. 2014 Mar 10. pii: S1471-4914(14)00023-9. doi: 10.1016/j.molmed.2014.02.002. [Epub ahead of print]


  333. Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C
    Ponziani FR1, Viganò R2, Iemmolo RM3, Donato MF4, Rendina M5, Toniutto P6, Pasulo L7, Morelli MC8, Burra P9, Miglioresi L10, Merli M11, Di Paolo D12, Fagiuoli S7, Gasbarrini A13, Pompili M13; on behalf of AISF RECOLT-C Group, Belli L, Gerunda GE, Marino M, Montalti R, Di Benedetto F, De Ruvo N, Rigamonti C, Colombo M, Rossi G, Di Leo A, Lupo L, Memeo V, Bringiotti R, Zappimbulso M, Bitetto D, Vero V, Colpani M, Fornasiere E, Pinna AD, Morelli MC, Bertuzzo V, De Martin E, Senzolo M, Ettorre GM, Visco-Comandini U, Antonucci G, Angelico M, Tisone G, Giannelli V, Giusto M. Dig Liver Dis. 2014 Mar 10. pii: S1590-8658(14)00207-2. doi: 10.1016/j.dld.2014.01.157. [Epub ahead of print]


  334. Impact of IL28B Genetic Variation on HCV-Induced Liver Fibrosis, Inflammation, and Steatosis: A Meta-Analysis
    Sato M1, Kondo M1, Tateishi R1, Fujiwara N1, Kato N2, Yoshida H1, Taguri M3, Koike K1. PLoS One. 2014 Mar 17;9(3):e91822. doi: 10.1371/journal.pone.0091822. eCollection 2014.


  335. Peginterferon and Ribavirin for Treatment of Recurrent Hepatitis C Disease in HCV-HIV Coinfected Liver Transplant Recipients
    Terrault N1, Reddy KR, Poordad F, Curry M, Schiano T, Johl J, Shaikh O, Dove L, Shetty K, Millis M, Schiff E, Regenstein F, Barnes D, Barin B, Peters M, Roland M, Stock P; for the HIVTR Investigators. Am J Transplant. 2014 Mar 17. doi: 10.1111/ajt.12668. [Epub ahead of print]


  336. Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score
    Virlogeux V1, Pradat P, Bailly F, Funingana G, Gonçalves F, Maynard M, Hartig-Lavie K, Amiri M, Zoulim F. J Viral Hepat. 2014 Feb 25. doi: 10.1111/jvh.12237. [Epub ahead of print]


  337. HCV Genotype 3 is Associated with an Increased Risk of Cirrhosis and Hepatocellular Cancer in a National Sample of U.S. Veterans with HCV
    Kanwal F1, Kramer JR, Ilyas J, Duan Z, El-Serag HB. Hepatology. 2014 Feb 24. doi: 10.1002/hep.27095. [Epub ahead of print]


  338. Review article: HCV genotype 3 - the new treatment challenge
    Ampuero J1, Romero-Gómez M, Reddy KR. Aliment Pharmacol Ther. 2014 Feb 20. doi: 10.1111/apt.12646. [Epub ahead of print]


  339. Prospective evaluation of Fibrotest®, Fibrometer® and Hepascore® for staging liver fibrosis in chronic hepatitis B: Comparison with hepatitis C
    Leroy V1, Sturm N2, Faure P3, Trocme C4, Marlu A5, Hilleret MN6, Morel F4, Zarski JP6. J Hepatol. 2014 Mar 11. pii: S0168-8278(14)00137-8. doi: 10.1016/j.jhep.2014.02.029. [Epub ahead of print]


  340. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection
    Kumada H1, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Damokosh A, Ishikawa H, Hughes E. Hepatology. 2014 Mar 6. doi: 10.1002/hep.27113. [Epub ahead of print]


  341. Simeprevir with Peginterferon and Ribavirin Leads to High Rates of SVR in Patients with HCV Genotype 1 Who Relapsed After Previous Therapy: a Phase 3 Trial
    Forns X1, Lawitz E2, Zeuzem S3, Gane E4, Bronowicki JP5, Andreone P6, Horban A7, Brown A8, Peeters M9, Lenz O9, Ouwerkerk-Mahadevan S10, Scott J11, De La Rosa G12, Kalmeijer R12, Sinha R9, Beumont-Mauviel M9. Gastroenterology. 2014 Mar 3. pii: S0016-5085(14)00293-5. doi: 10.1053/j.gastro.2014.02.051. [Epub ahead of print]


  342. Omega-3 Fatty Acids in the Prevention of Interferon-Alpha-Induced Depression: Results from a Randomized, Controlled Trial
    Su KP1, Lai HC2, Yang HT3, Su WP2, Peng CY2, Chang JP4, Chang HC5, Pariante CM6. Biol Psychiatry. 2014 Jan 24. pii: S0006-3223(14)00047-X. doi: 10.1016/j.biopsych.2014.01.008. [Epub ahead of print]


  343. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy
    Wyles DL1, Gutierrez JA. J Viral Hepat. 2014 Apr;21(4):229-40. doi: 10.1111/jvh.12230.


  344. Hepatitis C Virus Screening in Patients With Cancer Receiving Chemotherapy
    Hwang JP1, Suarez-Almazor ME, Torres HA, Palla SL, Huang DS, Fisch MJ, Lok AS. J Oncol Pract. 2014 Mar 4. [Epub ahead of print]


  345. Impact of birth cohort screening for hepatitis C
    Asrani SK1, Davis GL. Curr Gastroenterol Rep. 2014 Apr;16(4):381. doi: 10.1007/s11894-014-0381-5.


  346. Improving the Resistance Profile of Hepatitis C NS3/4A Inhibitors: Dynamic Substrate Envelope Guided Design
    Ozen A1, Sherman W2, Schiffer CA1. J Chem Theory Comput. 2013 Dec 10;9(12):5693-5705.


  347. Hepatitis C seroprevalence among prison inmates since 2001: still high but declining
    Varan AK1, Mercer DW1, Stein MS1, Spaulding AC2. Public Health Rep. 2014 Mar;129(2):187-95.


  348. Hepatitis C virus: Here comes all-oral treatment
    Dugum M1, O'Shea R. Cleve Clin J Med. 2014 Mar;81(3):159-72. doi: 10.3949/ccjm.81a.13155.


  349. Disease dependent qualitative and quantitative differences in the inflammatory response to ascites occurring in cirrhotics
    Attar BM, George M, Ion-Nedelcu N, Ramadori G, Thiel DH. World J Hepatol. 2014 Feb 27;6(2):85-91. doi: 10.4254/wjh.v6.i2.85.


  350. Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment
    Aggarwal J1, Vera-Llonch M, Donepudi M, Suthoff E, Younossi Z, Goss TF. J Viral Hepat. 2014 Feb 16. doi: 10.1111/jvh.12227. [Epub ahead of print]


  351. Cure of hepatitis C virus infection without interferon alfa: scientific basis and current clinical evidence
    Thomas DL. Top Antivir Med. 2013 Dec;21(5):152-6.


  352. Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness
    Sheahan T1, Imanaka N1, Marukian S2, Dorner M1, Liu P1, Ploss A1, Rice CM3. Cell Host Microbe. 2014 Feb 12;15(2):190-202. doi: 10.1016/j.chom.2014.01.007.


  353. The fragile relationship between hepatitis C virus and its human host
    Schooley RT. Top Antivir Med. 2013 Dec;21(5):148-51.


  354. HCV Core Residues Critical for Infectivity Are Also Involved in Core-NS5A Complex Formation
    Gawlik K, Baugh J, Chatterji U, Lim PJ, Bobardt MD, Gallay PA. PLoS One. 2014 Feb 12;9(2):e88866. doi: 10.1371/journal.pone.0088866. eCollection 2014.


  355. Transarterial Therapies for Primary Liver Tumors
    Talenfeld AD1, Sista AK1, Madoff DC2. Surg Oncol Clin N Am. 2014 Apr;23(2):323-351. doi: 10.1016/j.soc.2013.11.002.


  356. Hepatitis C virus infection and insulin resistance
    Bose SK, Ray R. World J Diabetes. 2014 Feb 15;5(1):52-58.


  357. Modeling the impact of hepatitis C viral clearance on end-stage liver disease in an HIV co-infected cohort with targeted maximum likelihood estimation
    Schnitzer ME1, Moodie EE, van der Laan MJ, Platt RW, Klein MB. Biometrics. 2013 Nov 13. doi: 10.1111/biom.12105. [Epub ahead of print]


  358. Racial Disparities in the Proportion of Current, Unresolved Hepatitis C Virus Infections in the United States, 2003-2010
    Liu G1, Holmberg SD, Kamili S, Xu F. Dig Dis Sci. 2014 Feb 27. [Epub ahead of print


  359. Hepatitis C and Work Impairment: A Review of Current Literature
    Manne V, Sassi K, Allen R, Saab S. J Clin Gastroenterol. 2014 Jan 31. [Epub ahead of print]


  360. Screening for hepatitis C virus infection in a high prevalence country by an antigen/antibody combination assay versus a rapid test
    Tagny CT1, Mbanya D1, Murphy EL2, Lefrère JJ3, Laperche S4. J Virol Methods. 2014 Jan 30. pii: S0166-0934(14)00012-3. doi: 10.1016/j.jviromet.2014.01.002. [Epub ahead of print]


  361. Hepatitis C screening trends in a large integrated health system
    Linas BP1, Hu H2, Barter DM3, Horberg M2. Am J Med. 2014 Jan 28. pii: S0002-9343(14)00078-3. doi: 10.1016/j.amjmed.2014.01.012. [Epub ahead of print]


  362. Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients
    Zeuzem S1, Demasi R2, Baldini A3, Coate B2, Luo D2, Mrus J4, Witek J2. J Hepatol. 2014 Jan 28. pii: S0168-8278(14)00059-2. doi: 10.1016/j.jhep.2014.01.013. [Epub ahead of print]


  363. A New Laboratory Based Algorithm to Predict Development of Hepatocellular Carcinoma in Patients with Hepatitis C and Cirrhosis
    El-Serag HB1, Kanwal F2, Davila JA3, Kramer J4, Richardson P5. Gastroenterology. 2014 Jan 23. pii: S0016-5085(14)00104-8. doi: 10.1053/j.gastro.2014.01.045. [Epub ahead of print]


  364. Acute hepatitis C: management in the rapidly evolving world of HCV
    Sharma SA, Feld JJ. Curr Gastroenterol Rep. 2014 Feb;16(2):371. doi: 10.1007/s11894-014-0371-7.


  365. Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection
    Picchio G1, De Meyer S2, Dierynck I2, Ghys A2, Gritz L3, Kieffer TL3, Bartels DJ3, Witek J4, Bengtsson L3, Luo D4, Kauffman RS3, Adda N5, Sarrazin C6. J Clin Virol. 2014 Jan 6. pii: S1386-6532(13)00542-8. doi: 10.1016/j.jcv.2013.12.011. [Epub ahead of print]


  366. Clearance of Hepatitis C infection is associated with early appearance of broad neutralizing antibody responses
    Osburn WO, Snider AE, Wells BL, Latanich R, Bailey JR, Thomas DL, Cox AL, Ray SC. Hepatology. 2014 Jan 15. doi: 10.1002/hep.27013. [Epub ahead of print]


  367. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
    Lok AS1, Gardiner DF2, Hézode C3, Lawitz EJ4, Bourlière M5, Everson GT6, Marcellin P7, Rodriguez-Torres M8, Pol S9, Serfaty L10, Eley T2, Huang SP11, Li J11, Wind-Rotolo M11, Yu F12, McPhee F12, Grasela DM2, Pasquinelli C2. J Hepatol. 2013 Oct 26. pii: S0168-8278(13)00744-7. doi: 10.1016/j.jhep.2013.10.019. [Epub ahead of print]


  368. Acute hepatitis C: A 24 week-course of Peg-Interferon alpha-2b versus a 12 week-course of Peg-Interferon alpha-2b alone or with ribavirin
    Santantonio T, Fasano M, Sagnelli E, Tundo P, Babudieri S, Fabris P, Toti M, Perri GD, Marino N, Pizzigallo E, Angarano G; Acute Hepatitis C Study Group. Hepatology. 2014 Jan 18. doi: 10.1002/hep.26991. [Epub ahead of print]


  369. Distinct Features in Natural History and Outcomes of Acute Hepatitis C
    Bunchorntavakul C, Jones LM, Kikuchi M, Valiga ME, Kaplan DE, Nunes FA, Aytaman A, Reddy KR, Chang KM. J Clin Gastroenterol. 2014 Jan 22. [Epub ahead of print]


  370. The impact of hepatitis C burden: an evidence-based approach
    Younossi ZM, Kanwal F, Saab S, Brown KA, El-Serag HB, Kim WR, Ahmed A, Kugelmas M, Gordon SC. Aliment Pharmacol Ther. 2014 Jan 26. doi: 10.1111/apt.12625. [Epub ahead of print]


  371. A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4
    Vince B1, Hill JM2, Lawitz EJ3, O'Riordan W4, Webster LR5, Gruener DM6, Mofsen RS7, Murillo A8, Donovan E9, Chen J9, McCarville JF9, Sullivan-Bólyai JZ9, Mayers D9, Zhou XJ10. J Hepatol. 2014 Jan 13. pii: S0168-8278(14)00014-2. doi: 10.1016/j.jhep.2014.01.003. [Epub ahead of print]


  372. Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1
    Kris V. Kowdley, M.D., Eric Lawitz, M.D., Fred Poordad, M.D., Daniel E. Cohen, M.D., David R. Nelson, M.D., Stefan Zeuzem, M.D., Gregory T. Everson, M.D., Paul Kwo, M.D., Graham R. Foster, F.C.R.P., Mark S. Sulkowski, M.D., Wangang Xie, Ph.D., Tami Pilot-Matias, Ph.D., George Liossis, B.A., Lois Larsen, Ph.D., Amit Khatri, Ph.D., Thomas Podsadecki, M.D., and Barry Bernstein, M.D.


  373. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6
    Wantuck JM, Ahmed A, Nguyen MH. Aliment Pharmacol Ther. 2014 Jan;39(2):137-47. doi: 10.1111/apt.12551. Epub 2013 Nov 19.


  374. An overview of emerging therapies for the treatment of chronic hepatitis C
    Ilyas JA, Vierling JM. Med Clin North Am. 2014 Jan;98(1):17-38. doi: 10.1016/j.mcna.2013.10.011.


  375. Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
    Mark S. Sulkowski, M.D., David F. Gardiner, M.D., Maribel Rodriguez-Torres, M.D., K. Rajender Reddy, M.D., Tarek Hassanein, M.D., Ira Jacobson, M.D., Eric Lawitz, M.D., Anna S. Lok, M.D., Federico Hinestrosa, M.D., Paul J. Thuluvath, M.D., Howard Schwartz, M.D., David R. Nelson, M.D., Gregory T. Everson, M.D., Timothy Eley, Ph.D., Megan Wind-Rotolo, Ph.D., Shu-Pang Huang, Ph.D., Min Gao, Ph.D., Dennis Hernandez, Ph.D., Fiona McPhee, Ph.D., Diane Sherman, M.S., Robert Hindes, M.D., William Symonds, Pharm.D., Claudio Pasquinelli, M.D., Ph.D., and Dennis M. Grasela, Pharm.D., Ph.D. for the AI444040 Study Group


  376. Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy
    Cooper C, Shafran S, Greenbloom S, Enns R, Farley J, Hilzenrat N, Williams K, Elkashab M, Abadir N, Neuman M. Can J Gastroenterol. 2014 Jan;28(1):35-40. Epub 2013 Nov 8.


  377. Hepatitis C virus infection and type 2 diabetes
    Fallahi P, Ferrari SM, Colaci M, Ruffilli I, Vita R, Azzi A, Ferri C, Antonelli A, Ferrannini E. Clin Ter. 2013;164(5):e393-404. doi: 10.7417/CT.2013.1620.


  378. Hepatitis C virus and type 1 diabetes
    Fallahi P, Di Domenicantonio A, Mazzi V, Santini F, Fabiani S, Sebastiani M, Zignego AL, Ferri C, Antonelli A. Clin Ter. 2013;164(5):e437-44. doi: 10.7417/CT.2013.1624.


  379. After the Cure: Management of HCV After Achievement of SVR
    Zator ZA, Chung RT. Curr HIV/AIDS Rep. 2013 Dec;10(4):428-35. doi: 10.1007/s11904-013-0181-9.


  380. Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection
    Lattimore S, Irving W, Collins S, Penman C, Ramsay M; On behalf of the collaboration for the sentinel surveillance of blood-borne virus testing. Hepatology. 2013 Nov 9. doi: 10.1002/hep.26926. [Epub ahead of print]


  381. Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection
    Rodríguez-Torres M. Expert Rev Anti Infect Ther. 2013 Dec;11(12):1269-79. doi: 10.1586/14787210.2013.855126.


  382. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
    Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, McHutchison JG, Membreno FE. Lancet. 2013 Nov 1. pii: S0140-6736(13)62121-2. doi: 10.1016/S0140-6736(13)62121-2. [Epub ahead of print]


  383. Hepatitis C transmission and treatment in contact networks of people who inject drugs
    Rolls DA, Sacks-Davis R, Jenkinson R, McBryde E, Pattison P, Robins G, Hellard M. PLoS One. 2013 Nov 1;8(11):e78286. doi: 10.1371/journal.pone.0078286.


  384. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort
    Backus LI, Belperio PS, Shahoumian TA, Cheung R, Mole LA. Aliment Pharmacol Ther. 2014 Jan;39(1):93-103. doi: 10.1111/apt.12546. Epub 2013 Nov 10.


  385. Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C?
    Grasso A, Malfatti F, Testa R. World J Gastroenterol. 2013 Nov 7;19(41):6947-56. doi: 10.3748/wjg.v19.i41.6947.


  386. Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis
    Park C, Jiang S, Lawson KA. J Clin Pharm Ther. 2014 Feb;39(1):14-24. doi: 10.1111/jcpt.12106. Epub 2013 Nov 16.


  387. HCV and host lipids: an intimate connection
    Schaefer EA, Chung RT. Semin Liver Dis. 2013 Nov;33(4):358-68. doi: 10.1055/s-0033-1358524. Epub 2013 Nov 12.


  388. Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies
    Roberts SK, Mitchell J, Leung R, Booth D, Bollipo S, Ostapowicz G, Sloss A, McCaughan GW, Dore GJ, Thompson A, Crawford DH, Sievert W, Weltman M, Cheng W, George J; Australian Liver Association Clinical Research Network. J Gastroenterol Hepatol. 2014 Jan;29(1):179-84. doi: 10.1111/jgh.12424.


  389. Managing HIV/hepatitis C co-infection in the era of direct acting antivirals
    Rockstroh JK, Bhagani S. BMC Med. 2013 Nov 1;11:234. doi: 10.1186/1741-7015-11-234.


  390. Isaacs D, Abdelaziz N, Keller M, Tibble J, Haq I. Hepat Res Treat. 2013;2013:910519. doi: 10.1155/2013/910519. Epub 2013 Oct 7.
    Isaacs D, Abdelaziz N, Keller M, Tibble J, Haq I. Hepat Res Treat. 2013;2013:910519. doi: 10.1155/2013/910519. Epub 2013 Oct 7.


  391. Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature
    Fusco F, D'Anzeo G, Rossi A, Sciorio C, Buonomo AR, d'Emmanuele di Villa Bianca R, Borgia G, Mirone V, Gentile I. Expert Opin Pharmacother. 2013 Dec;14(18):2533-44. doi: 10.1517/14656566.2013.850073. Epub 2013 Nov 12.


  392. New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database
    Yadav AD, Chang YH, Aqel BA, Byrne TJ, Chakkera HA, Douglas DD, Mulligan DC, Rakela J, Vargas HE, Carey EJ. J Transplant. 2013;2013:269096. doi: 10.1155/2013/269096. Epub 2013 Sep 24.


  393. Does Chemotherapy Cause Viral Relapse in Cancer Patients With Hepatitis C Infection Successfully Treated With Antivirals?
    Mahale P1, Okhuysen PC2, Torres HA3. Clin Gastroenterol Hepatol. 2013 Nov 7. pii: S1542-3565(13)01726-6. doi: 10.1016/j.cgh.2013.10.034. [Epub ahead of print]


  394. Can Antidepressants Prevent Pegylated Interferon-?/Ribavirin-Associated Depression in Patients with Chronic Hepatitis C: Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials?
    Hou XJ, Xu JH, Wang J, Yu YY. PLoS One. 2013 Oct 30;8(10):e76799. doi: 10.1371/journal.pone.0076799.


  395. Hepatitis C and alcohol exacerbate liver injury by suppression of FOXO3
    Tumurbaatar B, Tikhanovich I, Li Z, Ren J, Ralston R, Kuravi S, Campbell R, Chaturvedi G, Huang TT, Zhao J, Hao J, O'Neil M, Weinman SA. Am J Pathol. 2013 Dec;183(6):1803-14. doi: 10.1016/j.ajpath.2013.08.013. Epub 2013 Nov 11.


  396. Is the genotype 3 of the hepatitis C virus the new villain?
    Goossens N, Negro F. Hepatology. 2013 Oct 24. doi: 10.1002/hep.26905. [Epub ahead of print]


  397. Association between vitamin D and hepatitis C virus infection: a meta-analysis
    Villar LM, Del Campo JA, Ranchal I, Lampe E, Romero-Gomez M. World J Gastroenterol. 2013 Sep 21;19(35):5917-24. doi: 10.3748/wjg.v19.i35.5917.


  398. Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of Sustained Viral Response in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis
    Rodriguez-Torres M1, Stoehr A2, Gane EJ3, Serfaty L4, Lawitz E5, Zhou A6, Bourque M6, Bhanja S6, Strizki J6, Barnard RJ6, Hwang PM6, Dinubile MJ6, Mobashery N7. Clin Gastroenterol Hepatol. 2013 Oct 10. pii: S1542-3565(13)01519-X. doi: 10.1016/j.cgh.2013.09.067. [Epub ahead of print]


  399. α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype
    Shimada N, Tsubota A, Atsukawa M, Abe H, Ika M, Kato K, Sato Y, Kondo C, Sakamoto C, Tanaka Y, Aizawa Y. J Med Virol. 2013 Oct 28. doi: 10.1002/jmv.23824. [Epub ahead of print]


  400. Treatment of chronic HCV genotype 1 infection with telaprevir: a Bayesian mixed treatment comparison of fixed-length and response-guided treatment regimens in treatment-naïve and -experienced patients
    Goralczyk AD, Cameron S, Amanzada A. BMC Gastroenterol. 2013 Oct 14;13:148. doi: 10.1186/1471-230X-13-148.


  401. Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy
    Crismale JF, Martel-Laferrière V, Bichoupan K, Schonfeld E, Pappas A, Wyatt C, Odin JA, Liu LU, Schiano TD, Perumalswami PV, Bansal M, Dieterich DT, Branch AD. Liver Int. 2013 Oct 1. doi: 10.1111/liv.12342. [Epub ahead of print]


  402. Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial
    Zeuzem S1, Berg T2, Gane E3, Ferenci P4, Foster GR5, Fried MW6, Hezode C7, Hirschfield GM8, Jacobson I9, Nikitin I10, Pockros PJ11, Poordad F12, Scott J13, Lenz O14, Peeters M14, Sekar V15, De Smedt G14, Sinha R14, Beumont-Mauviel M14. Gastroenterology. 2013 Nov 1. pii: S0016-5085(13)01576-X. doi: 10.1053/j.gastro.2013.10.058. [Epub ahead of print]


  403. Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection?
    Hara K, Rivera MM, Koh C, Demino M, Page S, Nagabhyru PR, Rehermann B, Liang TJ, Hoofnagle JH, Heller T. J Infect Dis. 2014 Jan;209(1):38-45. doi: 10.1093/infdis/jit541. Epub 2013 Oct 14.


  404. Hepatitis C and pregnancy
    Floreani A. World J Gastroenterol. 2013 Oct 28;19(40):6714-20. doi: 10.3748/wjg.v19.i40.6714.


  405. The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection
    van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Manns MP, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. J Viral Hepat. 2013 Oct 10. doi: 10.1111/jvh.12185. [Epub ahead of print]


  406. Prevalence of insulin resistance in chronic hepatitis C genotype 1 and 3 patients
    Péres DP, Cheinquer H, Wolf FH, Cheinquer N, Falavigna M, Péres LD. Ann Hepatol. 2013 Nov-Dec;12(6):871-5.


  407. Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b
    Tsubota A, Shimada N, Atsukawa M, Abe H, Kato K, Ika M, Matsudaira H, Nagatsuma K, Matsuura T, Aizawa Y. J Gastroenterol Hepatol. 2014 Jan;29(1):144-50. doi: 10.1111/jgh.12402.


  408. Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy
    Afdhal NH1, Dusheiko GM2, Giannini EG3, Chen PJ4, Han KH5, Mohsin A6, Rodriguez-Torres M7, Rugina S8, Bakulin I9, Lawitz E10, Shiffman ML11, Tayyab GU12, Poordad F10, Kamel YM13, Brainsky A14, Geib J14, Vasey SY14, Patwardhan R14, Campbell FM13, Theodore D15. Gastroenterology. 2013 Oct 12. pii: S0016-5085(13)01436-4. doi: 10.1053/j.gastro.2013.10.012. [Epub ahead of print]


  409. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients
    Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, Wu MS, Liu YY, Wu CY. Hepatology. 2013 Oct 12. doi: 10.1002/hep.26892. [Epub ahead of print]


  410. The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C
    Maasoumy B, Port K, Calle Serrano B, Markova AA, Sollik L, Manns MP, Cornberg M, Wedemeyer H. Aliment Pharmacol Ther. 2013 Dec;38(11-12):1365-72. doi: 10.1111/apt.12523. Epub 2013 Oct 16.


  411. Daclatasvir: potential role in hepatitis C
    Lee C. Drug Des Devel Ther. 2013 Oct 16;7:1223-33. doi: 10.2147/DDDT.S40310.


  412. Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials
    Manns MP, McCone J Jr, Davis MN, Rossaro L, Schiff E, Shiffman ML, Bacon B, Bourliere M, Sulkowski MS, Bruno S, Balart L, Bronowicki JP, Kwo P, Poordad F, Felizarta F, Reddy KR, Helmond FA, Sings HL, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Vierling JM. Liver Int. 2013 Aug 2. doi: 10.1111/liv.12300. [Epub ahead of print]


  413. Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection
    Macaluso FS1, Maida M2, Cammà C2, Cabibi D3, Alessi N2, Cabibbo G2, Di Marco V2, Craxì A2, Petta S2. Clin Gastroenterol Hepatol. 2013 Oct 7. pii: S1542-3565(13)01507-3. doi: 10.1016/j.cgh.2013.09.059. [Epub ahead of print]


  414. α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype
    Shimada N, Tsubota A, Atsukawa M, Abe H, Ika M, Kato K, Sato Y, Kondo C, Sakamoto C, Tanaka Y, Aizawa Y. J Med Virol. 2013 Oct 28. doi: 10.1002/jmv.23824. [Epub ahead of print]


  415. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients
    Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G. J Med Econ. 2014 Jan;17(1):65-76. doi: 10.3111/13696998.2013.860033. Epub 2013 Nov 18.


  416. Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C
    Arase Y, Kobayashi M, Kawamura Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, Kumada H, Kobayashi T. J Med Virol. 2014 Jan;86(1):169-75. doi: 10.1002/jmv.23777. Epub 2013 Oct 24.


  417. Screening for Hepatitis C Virus Infection in Adults
    John M. Eisenberg Center for Clinical Decisions and Communications Science.


  418. Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature
    Cacopardo B, Benanti F, Pinzone MR, Nunnari G. BMC Res Notes. 2013 Oct 30;6(1):437. [Epub ahead of print]


  419. Hepatitis C Direct-acting Antiviral Agents: Changing the Paradigm of Hepatitis C Treatment in HIV-infected Patients
    Martel-Laferrière V, Bichoupan K, Dieterich DT. J Clin Gastroenterol. 2013 Oct 28. [Epub ahead of print]


  420. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices
    Afdhal NH, Zeuzem S, Schooley RT, Thomas DL, Ward JW, Litwin AH, Razavi H, Castera L, Poynard T, Muir A, Mehta SH, Dee L, Graham C, Church DR, Talal AH, Sulkowski MS, Jacobson IM; New Paradigm of HCV Therapy Meeting Participants. J Viral Hepat. 2013 Nov;20(11):745-60. doi: 10.1111/jvh.12173.


  421. Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor
    de Bruijne J, Thomas XV, Rebers SP, Weegink CJ, Treitel MA, Hughes E, Bergmann JF, de Knegt RJ, Janssen HL, Reesink HW, Molenkamp R, Schinkel J. J Viral Hepat. 2013 Nov;20(11):779-89. doi: 10.1111/jvh.12104. Epub 2013 Jun 27.


  422. The experience of hepatitis C treatment for people with a history of mental health problems: An interpretative phenomenological analysis
    Ware K, Davies J, Rowse G, Whittaker S. J Health Psychol. 2013 Oct 22. [Epub ahead of print]


  423. Role of hepatitis C virus substitutions and interleukin-28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy
    Liang CM, Hu TH, Lu SN, Hung CH, Huang CM, Wang JH, Yen YH, Chen CH, Chang KC, Tsai MC, Kuo YH, Lee CM. J Viral Hepat. 2013 Nov;20(11):761-9. doi: 10.1111/jvh.12097. Epub 2013 Apr 7.


  424. A fast and cost-effective method for identifying a polymorphism of interleukin 28B related to hepatitis C
    Ferreira Cda S, Abreu RM, da Silva MC, Ferreira AS, Nasser PD, Carrilho FJ, Ono SK. PLoS One. 2013 Oct 22;8(10):e78142. doi: 10.1371/journal.pone.0078142.


  425. Evolution of fibrosis during HCV recurrence after liver transplantation--influence of IL-28B SNP and response to peg-IFN and ribavirin treatment
    Ackefors M, Nyström J, Wernerson A, Gjertsen H, Sönnerborg A, Weiland O. J Viral Hepat. 2013 Nov;20(11):770-8. doi: 10.1111/jvh.12099. Epub 2013 Apr 23.


  426. Interferon-Free Regimens for Hepatitis C: Combine and Conquer
    Martel-Laferrière V, Bichoupan K, Dieterich DT. BioDrugs. 2013 Oct 30. [Epub ahead of print]


  427. Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis
    Di Marco V, Covolo L, Calvaruso V, Levrero M, Puoti M, Suter F, Gaeta GB, Ferrari C, Raimondo G, Fattovich G, Santantonio T, Alberti A, Bruno R, Mussini C, Mondelli M, Donato F, Craxì A; Multicenter Italian Group for the Study of Hepatitis C. J Viral Hepat. 2013 Nov;20(11):790-800. doi: 10.1111/jvh.12106. Epub 2013 Sep 15.


  428. Antiretroviral and anti-hepatitis C virus direct-acting antiviral-related hepatotoxicity
    Han H, Agarwal R, Martel-Laferriere V, Dieterich DT. Clin Liver Dis. 2013 Nov;17(4):657-70, ix. doi: 10.1016/j.cld.2013.07.007. Epub 2013 Sep 4.


  429. Boceprevir Plus Peginterferon α-2b/Ribavirin in Chronic Hepatitis C Genotype 1: Impact of Baseline Viral Load on Sustained Virologic Response
    Gordon SC, Reddy KR, Jacobson IM, Poordad F, Bronowicki JP, Bacon B, Buti M, Hu KQ, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Lawitz EJ. J Clin Gastroenterol. 2013 Oct 30. [Epub ahead of print]


  430. Efficacy and safety of peginterferon plus ribavirin for patients aged ≥ 65 years with chronic hepatitis C: A systematic review and meta-analysis
    Yang Z, Zhuang L, Yang L, Liu C, Lu Y, Xu Q, Chen X, Chen L. Clin Res Hepatol Gastroenterol. 2013 Oct 28. pii: S2210-7401(13)00187-3. doi: 10.1016/j.clinre.2013.08.013. [Epub ahead of print]


  431. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients
    Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, Wu MS, Liu YY, Wu CY. Hepatology. 2013 Oct 12. doi: 10.1002/hep.26892. [Epub ahead of print]


  432. Association between vitamin D and hepatitis C virus infection: a meta-analysis
    Villar LM, Del Campo JA, Ranchal I, Lampe E, Romero-Gomez M. World J Gastroenterol. 2013 Sep 21;19(35):5917-24. doi: 10.3748/wjg.v19.i35.5917.


  433. Clinical Outcomes of Hepatitis C Treated with Pegylated Interferon and Ribavirin via Telemedicine Consultation in Northern California
    Rossaro L, Torruellas C, Dhaliwal S, Botros J, Clark G, Li CS, Minoletti MM. Dig Dis Sci. 2013 Dec;58(12):3620-5. doi: 10.1007/s10620-013-2810-y. Epub 2013 Oct 24.


  434. Longitudinal Effects of Selective Serotonin Reuptake Inhibitor Therapy and Cytokine-Related Depression on Hepatitis C Viral Logs During Antiviral Therapy
    Sims OT, Whalen CC, Nackerud LG, Bride BE. J Clin Psychopharmacol. 2013 Oct 16. [Epub ahead of print]


  435. Simeprevir for the treatment of chronic hepatitis C
    You DM, Pockros PJ. Expert Opin Pharmacother. 2013 Dec;14(18):2581-9. doi: 10.1517/14656566.2013.850074. Epub 2013 Oct 19.


  436. "To Share or Not to Share?" Serosorting by Hepatitis C Status in the Sharing of Drug Injection Equipment Among NHBS-IDU2 Participants
    Smith BD, Jewett A, Burt RD, Zibbell JE, Yartel AK, Dinenno E. J Infect Dis. 2013 Dec;208(12):1934-42. doi: 10.1093/infdis/jit520. Epub 2013 Oct 16.


  437. Role of Ritonavir in the Drug Interactions Between Telaprevir and Ritonavir-Boosted Atazanavir
    Gutierrez-Valencia A, Ruiz-Valderas R, Torres-Cornejo A, Viciana P, Espinosa N, Castillo-Ferrando JR, Lopez-Cortes LF. Clin Infect Dis. 2013 Nov 8. [Epub ahead of print]


  438. Hara K, Rivera MM, Koh C, Demino M, Page S, Nagabhyru PR, Rehermann B, Liang TJ, Hoofnagle JH, Heller T. J Infect Dis. 2014 Jan;209(1):38-45. doi: 10.1093/infdis/jit541. Epub 2013 Oct 14.
    Hara K, Rivera MM, Koh C, Demino M, Page S, Nagabhyru PR, Rehermann B, Liang TJ, Hoofnagle JH, Heller T. J Infect Dis. 2014 Jan;209(1):38-45. doi: 10.1093/infdis/jit541. Epub 2013 Oct 14.


  439. Variation of transaminases, HCV-RNA levels and Th1/Th2 cytokine production during the post-partum period in pregnant women with chronic hepatitis C
    Ruiz-Extremera A, Muñoz-Gámez JA, Abril-Molina A, Salmerón-Ruiz MA, Muñoz-de-Rueda P, Pavón-Castillero EJ, Quiles-Pérez R, Carazo A, Gila A, Jimenez-Ruiz SM, Casado J, Martín AB, Sanjuán-Núñez L, Ocete-Hita E, Viota JL, León J, Salmerón J. PLoS One. 2013 Oct 10;8(10):e75613. doi: 10.1371/journal.pone.0075613.


  440. Novel therapeutic approaches for hepatitis C
    Au JS1, Pockros PJ2. Clin Pharmacol Ther. 2013 Jan;95(1):78-88. doi: 10.1038/clpt.2013.206. Epub 2013 Oct 14.


  441. Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease
    García-Monzón C, Lo Iacono O, Crespo J, Romero-Gómez M, García-Samaniego J, Fernández-Bermejo M, Domínguez-Díez A, Rodríguez de Cía J, Sáez A, Porrero JL, Vargas-Castrillón J, Chávez-Jiménez E, Soto-Fernández S, Díaz A, Gallego-Durán R, Madejón A, Miquilena-Colina ME. Eur J Clin Invest. 2014 Jan;44(1):65-73. doi: 10.1111/eci.12192. Epub 2013 Nov 23.


  442. The State of Infectious Diseases Clinical Trials: A Systematic Review of ClinicalTrials.gov
    Goswami ND, Pfeiffer CD, Horton JR, Chiswell K, Tasneem A, Tsalik EL. PLoS One. 2013 Oct 16;8(10):e77086. doi: 10.1371/journal.pone.0077086.


  443. Genetic variation in interleukin 28B and response to antiviral therapy in patients with dual chronic infection with hepatitis B and C viruses
    Guo X, Yang G, Yuan J, Ruan P, Zhang M, Chen X, Zhou B. PLoS One. 2013 Oct 17;8(10):e77911. doi: 10.1371/journal.pone.0077911.


  444. A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers
    Real LM, Caruz A, Rivero-Juarez A, Soriano V, Neukam K, Rivero A, Cifuentes C, Mira JA, Macías J, Pineda JA. Liver Int. 2013 Sep 25. doi: 10.1111/liv.12330. [Epub ahead of print]


  445. Viral evolution explains the associations among hepatitis C virus genotype, clinical outcomes, and human genetic variation
    Rose R, Markov PV, Lam TT, Pybus OG. Infect Genet Evol. 2013 Dec;20:418-21. doi: 10.1016/j.meegid.2013.09.029. Epub 2013 Oct 16.


  446. Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy
    Afdhal NH1, Dusheiko GM2, Giannini EG3, Chen PJ4, Han KH5, Mohsin A6, Rodriguez-Torres M7, Rugina S8, Bakulin I9, Lawitz E10, Shiffman ML11, Tayyab GU12, Poordad F10, Kamel YM13, Brainsky A14, Geib J14, Vasey SY14, Patwardhan R14, Campbell FM13, Theodore D15. Gastroenterology. 2013 Oct 12. pii: S0016-5085(13)01436-4. doi: 10.1053/j.gastro.2013.10.012. [Epub ahead of print]


  447. The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C
    Maasoumy B, Port K, Calle Serrano B, Markova AA, Sollik L, Manns MP, Cornberg M, Wedemeyer H. Aliment Pharmacol Ther. 2013 Dec;38(11-12):1365-72. doi: 10.1111/apt.12523. Epub 2013 Oct 16.


  448. Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents
    Kittner JM, Weiss NM, Wiltink J, Schattenberg JM, Grambihler A, Thieringer F, Weinmann A, Zimmermann T, Koch S, Schuchmann M, Galle PR. Dig Liver Dis. 2013 Oct 11. pii: S1590-8658(13)00424-6. doi: 10.1016/j.dld.2013.08.139. [Epub ahead of print]


  449. Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort
    Aronsohn A, Ancuta I, Caruntu F, Coppola C, Delic D, Digiacomo A, Dusheiko GM, Lengyel G, Marcellin P, Orlandini A, Pruthi J, Silva GF, Tallarico L, Schmitz M, Tatsch F, Korner E, Cheinquer H. J Viral Hepat. 2013 Oct 17. doi: 10.1111/jvh.12179. [Epub ahead of print]


  450. Clinical characteristics, treatment patterns and survival outcome of hepatocellular carcinoma patients aged 70 years or older: a single-center retrospective study from China
    Fan C, Jin G, Sun C, Ma D, Chen C, Qiao P, Wu D. Aging Clin Exp Res. 2013 Oct 16. [Epub ahead of print]


  451. Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study
    Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Aliment Pharmacol Ther. 2013 Nov;38(9):1076-85. doi: 10.1111/apt.12494. Epub 2013 Sep 17.


  452. Liver stiffness predicts hepatocellular carcinoma in chronic hepatitis C patients on interferon-based anti-viral therapy
    Narita Y, Genda T, Tsuzura H, Sato S, Kanemitsu Y, Ishikawa S, Kikuchi T, Hirano K, Iijima K, Wada R, Ichida T. J Gastroenterol Hepatol. 2013 Oct 3. doi: 10.1111/jgh.12401. [Epub ahead of print]


  453. Improved fibrosis staging by elastometry and blood test in chronic hepatitis C
    Calès P, Boursier J, Ducancelle A, Oberti F, Hubert I, Hunault G, de Lédinghen V, Zarski JP, Salmon D, Lunel F; the ANRS HC EP 23 Fibrostar Study. Liver Int. 2013 Sep 19. doi: 10.1111/liv.12327. [Epub ahead of print]


  454. The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection
    Kawaguchi-Suzuki M, Frye RF. Pharmacotherapy. 2013 Sep 30. doi: 10.1002/phar.1349. [Epub ahead of print]


  455. Prevalence of insulin resistance in chronic hepatitis C genotype 1 and 3 patients
    Péres DP, Cheinquer H, Wolf FH, Cheinquer N, Falavigna M, Péres LD. Ann Hepatol. 2013 Nov-Dec;12(6):871-5.


  456. Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with HCV genotype 1b
    Tsubota A, Shimada N, Atsukawa M, Abe H, Kato K, Ika M, Matsudaira H, Nagatsuma K, Matsuura T, Aizawa Y. J Gastroenterol Hepatol. 2013 Oct 3. doi: 10.1111/jgh.12402. [Epub ahead of print]


  457. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4
    Ragheb MM, Nemr NA, Kishk RM, Mandour MF, Abdou MM, Matsuura K, Watanabe T, Tanaka Y. Liver Int. 2013 Sep 16. doi: 10.1111/liv.12321. [Epub ahead of print]


  458. Hepatitis C Virus Genotype 5: Prospective Evaluation of Peginterferon/Ribavirin Treatment Efficacy and Predictive Value of On-treatment Virological Responses for Sustained Virological Response
    Papastergiou V, Skorda L, Lisgos P, Stampori M, Ntetskas G, Papakonstantinou L, Prodromidou K, Karatapanis S. J Clin Gastroenterol. 2013 Oct 4. [Epub ahead of print]


  459. A Double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects
    Gardner S, Cutrell A, Elko-Simms C, Adkison K, Hamatake R, Walker J, Rodriguez-Torres M, Hong Z. Liver Int. 2013 Sep 25. doi: 10.1111/liv.12334. [Epub ahead of print]


  460. Diagnostic accuracy of enhanced liver fibrosis test to assess liver fibrosis in patients with chronic hepatitis C
    Catanzaro R, Milazzo M, Arona S, Sapienza C, Vasta D, Arcoria D, Marotta F. Hepatobiliary Pancreat Dis Int. 2013 Oct;12(5):500-7.


  461. Emerging treatments for hepatitis C
    Flisiak R, Jaroszewicz J, Parfieniuk-Kowerda A. Expert Opin Emerg Drugs. 2013 Dec;18(4):461-75. doi: 10.1517/14728214.2013.847089. Epub 2013 Oct 8.


  462. Antidepressant prophylaxis reduces depression risk but does not improve sustained virological response in hepatitis C interferon recipients without depression at baseline: a systematic review and meta-analysis
    Al-Omari A, Cowan J, Turner L, Cooper C. Can J Gastroenterol. 2013 Oct;27(10):575-81.


  463. Impact of coffee on liver diseases: a systematic review
    Saab S, Mallam D, Cox Ii GA, Tong MJ. Liver Int. 2013 Aug 12. doi: 10.1111/liv.12304. [Epub ahead of print]


  464. Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection
    Macaluso FS, Maida M, Cammà C, Cabibi D, Alessi N, Cabibbo G, Di Marco V, Craxì A, Petta S. Clin Gastroenterol Hepatol. 2013 Oct 7. pii: S1542-3565(13)01507-3. doi: 10.1016/j.cgh.2013.09.059. [Epub ahead of print]


  465. Hepatitis B and C in the armed forces
    Freshwater DA. J R Army Med Corps. 2013 Sep;159(3):169-74. doi: 10.1136/jramc-2013-000096. Epub 2013 Jun 3.


  466. Expanded classification of hepatitis C Virus into 7 genotypes and 67 Subtypes: updated criteria and assignment web resource
    Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. Hepatology. 2013 Oct 1. doi: 10.1002/hep.26744. [Epub ahead of print]


  467. Preparing the patient for success: treat or wait?
    Buti M, Esteban R. Dig Liver Dis. 2013 Sep 30;45 Suppl 5:S332-6. doi: 10.1016/j.dld.2013.07.013.


  468. Safety of direct antiviral agents in real life
    D'Ambrosio R, Colombo M. Dig Liver Dis. 2013 Sep 30;45 Suppl 5:S363-6. doi: 10.1016/j.dld.2013.07.012.


  469. Evaluation of Hepatitis C Virus as a Risk Factor for HIV-Associated Neuroretinal Disorder
    Branch AD, Drye LT, Van Natta ML, Sezgin E, Fishman SL, Dieterich DT, Meinert CL, Jabs DA. Clin Infect Dis. 2013 Dec;57(11):1618-25. doi: 10.1093/cid/cit550. Epub 2013 Sep 30.


  470. Bone marrow suppression or active proliferation? An analysis of neutropenia after pegylated interferon treatment of patients with chronic hepatitis C
    Liu YL, Du XF, Chen XY, Ma LN, Guo DD, Lu JF, Cao ZH, Zhang YH. Scand J Infect Dis. 2013 Dec;45(12):939-43. doi: 10.3109/00365548.2013.835067. Epub 2013 Oct 3.


  471. Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response
    Furusyo N, Ogawa E, Murata M, Toyoda K, Ohnishi H, Eiraku K, Shimizu M, Harada Y, Mitsumoto F, Takayama K, Kainuma M, Okada K, Hayashi J. J Antimicrob Chemother. 2013 Oct 3. [Epub ahead of print]


  472. Risk of nonpsychotic mental disorders development in antiviral-treated mentally healthy chronic hepatitis C patients: A population-based study
    Chang SC, Hung CT, Li SF, Lee HM, Chung YC, Pai LW, Yang SS. J Formos Med Assoc. 2013 Sep 30. pii: S0929-6646(13)00296-9. doi: 10.1016/j.jfma.2013.08.011. [Epub ahead of print]


  473. Treatment of chronic hepatitis C virus infection after liver transplantation
    Agarwal K, Barnabas A. Dig Liver Dis. 2013 Sep 30;45 Suppl 5:S349-54. doi: 10.1016/j.dld.2013.07.014.


  474. Emerging concepts in immunity to hepatitis C virus infection
    Rosen HR. J Clin Invest. 2013 Oct 1;123(10):4121-30. doi: 10.1172/JCI67714. Epub 2013 Oct 1.


  475. Association of the interleukin-28B gene polymorphism with development of hepatitis virus-related hepatocellular carcinoma and liver cirrhosis: a meta-analysis
    Suo GJ, Zhao ZX. Genet Mol Res. 2013 Sep 19;12(3):3708-17. doi: 10.4238/2013.September.19.1.


  476. Host-targeting agents in the treatment of hepatitis C: A beginning and an end?
    Baugh JM, Garcia-Rivera JA, Gallay PA. Antiviral Res. 2013 Nov;100(2):555-61. doi: 10.1016/j.antiviral.2013.09.020. Epub 2013 Sep 30.


  477. Optimizing treatment in HIV/HCV coinfection
    Puoti M, Rossotti R, Travi G, Panzeri C, Morreale M, Chiari E, Cocca G, Orso M, Moioli MC. Dig Liver Dis. 2013 Sep 30;45 Suppl 5:S355-62. doi: 10.1016/j.dld.2013.09.001.


  478. Antiretroviral and anti-hepatitis C virus direct-acting antiviral-related hepatotoxicity
    Han H, Agarwal R, Martel-Laferriere V, Dieterich DT. Clin Liver Dis. 2013 Nov;17(4):657-70, ix. doi: 10.1016/j.cld.2013.07.007. Epub 2013 Sep 4.


  479. Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy
    Chang KC, Wu YY, Hung CH, Lu SN, Lee CM, Chiu KW, Tsai MC, Tseng PL, Huang CM, Cho CL, Chen HH, Hu TH. Br J Cancer. 2013 Oct 29;109(9):2481-8. doi: 10.1038/bjc.2013.564. Epub 2013 Oct 1.


  480. A new subtype of hepatitis C virus genotype 3: analysis of available evidence
    Salehi Moghadam F, Mohebbi SR, Hosseini SM, Damavand B, Zali MR. Hepat Mon. 2013 Aug 17;13(8):e13380. doi: 10.5812/hepatmon.13380


  481. Genotype impact on HCV RNA levels determined with the VERSANT HCV RNA 1.0 assay (kPCR)
    Kessler HH, Hübner M, Konrad PM, Stelzl E, Stübler MM, Baser MH, Santner BI. J Clin Virol. 2013 Nov;58(3):522-7. doi: 10.1016/j.jcv.2013.09.005. Epub 2013 Sep 12.


  482. Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: A longitudinal long-term cohort study
    Kielland KB, Delaveris GJ, Rogde S, Eide TJ, Amundsen EJ, Dalgard O. J Hepatol. 2013 Oct 2. pii: S0168-8278(13)00682-X. doi: 10.1016/j.jhep.2013.09.022. [Epub ahead of print]


  483. The importance of drug-drug interactions in the DAA era
    Back D, Else L. Dig Liver Dis. 2013 Sep 30;45 Suppl 5:S343-8. doi: 10.1016/j.dld.2013.07.008.


  484. Management of anaemia and other treatment complications
    Hézode C. Dig Liver Dis. 2013 Sep 30;45 Suppl 5:S337-42. doi: 10.1016/j.dld.2013.07.010.


  485. High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients
    Yu ML, Dai CY, Huang CF, Lee JJ, Yeh ML, Yeh SM, Kuo HT, Huang JF, Chang JM, Chen HC, Juo SH, Hwang SJ, Chuang WL; FORMOSA-LIKE group. J Hepatol. 2013 Oct 2. pii: S0168-8278(13)00683-1. doi: 10.1016/j.jhep.2013.09.023. [Epub ahead of print]


  486. Influence of vitamin D-related gene polymorphisms (CYP27B and VDR) on the response to interferon/ribavirin therapy in chronic hepatitis C
    García-Martín E, Agúndez JA, Maestro ML, Suárez A, Vidaurreta M, Martínez C, Fernández-Pérez C, Ortega L, Ladero JM. PLoS One. 2013 Sep 20;8(9):e74764. doi: 10.1371/journal.pone.0074764.


  487. Telaprevir-induced, but not pegylated interferon-associated, retinopathy as a noteworthy adverse effect during triple antiviral therapy in patients with chronic hepatitis C
    Sugawara K, Inao M, Nakayama N, Mochida S. J Gastroenterol. 2013 Oct 1. [Epub ahead of print]


  488. Characterization of hepatitis C infection in tuberculosis patients in an urban city in the USA
    Campo M, Shrestha A, Oren E, Thiede H, Duchin J, Narita M, Crothers K. Epidemiol Infect. 2013 Sep 25:1-8. [Epub ahead of print]


  489. Less-established risk factors are common in asian americans with hepatitis C virus: a case-controlled study
    Kin KC, Lin B, Chaung KT, Ha NB, Trinh HN, Garcia RT, Nguyen HA, Nguyen KK, Levitt BS, da Silveira EB, Nguyen MH. Dig Dis Sci. 2013 Nov;58(11):3342-7. doi: 10.1007/s10620-013-2884-6. Epub 2013 Oct 1.


  490. Resistance to HCV nucleoside analogue inhibitors of hepatitis C virus RNA-dependent RNA polymerase
    Najera I. Curr Opin Virol. 2013 Oct;3(5):508-13. doi: 10.1016/j.coviro.2013.08.011. Epub 2013 Sep 24.


  491. Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment
    Brennan BJ, Wang K, Blotner S, Magnusson MO, Wilkins JJ, Martin P, Solsky J, Nieforth K, Wat C, Grippo JF. Antimicrob Agents Chemother. 2013 Dec;57(12):6097-105. doi: 10.1128/AAC.00608-13. Epub 2013 Sep 30.


  492. Discovery of a Novel Series of Potent Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B
    Schoenfeld RC, Bourdet DL, Brameld KA, Chin E, de Vicente J, Fung A, Harris SF, Lee EK, Le Pogam S, Leveque V, Li J, Lui AS, Najera I, Rajyaguru S, Sangi M, Steiner S, Talamas FX, Taygerly JP, Zhao J. J Med Chem. 2013 Oct 10. [Epub ahead of print]


  493. Hepatitis C virus infection, microRNA and liver disease progression
    Shrivastava S, Mukherjee A, Ray RB. World J Hepatol. 2013 Sep 27;5(9):479-486.


  494. Lambda Interferon Serum Levels in Patients with Chronic Hepatitis C Virus Infection According to Their Response to Therapy with Pegylated Interferon and Ribavirin
    Torres C, Brahm J, Venegas M. J Interferon Cytokine Res. 2013 Sep 26. [Epub ahead of print]


  495. Hepatitis C genotype 6: A concise review and response-guided therapy proposal
    Bunchorntavakul C, Chavalitdhamrong D, Tanwandee T. World J Hepatol. 2013 Sep 27;5(9):496-504.


  496. Prevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific region
    Wu S, Kanda T, Nakamoto S, Jiang X, Miyamura T, Nakatani SM, Ono SK, Takahashi-Nakaguchi A, Gonoi T, Yokosuka O. PLoS One. 2013 Sep 17;8(9):e73615. doi: 10.1371/journal.pone.0073615.


  497. Diagnostics and Treatment of Cryoglobulinaemia: It Takes Two to Tango
    Damoiseaux J, Cohen Tervaert JW. Clin Rev Allergy Immunol. 2013 Sep 26. [Epub ahead of print]


  498. The pharmacokinetic evaluation of boceprevir for treatment of Hepatitis C virus
    Shankar H, Bichoupan K, Dieterich DT. Expert Opin Drug Metab Toxicol. 2013 Nov;9(12):1647-57. doi: 10.1517/17425255.2013.840290. Epub 2013 Oct 1.


  499. The discovery and development of boceprevir
    Rotella DP. Expert Opin Drug Discov. 2013 Nov;8(11):1439-47. doi: 10.1517/17460441.2013.843525. Epub 2013 Sep 30.


  500. New triple therapy for chronic hepatitis C: real life clinical experience in a community setting
    Akiyama MJ, Piotrowski JI, Roytman MM, Chan SM, Hong LK, Huddleston L, Trujillo R, Tsai NC. Hawaii J Med Public Health. 2013 Sep;72(9 Suppl 4):6-13.


  501. Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C
    Aizawa N, Enomoto H, Takashima T, Sakai Y, Iwata K, Ikeda N, Tanaka H, Iwata Y, Saito M, Imanishi H, Iijima H, Nishiguchi S. J Gastroenterol. 2013 Sep 25. [Epub ahead of print]


  502. Adapted J6/JFH1-Based Hepatitis C Virus Recombinants with Genotype-Specific NS4A Show Similar Efficacies against Lead Protease Inhibitors, Alpha Interferon, and a Putative NS4A Inhibitor
    Gottwein JM, Jensen SB, Serre SB, Ghanem L, Scheel TK, Jensen TB, Krarup H, Uzcategui N, Mikkelsen LS, Bukh J. Antimicrob Agents Chemother. 2013 Dec;57(12):6034-49. doi: 10.1128/AAC.01176-13. Epub 2013 Sep 23.


  503. Hepatitis C: A mouse at the end of the tunnel
    Binder M, Bartenschlager R. Cell Res. 2013 Sep 24. doi: 10.1038/cr.2013.132. [Epub ahead of print]


  504. Association between insulin resistance and sustained virologic response in hepatitis C treatment, genotypes 1 versus 2 and 3: systematic literature review and meta-analysis
    Laurito MP, Parise ER. Braz J Infect Dis. 2013 Sep-Oct;17(5):555-63. doi: 10.1016/j.bjid.2013.02.009. Epub 2013 Sep 19.


  505. The impact of interleukin 28b gene polymorphism on the virological response to combined pegylated interferon and ribavirin therapy in chronic HCV genotype 4 infected egyptian patients using data mining analysis
    Khairy M, Fouad R, Mabrouk M, El-Akel W, Awad AB, Salama R, Elnegouly M, Shaker O. Hepat Mon. 2013 Jul 17;13(7):e10509. doi: 10.5812/hepatmon.10509.


  506. Predictors of consent to pharmacogenomics testing in the IDEAL study
    Jazwinski AB, Clark PJ, Thompson AJ, Gordon SC, Lawitz EJ, Noviello S, Brass CA, Pedicone LD, Albrecht JK, Sulkowski MS, Muir AJ. Pharmacogenet Genomics. 2013 Nov;23(11):619-23. doi: 10.1097/FPC.0000000000000002.


  507. Histopathologic distinction between fibrosing cholestatic hepatitis C and biliary obstruction
    Salomao M, Verna EC, Lefkowitch JH, Moreira RK. Am J Surg Pathol. 2013 Dec;37(12):1837-44. doi: 10.1097/PAS.0b013e31829b626c.


  508. A 24-Week Treatment Strategy With Pegylated Interferon/Ribavirin in HIV/Hepatitis C Virus Genotype 3-Coinfected Patients Who Achieved a Rapid Virologic Response Results in a High Sustained Virologic Response Rate
    Rivero-Juarez A, López-Cortés LF, Camacho A, Mira JA, Téllez F, Marquez M, Merino D, Pineda JA, Rivero A; for the Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR), part of the Sociedad Andaluza de Enfermedades Infecciosas. Clin Infect Dis. 2013 Oct 21. [Epub ahead of print]


  509. Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study
    Silva GF, Villela-Nogueira CA, Mello CE, Soares EC, Coelho HS, Ferreira PR, Ruiz FJ; Brazilian HCV-Related Advanced Fibrosis Study Group. Braz J Infect Dis. 2013 Sep 20. pii: S1413-8670(13)00202-X. doi: 10.1016/j.bjid.2013.05.007. [Epub ahead of print]


  510. Complexities of HCV management in the new era of direct-acting antiviral agents
    Rosenberg WM, Tanwar S, Trembling P. QJM. 2013 Sep 23. [Epub ahead of print]


  511. Decreased level of intracellular cholesterol in peripheral blood mononuclear cells is associated with chronic hepatitis C virus infection
    Sidorkiewicz M, Grek M, Jozwiak B, Piekarska A. Virus Res. 2013 Dec 26;178(2):539-42. doi: 10.1016/j.virusres.2013.09.019. Epub 2013 Sep 18.


  512. An Association of Virus Infection with Type 2 Diabetes and Alzheimer's Disease
    Karim S, Mirza Z, Kamal MA, Abuzenadah AM, Azhar EI, Al-Qahtani MH, Sohrab SS. CNS Neurol Disord Drug Targets. 2013 Sep 19. [Epub ahead of print]


  513. Development and Validation of a Comorbidity Scoring System for Patients With Cirrhosis
    Jepsen P, Vilstrup H, Lash TL. Gastroenterology. 2013 Sep 18. pii: S0016-5085(13)01347-4. doi: 10.1053/j.gastro.2013.09.019. [Epub ahead of print]


  514. Treatment decisions and contemporary versus pending treatments for hepatitis C
    Trembling PM, Tanwar S, Rosenberg WM, Dusheiko GM.


  515. Is universal screening for hepatitis C infection (HCV) prior to commencing anti-TNF-? therapy necessary?
    Reid CT, De Gascun C, Hall W, Collins P, Lally A, Kirby B. Br J Dermatol. 2013 Aug 21. doi: 10.1111/bjd.12598. [Epub ahead of print]


  516. Targeted hepatitis C screening among ex-injection drug users in the community
    Wong VW, Wong GL, Chim AM, Cheng TF, Cheung SW, Lai CM, Szeto KJ, Tsang S, Wu SH, Yan KK, Hui AY, Yiu DC, Wu BB, Cheung D, Chung CS, Lai CW, Chan HL. J Gastroenterol Hepatol. 2013 Aug 22. doi: 10.1111/jgh.12355. [Epub ahead of print]


  517. MicroRNA profile before and after antiviral therapy in liver transplant recipients for Hepatitis C virus cirrhosis
    Gelley F, Zadori G, Nemes B, Fassan M, Lendvai G, Sarvary E, Doros A, Gerlei Z, Nagy P, Schaff Z, Kiss A. J Gastroenterol Hepatol. 2013 Aug 22. doi: 10.1111/jgh.12362. [Epub ahead of print]


  518. The impact of chronic hepatitis C on resource utilisation and in-patient mortality for Medicare beneficiaries between 2005 and 2010
    Younossi ZM, Stepanova M, Mishra A, Venkatesan C, Henry L, Hunt S. Aliment Pharmacol Ther. 2013 Nov;38(9):1065-75. doi: 10.1111/apt.12485. Epub 2013 Sep 12.


  519. Individualized Therapy for Hepatitis C Infection: Focus on the Interleukin-28B Polymorphism in Directing Therapy
    Lee TH, Tillmann HL, Patel K. Mol Diagn Ther. 2013 Sep 11. [Epub ahead of print]


  520. Hepatitis C virus (HCV) Infection Rate among Seronegative Hemodialysis Patients Screened by Two Methods; HCV Core Antigen and Polymerase Chain Reaction
    Moini M, Ziyaeyan M, Aghaei S, Sagheb MM, Taghavi SA, Moeini M, Jamalidoust M, Hamidpour L. Hepat Mon. 2013 May 30;13(6):e9147. doi: 10.5812/hepatmon.9147.


  521. Noninvasive assessment of liver fibrosis in patients with chronic hepatitis C (and congenital bleeding disorders): where do we stand?
    Coppola A, Di Capua M, Conca P, Cimino E, Tufano A, Cerbone AM, Di Minno G, Tarantino G. Semin Thromb Hemost. 2013 Oct;39(7):803-15. doi: 10.1055/s-0033-1354421. Epub 2013 Sep 10.


  522. Protective effects of higher cognitive reserve for neuropsychological and daily functioning among individuals infected with hepatitis C
    Sakamoto M, Woods SP, Kolessar M, Kriz D, Anderson JR, Olavarria H, Sasaki AW, Chang M, Flora KD, Loftis JM, Huckans M. J Neurovirol. 2013 Oct;19(5):442-51. doi: 10.1007/s13365-013-0196-4. Epub 2013 Sep 10.


  523. Investigation of the factors associated with circulating soluble CD36 levels in patients with HCV-related chronic liver disease
    Himoto T, Tani J, Miyoshi H, Morishita A, Yoneyama H, Kurokohchi K, Inukai M, Masugata H, Goda F, Senda S, Haba R, Ueno M, Yamaoka G, Masaki T. Diabetol Metab Syndr. 2013 Sep 9;5(1):51. [Epub ahead of print]


  524. Birth cohort testing for hepatitis C virus: implications for clinical social workers in health care settings
    Sims OT, Whalen CC, Nackerud LG, Bride BE. Soc Work Health Care. 2013;52(8):689-703. doi: 10.1080/00981389.2013.806385.


  525. The ins and outs of hepatitis C virus entry and assembly
    Lindenbach BD, Rice CM. Nat Rev Microbiol. 2013 Oct;11(10):688-700. doi: 10.1038/nrmicro3098. Epub 2013 Sep 10.


  526. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
    Karino Y, Ozeki I, Hige S, Kimura M, Arakawa T, Nakajima T, Kuwata Y, Sato T, Ohmura T, Toyota J. J Viral Hepat. 2013 Aug 25. doi: 10.1111/jvh.12162. [Epub ahead of print]


  527. Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration
    Castera L, Winnock M, Pambrun E, Paradis V, Perez P, Loko MA, Asselineau J, Dabis F, Degos F, Salmon D. HIV Med. 2013 Sep 6. doi: 10.1111/hiv.12082. [Epub ahead of print]


  528. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study
    Hayashi N, Seto C, Kato M, Komada Y, Goto S. J Gastroenterol. 2013 Sep 5. [Epub ahead of print]


  529. Development and initial psychometric evaluation of the hepatitis C virus-patient-reported outcomes (HCV-PRO) instrument
    Anderson RT, Baran RW, Dietz B, Kallwitz E, Erickson P, Revicki DA. Qual Life Res. 2013 Sep 5. [Epub ahead of print]


  530. Hepatitis C virus-associated thrombocytopenia in pregnancy: impact upon multidisciplinary care provision
    Monteith C, Ainle FN, Cooley S, Lambert JS, Kelleher B, Jackson V, Eogan M. J Perinat Med. 2013 Sep 4:1-4. doi: 10.1515/jpm-2013-0080. [Epub ahead of print]


  531. All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear)
    Lawitz EJ, Rodriguez-Torres M, Denning J, Mathias A, Mo H, Gao B, Cornpropst MT, Berrey MM, Symonds WT. J Viral Hepat. 2013 Oct;20(10):699-707. doi: 10.1111/jvh.12091. Epub 2013 Mar 31.


  532. Hepatitis C Virus Induces Interleukin-1? (IL-1?)/IL-18 in Circulatory and Resident Liver Macrophages
    Shrivastava S, Mukherjee A, Ray R, Ray RB. J Virol. 2013 Nov;87(22):12284-90. doi: 10.1128/JVI.01962-13. Epub 2013 Sep 4.


  533. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons
    Yu M, Corsa AC, Xu S, Peng B, Gong R, Lee YJ, Chan K, Mo H, Delaney W 4th, Cheng G. Antiviral Res. 2013 Nov;100(2):439-45. doi: 10.1016/j.antiviral.2013.08.018. Epub 2013 Sep 5.


  534. Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3
    Tapper EB, Afdhal NH. J Viral Hepat. 2013 Oct;20(10):669-77. doi: 10.1111/jvh.12168.


  535. Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected patients
    Saludes V, Bascuñana E, Jordana-Lluch E, Casanovas S, Ardèvol M, Soler E, Planas R, Ausina V, Martró E. PLoS One. 2013 Aug 28;8(8):e72600. doi: 10.1371/journal.pone.0072600.


  536. Antidepressant Pretreatment for the Prevention of Interferon Alfa-Associated Depression: A Systematic Review and Meta-Analysis
    Sarkar S, Schaefer M. Psychosomatics. 2013 Sep 4. pii: S0033-3182(13)00130-8. doi: 10.1016/j.psym.2013.06.015. [Epub ahead of print]


  537. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents
    Conteduca V, Sansonno D, Russi S, Pavone F, Dammacco F. J Infect. 2013 Sep 4. pii: S0163-4453(13)00251-X. doi: 10.1016/j.jinf.2013.08.019. [Epub ahead of print]


  538. Viral Breakthrough Is Associated With Resistance Using Direct Acting Agents in Patients Treated for Chronic Hepatitis C Infection
    Zhou K, Ferguson J, Bau S, Saab S. J Clin Gastroenterol. 2013 Sep 16. [Epub ahead of print]


  539. Knowledge and attitudes about hepatitis C virus (HCV) infection and its treatment in HCV mono-infected and HCV/HIV co-infected adults
    Chen EY, North CS, Fatunde O, Bernstein I, Salari S, Day B, Jain MK. J Viral Hepat. 2013 Oct;20(10):708-14. doi: 10.1111/jvh.12095. Epub 2013 Apr 1.


  540. Locations and reasons for initial testing for hepatitis C infection--chronic hepatitis cohort study, United States, 2006-2010
    Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2013 Aug 16;62(32):645-8.


  541. Prevalence of type 2 diabetes mellitus in hepatitis C virus infected population: a Southeast Asian study
    Memon MS, Arain ZI, Naz F, Zaki M, Kumar S, Burney AA. J Diabetes Res. 2013;2013:539361. doi: 10.1155/2013/539361. Epub 2013 Aug 1.


  542. Spleen stiffness correlates with the presence of ascites but not esophageal varices in chronic hepatitis C patients
    Mori K, Arai H, Abe T, Takayama H, Toyoda M, Ueno T, Sato K. Biomed Res Int. 2013;2013:857862. doi: 10.1155/2013/857862. Epub 2013 Aug 1.


  543. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial
    Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, Sneller M, Kohli A, Barrett L, Proschan M, Herrmann E, Shivakumar B, Gu W, Kwan R, Teferi G, Talwani R, Silk R, Kotb C, Wroblewski S, Fishbein D, Dewar R, Highbarger H, Zhang X, Kleiner D, Wood BJ, Chavez J, Symonds WT, Subramanian M, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S. JAMA. 2013 Aug 28;310(8):804-11. doi: 10.1001/jama.2013.109309.


  544. A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C
    Gentile I, Coppola N, Pasquale G, Liuzzi R, D'Armiento M, Di Lorenzo ME, Capoluongo N, Buonomo AR, Sagnelli E, Morisco F, Caporaso N, Borgia G. Hepat Mon. 2013 May 8;13(5):e8352. doi: 10.5812/hepatmon.8352. eCollection 2013.


  545. Metabolic factors and chronic hepatitis C: a complex interplay
    Macaluso FS, Maida M, Minissale MG, Li Vigni T, Attardo S, Orlando E, Petta S. Biomed Res Int. 2013;2013:564645. doi: 10.1155/2013/564645. Epub 2013 Jul 17.


  546. Dynamics of serum metabolites in patients with chronic hepatitis C receiving pegylated interferon plus ribavirin: A metabolomics analysis
    Saito T, Sugimoto M, Igarashi K, Saito K, Shao L, Katsumi T, Tomita K, Sato C, Okumoto K, Nishise Y, Watanabe H, Tomita M, Ueno Y, Soga T. Metabolism. 2013 Nov;62(11):1577-86. doi: 10.1016/j.metabol.2013.07.002. Epub 2013 Aug 15.


  547. Many Patients with IL28B Genotypes Associated with Response to Therapy are Ineligible for Treatment Because of Comorbidities
    Kanwal F, White DL, Tavakoli-Tabasi S, Jiao L, Lin D, Ramsey DJ, Spiegelman A, Kuzniarek J, El-Serag HB. Clin Gastroenterol Hepatol. 2013 Aug 23. pii: S1542-3565(13)01236-6. doi: 10.1016/j.cgh.2013.08.034. [Epub ahead of print]


  548. Association of the IFNL4-?G Allele With Impaired Spontaneous Clearance of Hepatitis C Virus
    Aka PV, Kuniholm MH, Pfeiffer RM, Wang AS, Tang W, Chen S, Astemborski J, Plankey M, Villacres MC, Peters MG, Desai S, Seaberg EC, Edlin BR, Strickler HD, Thomas DL, Prokunina-Olsson L, Sharp GB, O'Brien TR. J Infect Dis. 2013 Sep 4. [Epub ahead of print]


  549. Fibrosis evaluation by transient elastography in patients with long-term sustained HCV clearance
    Calvaruso V, Di Marco V, Ferraro D, Petta S, Calì A, Grazia Bavetta M, Conte E, Luigi Almasio P. Hepat Mon. 2013 May 11;13(5):e7176. doi: 10.5812/hepatmon.7176. eCollection 2013.


  550. Pretreatment predictive factors for hepatitis C therapy outcome: relevance of anti-E1E2 antibodies compared to IP-10 and IL28B genotypes
    Arnaud C, Pradat P, Spaziante M, Berthillon P, Maynard M, Taliani G, Chemin I, Trépo C, Petit MA. Antivir Ther. 2013 Aug 15. doi: 10.3851/IMP2671. [Epub ahead of print]


  551. Life-Threatening Cryoglobulinemic Patients With Hepatitis C: Clinical Description and Outcome of 279 Patients
    Retamozo S, Díaz-Lagares C, Bosch X, Bové A, Brito-Zerón P, Gómez ME, Yagüe J, Forns X, Cid MC, Ramos-Casals M. Medicine (Baltimore). 2013 Aug 22. [Epub ahead of print]


  552. Impact of Cryoglobulinemic Syndrome on the Outcome of Chronic Hepatitis C Virus Infection: A 15-Year Prospective Study
    Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F, Sansonno D. Medicine (Baltimore). 2013 Aug 26. [Epub ahead of print]


  553. The role of chemokines in acute and chronic hepatitis C infection
    Fahey S, Dempsey E, Long A. Cell Mol Immunol. 2013 Aug 19. doi: 10.1038/cmi.2013.37. [Epub ahead of print]


  554. Evaluation of commercialized rapid diagnostic testing for some Hepatitis B biomarkers in an area of intermediate endemicity
    El-Ghitany EM, Farghaly AG. J Virol Methods. 2013 Sep 1;194(1-2):190-193. doi: 10.1016/j.jviromet.2013.08.026. [Epub ahead of print]


  555. The End-of-Treatment Ribavirin Concentration Predicts Hepatitis C Virus Relapse
    Bodeau S, Durand-Maugard C, Lemaire-Hurtel AS, François C, Castelain S, Helle F, Andréjak M, Nguyen-Khac E, Duverlie G, Brochot E. Ther Drug Monit. 2013 Aug 12. [Epub ahead of print]


  556. HCV infected prisoners: should they be still considered a difficult to treat population?
    Iacomi F, Iannicelli G, Franceschini A, Migliorisi P, Rosati S, Piselli P, Scognamiglio P, De Carli G, Marcellini S, Palmieri F. BMC Infect Dis. 2013 Aug 14;13:374. doi: 10.1186/1471-2334-13-374.


  557. Effects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C--a randomized trial
    Rusu E, Jinga M, Enache G, Rusu F, Dragomir AD, Ancuta I, Dragu? R, Parpala C, Nan R, Sima I, Ateia S, Stoica V, Che?a DM, Radulian G. Nutr J. 2013 Aug 14;12:119. doi: 10.1186/1475-2891-12-119.


  558. IL28B gene polymorphisms and US liver fatty changes in patients who spontaneously cleared hepatitis C virus infection
    Taliani G, Spaziante M, Biliotti E, Borro M, Palazzo D, Grieco S, Franchi C, Iaiani G, Furlan C, Gallinaro V, Simmaco M. PLoS One. 2013 Aug 1;8(8):e67301. doi: 10.1371/journal.pone.0067301. Print 2013.


  559. Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients
    Aghemo A, Degasperi E, Rumi MG, Galmozzi E, Valenti L, De Francesco R, De Nicola S, Cheroni C, Grassi E, Colombo M. Biomed Res Int. 2013;2013:580796. doi: 10.1155/2013/580796. Epub 2013 Jul 9.


  560. Pathological characteristics of patients who develop hepatocellular carcinoma with negative results of both serous hepatitis B surface antigen and hepatitis C virus antibody
    Kondo R, Nakashima O, Sata M, Imazeki F, Yokosuka O, Tanikawa K, Kage M, Yano H; The Liver Cancer Study Group of Kyushu. Hepatol Res. 2013 Aug 13. doi: 10.1111/hepr.12219. [Epub ahead of print]


  561. Interferon-stimulated genes and their role in controlling hepatitis C virus
    Metz P, Reuter A, Bender S, Bartenschlager R. J Hepatol. 2013 Aug 8. pii: S0168-8278(13)00548-5. doi: 10.1016/j.jhep.2013.07.033. [Epub ahead of print]


  562. Faldaprevir and deleobuvir for HCV genotype 1 infection
    Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Müllhaupt B, Schuchmann M, Bourlière M, Buti M, Roberts SK, Gane EJ, Stern JO, Vinisko R, Kukolj G, Gallivan JP, Böcher WO, Mensa FJ. N Engl J Med. 2013 Aug 15;369(7):630-9. doi: 10.1056/NEJMoa1213557.


  563. Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection
    Nishiguchi S, Sakai Y, Kuboki M, Tsunematsu S, Urano Y, Sakamoto W, Tsuda Y, Steinmann G, Omata M. Liver Int. 2013 Jun 19. doi: 10.1111/liv.12254. [Epub ahead of print]


  564. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons
    Martin NK, Hickman M, Miners A, Hutchinson SJ, Taylor A, Vickerman P. BMJ Open. 2013 Aug 13;3(8). pii: e003153. doi: 10.1136/bmjopen-2013-003153.


  565. Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV-infected cirrhotic patients by 2-D DIGE
    Ferrín G, Ranchal I, Llamoza C, Rodríguez-Perálvarez ML, Romero-Ruiz A, Aguilar-Melero P, López-Cillero P, Briceño J, Muntané J, Montero-Álvarez JL, De la Mata M. Liver Int. 2013 Jul 22. doi: 10.1111/liv.12277. [Epub ahead of print]


  566. Efficacy and tolerance of telaprevir in HIV-hepatitis C virus genotype 1-coinfected patients failing previous antihepatitis C virus therapy: 24-week results
    Lacombe K, Valin N, Stitou H, Gozlan J, Thibault V, Boyd A, Poirier JM, Meynard JL, Valantin MA, Bottero J, Girard PM. AIDS. 2013 May 15;27(8):1356-9. doi: 10.1097/QAD.0b013e32836138d0.


  567. AST/ALT ratio is not an index of liver fibrosis in chronic hepatitis C when aminotransferase activities are determinate according to the international recommendations
    Guéchot J, Boisson RC, Zarski JP, Sturm N, Calès P, Lasnier E; the ANRS HCEP 23 Fibrostar Group. Clin Res Hepatol Gastroenterol. 2013 Aug 7. pii: S2210-7401(13)00146-0. doi: 10.1016/j.clinre.2013.07.003. [Epub ahead of print]


  568. Polypharmacy and Comorbidity Are Associated with a Lower Early Virologic Response in Hepatitis C Patients Treated with First Generation Protease Inhibitor Triple Therapy: A Preliminary Analysis
    Juneja M, Euliano R, Satoskar R, Lewis JH. Dig Dis Sci. 2013 Aug 8. [Epub ahead of print]


  569. Association Between Facility Characteristics and the Process of Care Delivered to Patients with Hepatitis C Virus Infection
    Kanwal F, Hoang T, Chrusciel T, Kramer JR, El-Serag HB, Durfee J, Dominitz JA, Yano EM, Asch SM. Dig Dis Sci. 2013 Aug 10. [Epub ahead of print]


  570. The impact of network medicine in gastroenterology and hepatology
    Baffy G. Clin Gastroenterol Hepatol. 2013 Oct;11(10):1240-4. doi: 10.1016/j.cgh.2013.07.033. Epub 2013 Aug 7.


  571. Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C
    Brochot E, Riachi G, Plantier JC, Guillemard C, Vabret A, Mathurin P, Nguyen-Khac E, Duverlie G; G4 group. J Med Virol. 2013 Jul;85(7):1191-8. doi: 10.1002/jmv.23592.


  572. Health related quality of life among patients with chronic hepatitis C: a cross-sectional study of sociodemographic, psychopathological and psychiatric determinants
    Fábregas BC, de Ávila RE, Faria MN, Moura AS, Carmo RA, Teixeira AL. Braz J Infect Dis. 2013 Jul 31. pii: S1413-8670(13)00167-0. doi: 10.1016/j.bjid.2013.03.008. [Epub ahead of print]


  573. Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients
    Petta S, Marchesini G, Caracausi L, Macaluso FS, Cammà C, Ciminnisi S, Cabibi D, Porcasi R, Craxì A, Di Marco V. J Hepatol. 2013 Aug 6. pii: S0168-8278(13)00553-9. doi: 10.1016/j.jhep.2013.07.037. [Epub ahead of print]


  574. NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection
    Herbst DA, Reddy KR. Expert Opin Investig Drugs. 2013 Oct;22(10):1337-46. doi: 10.1517/13543784.2013.826189. Epub 2013 Aug 9.


  575. Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection-A Randomized Trial
    Poordad F, Lawitz E, Reddy KR, Afdhal NH, Hézode C, Zeuzem S, Lee SS, Calleja JL, Brown RS Jr, Craxi A, Wedemeyer H, Nyberg L, Nelson DR, Rossaro L, Balart L, Morgan TR, Bacon BR, Flamm SL, Kowdley KV, Deng W, Koury KJ, Pedicone LD, Dutko FJ, Burroughs MH, Alves K, Wahl J, Brass CA, Albrecht JK, Sulkowski MS; Protocol 6086 Investigators. Gastroenterology. 2013 Nov;145(5):1035-1044.e5. doi: 10.1053/j.gastro.2013.07.051. Epub 2013 Aug 4.


  576. Determination of telaprevir in plasma of HCV-infected patients by HPLC-UV
    Tempestilli M, Milano E, D'Offizi G, Montalbano M, D'Avolio A, Gasperi T, Narciso P, Ascenzi P, Pucillo LP. IUBMB Life. 2013 Sep;65(9):800-5. doi: 10.1002/iub.1197. Epub 2013 Jul 29.


  577. Hepatitis C virus induced up-regulation of microRNA-27: A novel mechanism for hepatic steatosis
    Singaravelu R, Chen R, Lyn RK, Jones DM, O'Hara S, Rouleau Y, Cheng J, Srinivasan P, Nasheri N, Russell RS, Lorne D, Pezacki JP. Hepatology. 2013 Jul 29. doi: 10.1002/hep.26634. [Epub ahead of print]


  578. A Unique Model for Treating Chronic Hepatitis C in Patients With Psychiatric Disorders, Substance Abuse, and/or Housing Instability
    Ho CJ, Preston C, Fredericks K, Doorley SL, Kramer RJ, Kwan L, Kamal A. J Addict Med. 2013 September/October;7(5):320-324.



  579. Brunings P, Klar S, Butt G, Nijkamp MD, Buxton JA. Gastroenterol Nurs. 2013 Jul-Aug;36(4):249-57. doi: 10.1097/SGA.0b013e31829f3f9e.


  580. Antiviral activity and resistance of HCV NS5A replication complex inhibitors
    Gao M. Curr Opin Virol. 2013 Oct;3(5):514-520. doi: 10.1016/j.coviro.2013.06.014. Epub 2013 Jul 27.


  581. Effects of metabolic syndrome on fibrosis in chronic viral hepatitis
    Yoon H, Lee JG, Yoo JH, Son MS, Kim DY, Hwang SG, Rim KS. Gut Liver. 2013 Jul;7(4):469-74. doi: 10.5009/gnl.2013.7.4.469. Epub 2013 Jun 20.


  582. Iron and proinflammatory cytokines in chronic hepatitis C virus infection
    López-Prieto J, González-Reimers E, Alemán-Valls MR, de la Vega-Prieto MJ, Abreu-González P, Pelazas-González R, Hernández-Luis R, Jorge-Ripper C, Santolaria-Fernández F. Biol Trace Elem Res. 2013 Oct;155(1):5-10. doi: 10.1007/s12011-013-9760-2. Epub 2013 Jul 28.


  583. Efficacy and Safety of Treatment of Hepatitis C in Patients With Inflammatory Bowel Disease
    Allen AM, Kim WR, Larson J, Loftus EV Jr. Clin Gastroenterol Hepatol. 2013 Jul 23. pii: S1542-3565(13)01055-0. doi: 10.1016/j.cgh.2013.07.014. [Epub ahead of print]


  584. Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GSK2336805, an Inhibitor of Hepatitis C Virus (HCV) NS5A, in Healthy Subjects and Subjects Chronically Infected with HCV Genotype 1
    Wilfret DA, Walker J, Adkison KK, Jones LA, Lou Y, Gan J, Castellino S, Moseley CL, Horton J, de Serres M, Culp A, Goljer I, Spreen W.


  585. The role of ultrasound elastographic techniques in chronic liver disease: Current status and future perspectives
    Piscaglia F, Marinelli S, Bota S, Serra C, Venerandi L, Leoni S, Salvatore V. Eur J Radiol. 2013 Jul 23. pii: S0720-048X(13)00326-4. doi: 10.1016/j.ejrad.2013.06.009. [Epub ahead of print]


  586. Vitamin D in liver diseases: from mechanisms to clinical trials
    Han YP, Kong M, Zheng S, Ren Y, Zhu L, Shi H, Duan Z. J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:49-55. doi: 10.1111/jgh.12016.


  587. Anesthetic management of totally robotic right lobe living-donor hepatectomy: new tools ask for perioperative care
    Martucci G, Burgio G, Spada M, Arcadipane AF. Eur Rev Med Pharmacol Sci. 2013 Jul;17(14):1974-7.


  588. Nucleotide prodrugs for the treatment of HCV infection
    Sofia MJ. Adv Pharmacol. 2013;67:39-73. doi: 10.1016/B978-0-12-405880-4.00002-0.


  589. Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment
    Paul D, Hoppe S, Saher G, Krijnse-Locker J, Bartenschlager R. J Virol. 2013 Oct;87(19):10612-27. doi: 10.1128/JVI.01370-13. Epub 2013 Jul 24.


  590. Hepatic stellate cells, liver innate immunity, and hepatitis C virus
    Wang Y, Li J, Wang X, Sang M, Ho W. J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:112-5. doi: 10.1111/jgh.12023.


  591. Characterization of Hepatitis C Virus Resistance from a Multiple Dose Clinical Trial of the novel NS5A Inhibitor GS-5885
    Wong KA, Worth A, Martin R, Svarovskaia E, Brainard DM, Lawitz E, Miller MD, Mo H. Antimicrob Agents Chemother. 2013 Jul 22. [Epub ahead of print]


  592. Viral Resistance in Hepatitis C Virus Genotype 1-Infected Patients Receiving the NS3 Protease Inhibitor Faldaprevir (BI 201335) in a Phase 1b Multiple-Rising-Dose Study
    Berger KL, Lagacé L, Triki I, Cartier M, Marquis M, Lawetz C, Bethell R, Scherer J, Kukolj G. Antimicrob Agents Chemother. 2013 Oct;57(10):4928-36. doi: 10.1128/AAC.00822-13. Epub 2013 Jul 22.


  593. Hepatitis C screening beyond CDC guidelines in an Egyptian immigrant community
    Perumalswami PV, Miller FD, Orabee H, Regab A, Adams M, Kapelusznik L, Aljibawi F, Pagano W, Tong V, Dieterich DT. Liver Int. 2013 Jun 22. doi: 10.1111/liv.12259. [Epub ahead of print]


  594. What are the costs and benefits of patient notification exercises following poor infection control practices in dentistry?
    Close RM, Gray S, Bennett S, Appleby S, Khan F, Payne C, Oliver I. Public Health. 2013 Jul 20. pii: S0033-3506(13)00164-9. doi: 10.1016/j.puhe.2013.04.029. [Epub ahead of print]


  595. Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor
    Pearlman BL, Ehleben C. Hepatology. 2013 Jul 19. doi: 10.1002/hep.26624. [Epub ahead of print]


  596. Explaining differences in hepatitis C between U.S. veterans and nonveterans in treatment for substance abuse: results from a regression decomposition
    Heslin KC, Guerrero EG, Mitchell MN, Afable MK, Dobalian A. Subst Use Misuse. 2013 Jul;48(10):854-62. doi: 10.3109/10826084.2013.808222.


  597. Perioperative blood transfusion affects hepatitis C virus (HCV)-specific immune responses and outcome following liver transplantation in HCV-infected patients
    Subramanian V, Bharat A, Vachharajani N, Crippin J, Shenoy S, Mohanakumar T, Chapman WC. HPB (Oxford). 2013 Jul 22. doi: 10.1111/hpb.12128. [Epub ahead of print]


  598. A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C
    Hara T, Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Kumada H. J Med Virol. 2013 Oct;85(10):1746-53. doi: 10.1002/jmv.23673. Epub 2013 Jul 16.


  599. A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail
    Morcos PN, Chang L, Kulkarni R, Giraudon M, Shulman N, Brennan BJ, Smith PF, Tran JQ. Eur J Clin Pharmacol. 2013 Jul 20. [Epub ahead of print]


  600. Assessment of health-related quality of life predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C
    Matsushita H, Ikeda F, Iwasaki Y, Seki H, Nanba S, Takeuchi Y, Moritou Y, Yasunaka T, Onishi H, Miyake Y, Takaki A, Nouso K, Yamamoto K. J Gastroenterol Hepatol. 2013 Jul 22. doi: 10.1111/jgh.12337. [Epub ahead of print]


  601. Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C
    Stättermayer AF, Rutter K, Beinhardt S, Wrba F, Scherzer TM, Strasser M, Hofer H, Steindl-Munda P, Trauner M, Ferenci P. Liver Int. 2013 Jun 27. doi: 10.1111/liv.12269. [Epub ahead of print]


  602. Molecular evolution in court: analysis of a large hepatitis C virus outbreak from an evolving source
    González-Candelas F, Bracho MA, Wróbel B, Moya A. BMC Biol. 2013 Jul 19;11:76. doi: 10.1186/1741-7007-11-76.


  603. Direct Acting Antiviral Agents and the Path to Interferon Independence
    Schmidt WN, Nelson DR, Pawlotsky JM, Sherman KE, Thomas DL, Chung RT. Clin Gastroenterol Hepatol. 2013 Jul 17. pii: S1542-3565(13)01036-7. doi: 10.1016/j.cgh.2013.06.024. [Epub ahead of print]


  604. Increased baseline proinflammatory cytokine production in chronic hepatitis C patients with rapid virological response to peginterferon plus ribavirin
    Par G, Szereday L, Berki T, Palinkas L, Halasz M, Miseta A, Hegedus G, Szekeres-Bartho J, Vincze A, Hunyady B, Par A. PLoS One. 2013 Jul 9;8(7):e67770. doi: 10.1371/journal.pone.0067770. Print 2013.


  605. Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations
    Romero-Gómez M, Berenguer M, Molina E, Calleja JL. J Hepatol. 2013 Jul 15. pii: S0168-8278(13)00461-3. doi: 10.1016/j.jhep.2013.07.014. [Epub ahead of print]


  606. Management algorithm for genotype 1 hepatitis C virus
    Kim AY. F1000Prime Rep. 2013 Jul 1;5:24. doi: 10.12703/P5-24. Print 2013.


  607. Vitamin D status and serum ferritin concentration in chronic hepatitis C virus type 1 infection
    Amanzada A, Goralczyk AD, Moriconi F, van Thiel DH, Ramadori G, Mihm S.


  608. Temperature rise after peginterferon alfa-2a injection in patients with chronic hepatitis C is associated with virological response and is modulated by IL28B genotype
    Han H, Noureddin M, Witthaus M, Park YJ, Hoofnagle JH, Liang TJ, Rotman Y. J Hepatol. 2013 Jul 10. pii: S0168-8278(13)00451-0. doi: 10.1016/j.jhep.2013.07.004. [Epub ahead of print]


  609. Excellent liver retransplantation outcomes in hepatitis C-infected recipients
    Kressel A, Therapondos G, Bohorquez H, Borg B, Bruce D, Carmody I, Cohen A, Girgrah N, Joshi S, Reichman T, Loss GE. Clin Transplant. 2013 Jul;27(4):E512-20. doi: 10.1111/ctr.12182. Epub 2013 Jul 16.


  610. Hepatitis C virus screening and management of seroconversions in hemodialysis facilities
    Mbaeyi C, Thompson ND. Semin Dial. 2013 Jul-Aug;26(4):439-46. doi: 10.1111/sdi.12097. Epub 2013 May 31.


  611. Antiviral Effect, Safety, and Pharmacokinetics of Five-Day Oral Administration of Deleobuvir (BI 207127), an Investigational Hepatitis C Virus RNA Polymerase Inhibitor, in Patients with Chronic Hepatitis C
    Larrey D, Lohse AW, Trepo C, Bronowicki JP, Arastéh K, Bourlière M, Calleja JL, Stern JO, Nehmiz G, Abdallah N, Berger KL, Marquis M, Steffgen J, Kukolj G; BI 207127 Study Group. Antimicrob Agents Chemother. 2013 Oct;57(10):4727-35. doi: 10.1128/AAC.00565-13. Epub 2013 Jul 15.


  612. Development of boceprevir: a first-in-class direct antiviral treatment for chronic hepatitis C infection
    Hazuda DJ, Burroughs M, Howe AY, Wahl J, Venkatraman S. Ann N Y Acad Sci. 2013 Jul;1291:69-76. doi: 10.1111/nyas.12218.


  613. A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection
    Beinhardt S, Payer BA, Datz C, Strasser M, Maieron A, Dorn L, Grilnberger-Franz E, Dulic-Lakovic E, Stauber R, Laferl H, Aberle JH, Holzmann H, Krall C, Vogel W, Ferenci P, Hofer H. J Hepatol. 2013 Jul 10. pii: S0168-8278(13)00446-7. doi: 10.1016/j.jhep.2013.06.028. [Epub ahead of print]


  614. In a 'real-world', clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellualr carcimona, with better tolerance and similar survival
    Shingina A, Hashim AM, Haque M, Suen M, Yoshida EM, Gill S, Donnellan F, Weiss AA. Can J Gastroenterol. 2013 Jul;27(7):393-6.


  615. Sorafenib Alone versus Sorafenib Combined with Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: Results of Propensity Score Analyses
    Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, Kang YK, Shin YM, Kim KM, Lim YS, Lee HC. Radiology. 2013 Jul 17. [Epub ahead of print]


  616. High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen
    Cachay ER, Wyles DL, Torriani FJ, Ballard C, Colwell B, Lin JC, Hill L, Mathews WC. AIDS. 2013 Jul 24. [Epub ahead of print]


  617. A Novel Promising Therapeutic Option Against Hepatitis C Virus: An Oral Nucleotide NS5B Polymerase Inhibitor Sofosbuvir
    Gentile I, Borgia F, Buonomo AR, Castaldo G, Borgia G. Curr Med Chem. 2013;20(30):3733-42.


  618. Interpreting discordant indirect and multiple treatment comparison meta-analyses: an evaluation of direct acting antivirals for chronic hepatitis C infection
    Druyts E, Thorlund K, Humphreys S, Lion M, Cooper CL, Mills EJ. Clin Epidemiol. 2013 Jun 20;5:173-83. doi: 10.2147/CLEP.S44273. Print 2013.


  619. Association of IL28B polymorphisms with virological response to peginterferon and ribavirin therapy in children and adolescents with chronic hepatitis C
    Tajiri H, Tanaka Y, Takano T, Suzuki M, Abukawa D, Miyoshi Y, Shimizu T, Brooks S. Hepatol Res. 2013 Jul 11. doi: 10.1111/hepr.12206. [Epub ahead of print]


  620. Factors contributing to health disparities in liver transplantation in a Hispanic population
    Rivera MN, Jowsey S, Alsina AE, Torres EA. P R Health Sci J. 2012 Dec;31(4):199-204.


  621. Predictive factors of risk of hepatocellular carcinoma in chronic hepatitis C
    Gavilán JC, Ojeda G, Arnedo R, Puerta S. Eur J Intern Med. 2013 Jul 9. pii: S0953-6205(13)00175-1. doi: 10.1016/j.ejim.2013.06.010. [Epub ahead of print]


  622. Effect of hepatitis C virus infection on erythropoiesis in patients on hemodialysis
    Saifan C, El-Charabaty E, Kleiner M, El-Sayegh S. Int J Nephrol Renovasc Dis. 2013 Jun 28;6:121-4. doi: 10.2147/IJNRD.S44656. Print 2013.


  623. Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectives
    Chae HB, Park SM, Youn SJ. ScientificWorldJournal. 2013 Jun 5;2013:704912. doi: 10.1155/2013/704912.


  624. Various predictors of sustained virologic response in different age groups of patients with genotype-1 chronic hepatitis C
    Lin CY, Sheen IS, Chen JY, Huang CW, Huang CH, Jeng WJ, Chen WT. J Clin Gastroenterol. 2013 Oct;47(9):794-9. doi: 10.1097/MCG.0b013e31829d2064.


  625. Current progress in development of hepatitis C virus vaccines
    Liang TJ. Nat Med. 2013 Jul;19(7):869-78. doi: 10.1038/nm.3183.


  626. Splenectomy prior to antiviral therapy in patients with hepatitis C virus related decompensated cirrhosis
    Ji F, Zhang S, Huang N, Deng H, Li Z. Braz J Infect Dis. 2013 Jul 2. pii: S1413-8670(13)00146-3. doi: 10.1016/j.bjid.2013.02.004. [Epub ahead of print]


  627. Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection
    Sagrini E, Ardoino I, Marano G, Gianstefani A, Orlandini A, Sebastiani G, Donati G, Cucchetti A, Pelosi G, Ferrari C, Alberti A, Biganzoli E, Piscaglia F, Bolondi L. Eur J Gastroenterol Hepatol. 2013 Jul 3. [Epub ahead of print]


  628. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
    Scheel TK, Rice CM. Nat Med. 2013 Jul;19(7):837-49. doi: 10.1038/nm.3248.


  629. Regulation of hepatic innate immunity by hepatitis C virus
    Horner SM, Gale M Jr. Nat Med. 2013 Jul;19(7):879-88. doi: 10.1038/nm.3253.


  630. Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients
    Lee HS, Kweon YO, Tak WY, Park SY, Kang EJ, Lee YL, Yang HM, Park HW. Clin Mol Hepatol. 2013 Jun;19(2):148-55. doi: 10.3350/cmh.2013.19.2.148. Epub 2013 Jun 27.


  631. Non-invasive assessment of liver fibrosis using magnetic resonance elastography in liver transplant recipients with hepatitis C
    Crespo S, Bridges M, Nakhleh R, McPhail A, Pungpapong S, Keaveny AP. Clin Transplant. 2013 Jul 10. doi: 10.1111/ctr.12180. [Epub ahead of print]


  632. Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients
    Ciccarelli N, Fabbiani M, Grima P, Falasca K, Tana M, Baldonero E, Colafigli M, Silveri MC, Vecchiet J, Cauda R, Di Giambenedetto S. Infection. 2013 Jul 10. [Epub ahead of print]


  633. Lack of Access to Treatment as a Barrier to HCV Screening: A Facility-Based Assessment in the Indian Health Service
    Reilley B, Leston J, Redd JT, Geiger R. J Public Health Manag Pract. 2013 Jul 8. [Epub ahead of print]


  634. Assessment of Alternative Treatment Strategies for Chronic Genotype 1 Hepatitis C
    Goldhaber-Fiebert JD, Barnett PG, Dally S, Asch SM, Liu S, Cipriano L, Owens DK, Miake-Lye IM, Beroes JM, Shekelle PG.


  635. Women with chronic hepatitis C virus infection: recommendations for clinical practice
    Burton MJ, Brock JB, Geraci SA. South Med J. 2013 Jul;106(7):422-6. doi: 10.1097/SMJ.0b013e31829b99f5.


  636. Hepatitis C--an update
    Holmes J, Thompson A, Bell S. Aust Fam Physician. 2013 Jul;42(7):452-6.


  637. Sequencing of the Hepatitis C Virus: A Systematic Review
    Jacka B, Lamoury F, Simmonds P, Dore GJ, Grebely J, Applegate T. PLoS One. 2013 Jun 27;8(6):e67073. Print 2013.


  638. Hepatitis C treatment in patients with kidney disease
    Fabrizi F, Aghemo A, Messa P. Kidney Int. 2013 Jul 3. doi: 10.1038/ki.2013.264. [Epub ahead of print]


  639. Insulin resistance is associated with DNA damage in peripheral blood cells in non-diabetic patients with genotype 1 chronic hepatitis C
    Sakae PN, Ihara SS, Ribeiro DA, de Carvalho L, Parise ER. Free Radic Res. 2013 Sep;47(9):750-6. doi: 10.3109/10715762.2013.821700. Epub 2013 Jul 29.


  640. Value of Interleukin 28B Genetic Polymorphism on Retreatment Outcomes of Chronic Hepatitis C Genotype 1 Relapsers by Peginterferon Alfa plus Ribavirin
    Chen MY, Liu CH, Chen TC, Su TH, Chen PJ, Chen DS, Kao JH, Liu CJ. J Gastroenterol Hepatol. 2013 Jul 5. doi: 10.1111/jgh.12329. [Epub ahead of print]


  641. Global control of hepatitis C: where challenge meets opportunity
    Thomas DL. Nat Med. 2013 Jul;19(7):850-8. doi: 10.1038/nm.3184.


  642. Epidemiological factors affecting
    Diomidous M, Zimeras S, Elefsiniotis IS. Stud Health Technol Inform. 2013;190:261-3.


  643. Drug-drug interactions during antiviral therapy for chronic hepatitis C
    Kiser JJ, Burton JR Jr, Everson GT. Nat Rev Gastroenterol Hepatol. 2013 Jul 2. doi: 10.1038/nrgastro.2013.106. [Epub ahead of print]


  644. Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link
    Hernández-Bartolomé A, López-Rodríguez R, Rodríguez-Muñoz Y, Martín-Vílchez S, Borque MJ, García-Buey L, González-Moreno L, Real Y, Moreno-Otero R, Sanz-Cameno P. PLoS One. 2013 Jun 18;8(6):e66143. Print 2013.


  645. Efficacy and safety of interferon-based therapy in the treatment of adult thalassemic patients with chronic hepatitis C: a 12 years audit
    Vafiadis I, Trilianos P, Vlachogiannakos J, Karagiorga M, Hatziliami A, Voskaridou E, Ladas SD. Ann Hepatol. 2013 Jul-Aug;12(4):532-8.


  646. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir
    Mauss S, Hueppe D, Alshuth U. Hepatology. 2013 Jun 28. doi: 10.1002/hep.26602. [Epub ahead of print]


  647. Serum proteome predicts virological response in chronic hepatitis C genotype 1b patients treated with pegylated interferon plus ribavirin
    Yen YH, Wang JC, Hung CH, Lu SN, Wang JH, Hu TH, Kee KM, Hsiao CC, Lee CM. J Formos Med Assoc. 2013 Jun 26. pii: S0929-6646(13)00163-0. doi: 10.1016/j.jfma.2013.04.013. [Epub ahead of print]


  648. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C
    Carrión JA, Gonzalez-Colominas E, García-Retortillo M, Cañete N, Cirera I, Coll S, Giménez MD, Márquez C, Martin-Escudero V, Castellví P, Navinés R, Castaño JR, Galeras JA, Salas E, Bory F, Martín-Santos R, Solà R. J Hepatol. 2013 Jun 26. pii: S0168-8278(13)00435-2. doi: 10.1016/j.jhep.2013.06.019. [Epub ahead of print]


  649. Marijuana Smoking Does Not Accelerate Progression of Liver Disease in HIV-Hepatitis C Coinfection: A Longitudinal Cohort Analysis
    Brunet L, Moodie EE, Rollet K, Cooper C, Walmsley S, Potter M, Klein MB; Canadian Co-infection Cohort Investigators. Clin Infect Dis. 2013 Sep;57(5):663-70. doi: 10.1093/cid/cit378. Epub 2013 Jun 28.


  650. Intravenous Interferon Administered During Liver Transplantation Is Not Effective in Preventing Hepatitis C Reinfection
    Russo MW, Narang T, Eskind L, Hayes D, Casingal V, Purdum PP, Hanson JS, Ahrens W, Norton J, Bonkovsky H. Dig Dis Sci. 2013 Jun 29. [Epub ahead of print]


  651. Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection
    Marcellin P, Cooper C, Balart L, Larrey D, Box T, Yoshida E, Lawitz E, Buggisch P, Ferenci P, Weltman M, Labriola-Tompkins E, Le Pogam S, Nájera I, Thomas D, Hooper G, Shulman NS, Zhang Y, Navarro MT, Lim CY, Brunda M, Terrault NA, Yetzer ES. Gastroenterology. 2013 Jun 26. pii: S0016-5085(13)00995-5. doi: 10.1053/j.gastro.2013.06.051. [Epub ahead of print]


  652. Impact of Hepatitis C Virus (HCV) infection on biomolecular markers influencing the pathogenesis of bladder cancer
    Hemmaid KZ, Awadalla A, Elsawy E, Hussein AA, Abdel-Aziz A, Shokeir AA, El-Hefnawy AS, Abol-Enein H. Infect Agent Cancer. 2013 Jun 28;8(1):24. doi: 10.1186/1750-9378-8-24.


  653. Non-invasive assessment of liver fibrosis using ARFI with pathological correlation, a prospective study
    Yap WW, Kirke R, Yoshida EM, Owen D, Harris AC. Ann Hepatol. 2013 Jul-Aug;12(4):608-15.


  654. Hepatitis B and C in African Americans: Current Status and Continued Challenges
    Forde KA, Tanapanpanit O, Reddy KR. Clin Gastroenterol Hepatol. 2013 Jun 28. pii: S1542-3565(13)00865-3. doi: 10.1016/j.cgh.2013.06.006. [Epub ahead of print]


  655. Baseline MELD Score Predicts Hepatic Decompensation during Antiviral Therapy in Patients with Chronic Hepatitis C and Advanced Cirrhosis
    Dultz G, Seelhof M, Herrmann E, Welker MW, Friedrich-Rust M, Teuber G, Kronenberger B, von Wagner M, Vermehren J, Sarrazin C, Zeuzem S, Hofmann WP. PLoS One. 2013 Aug 1;8(8):e71262. doi: 10.1371/journal.pone.0071262. Print 2013.


  656. Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma
    Torres HA, Mahale P, Miller ED, Oo TH, Frenette C, Kaseb AO. World J Hepatol. 2013 Jun 27;5(6):332-5. doi: 10.4254/wjh.v5.i6.332.


  657. A report from the 26th International Conference on Antiviral Research (May 11-15, San Francisco, California, USA)
    Rabasseda X. Drugs Today (Barc). 2013 Jun;49(6):411-7. doi: 10.1358/dot.2013.49.6.2002838.


  658. Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C
    Younossi ZM, Stepanova M, Afendy M, Lam BP, Mishra A. J Viral Hepat. 2013 Aug;20(8):550-5. doi: 10.1111/jvh.12080. Epub 2013 Mar 25.


  659. Chronic hepatitis C infection is associated with insulin resistance and lipid profiles
    Dai CY, Yeh ML, Huang CF, Hou CH, Hsieh MY, Huang JF, Lin IL, Lin ZY, Chen SC, Wang LY, Chuang WL, Yu ML, Tung HD. J Gastroenterol Hepatol. 2013 Jun 28. doi: 10.1111/jgh.12313. [Epub ahead of print]


  660. Is There any Difference Between the Glomerular Filtration Rate of Patients With Chronic Hepatitis B and C and Patients With Cirrhosis?
    Gluhovschi C, Velciov S, Buzas R, Petrica L, Bozdog G, Gadalean F, Gluhovschi A, Balgradean C, Vernic C, Sporea I. Hepat Mon. 2013 Apr 15;13(4):e6789. doi: 10.5812/hepatmon.6789. Print 2013 Apr.


  661. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C
    Zampino R, Coppola N, Cirillo G, Boemio A, Pisaturo M, Marrone A, Macera M, Sagnelli E, Perrone L, Adinolfi LE, Miraglia del Giudice E. J Viral Hepat. 2013 Aug;20(8):517-23. doi: 10.1111/jvh.12053. Epub 2013 Jan 7.


  662. The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting
    Manos MM, Darbinian J, Rubin J, Ray GT, Shvachko V, Denis B, Velez F, Quesenberry C. J Manag Care Pharm. 2013 Jul-Aug;19(6):438-47.


  663. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C
    Galán RJ, Cidoncha EC, Martin MF, Rodriguez CC, Almeida CV, Verdugo RM. J Manag Care Pharm. 2013 Jul-Aug;19(6):448-53.


  664. Long-term clearance of hepatitis C virus following interferon ?-2b or peginterferon ?-2b, alone or in combination with ribavirin
    Manns MP, Pockros PJ, Norkrans G, Smith CI, Morgan TR, Häussinger D, Shiffman ML, Hadziyannis SJ, Schmidt WN, Jacobson IM, Bárcena R, Schiff ER, Shaikh OS, Bacon B, Marcellin P, Deng W, Esteban-Mur R, Poynard T, Pedicone LD, Brass CA, Albrecht JK, Gordon SC. J Viral Hepat. 2013 Aug;20(8):524-9. doi: 10.1111/jvh.12074. Epub 2013 Mar 3.


  665. Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence
    Evon DM, Esserman DA, Bonner JE, Rao T, Fried MW, Golin CE. J Viral Hepat. 2013 Aug;20(8):536-49. doi: 10.1111/jvh.12079. Epub 2013 Feb 25.


  666. Telaprevir Activity in Treatment-Naive Patients Infected Hepatitis C Virus Genotype 4: A Randomized Trial
    Benhamou Y, Moussalli J, Ratziu V, Lebray P, De Backer K, De Meyer S, Ghys A, Luo D, Picchio GR, Beumont M. J Infect Dis. 2013 Jul 11. [Epub ahead of print]


  667. Performance of unidimensional transient elastography in staging chronic hepatitis C. Results from a cohort of 1,202 biopsied patients from one single center
    Lupsor Platon M, Stefanescu H, Feier D, Maniu A, Badea R. J Gastrointestin Liver Dis. 2013 Jun;22(2):157-66.


  668. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan
    Hsu CS, Kao JH, Chao YC, Lin HH, Fan YC, Huang CJ, Tsai PS. Aliment Pharmacol Ther. 2013 Aug;38(4):415-23. doi: 10.1111/apt.12391. Epub 2013 Jun 26.


  669. Patient perspectives on hepatitis C and its treatment
    North CS, Devereaux R, Pollio DE, Hong BA, Jain MK. Eur J Gastroenterol Hepatol. 2013 Jun 19. [Epub ahead of print]


  670. The effects of a maintenance therapy with peg-interferon alpha-2a on liver fibrosis in HIV/HCV co-infected patients: A randomized controlled trial
    Chapplain JM, Bellissant E, Guyader D, Molina JM, Poizot-Martin I, Perré P, Pialoux G, Turlin B, Mouchel C, Renault A, Michelet C; ANRS HC-12 Study Group. J Infect. 2013 Jun 22. pii: S0163-4453(13)00152-7. doi: 10.1016/j.jinf.2013.05.007. [Epub ahead of print]


  671. Infection status outcome, machine learning method and virus type interact to affect the optimised prediction of hepatitis virus immunoassay results from routine pathology laboratory assays in unbalanced data
    Richardson AM, Lidbury BA. BMC Bioinformatics. 2013 Jun 25;14:206. doi: 10.1186/1471-2105-14-206.


  672. Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse
    Lagging M, Rembeck K, Rauning Buhl M, Christensen P, Dalgard O, Färkkilä M, Hellstrand K, Langeland N, Lindh M, Westin J, Norkrans G. Scand J Gastroenterol. 2013 Jul;48(7):839-47. doi: 10.3109/00365521.2013.793389.


  673. Prediction of hepatic fibrosis in patients coinfected with human immunodeficiency virus and hepatitis C virus based on genetic markers
    Fernández-Rodríguez A, Berenguer J, Jiménez-Sousa MA, Guzmán-Fulgencio M, Micheloud D, Miralles P, López JC, Bellón JM, Aldamiz-Echevarria T, García-Broncano P, Carrero A, Alvarez E, Resino S. J Acquir Immune Defic Syndr. 2013 Jun 21. [Epub ahead of print]


  674. Modelling the prevalence of HCV amongst people who inject drugs: An investigation into the risks associated with injecting paraphernalia sharing
    Corson S, Greenhalgh D, Taylor A, Palmateer N, Goldberg D, Hutchinson S. Drug Alcohol Depend. 2013 Jun 19. pii: S0376-8716(13)00189-0. doi: 10.1016/j.drugalcdep.2013.05.014. [Epub ahead of print]


  675. Randomized study of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 chronic hepatitis C
    Bronowicki JP, Pol S, Thuluvath PJ, Larrey D, Martorell CT, Rustgi VK, Morris DW, Younes Z, Fried MW, Bourlière M, Hézode C, Reddy KR, Massoud O, Abrams GA, Ratziu V, He B, Eley T, Ahmad A, Cohen D, Hindes R, McPhee F, Reilly B, Mendez P, Hughes E. Antivir Ther. 2013 Jun 26. doi: 10.3851/IMP2660. [Epub ahead of print]


  676. Alanine Aminotransferase Elevation during Peginterferon Alpha-2a or Alpha-2b plus Ribavirin Treatment
    Nakamura M, Kanda T, Miyamura T, Wu S, Nakamoto S, Yokosuka O. Int J Med Sci. 2013 Jun 15;10(8):1015-21. doi: 10.7150/ijms.6402. Print 2013.


  677. Autoimmune thyroid disorders in hepatitis C virus infection: Effect of interferon therapy
    Jadali Z. Indian J Endocrinol Metab. 2013 Jan;17(1):69-75. doi: 10.4103/2230-8210.107856.


  678. Prediction of Treatment Efficacy and Telaprevir-Resistant Variants after Triple Therapy in Patients Infected with HCV Genotype 1
    Akuta N, Suzuki F, Fukushima T, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. J Clin Microbiol. 2013 Jun 19. [Epub ahead of print]


  679. Hepatitis C in men who have sex with men in London - a community survey
    Price H, Gilson R, Mercey D, Copas A, Parry J, Nardone A, Hart G. HIV Med. 2013 Jun 18. doi: 10.1111/hiv.12050. [Epub ahead of print]


  680. Role of IL28B Gene Polymorphism and Cell-Mediated Immunity in Spontaneous Resolution of Acute Hepatitis C
    Spada E, Amoroso P, Taliani G, Zuccaro O, Chiriacò P, Maio P, Maio G, Esposito ML, Mariano C, Rinaldi R, Bellissima P, Tosti ME, Del Porto P, Francavilla R, Mellace V, Garbuglia AR, Folgori A, Mele A; for the Acute Hepatitis Italian Study Group. Clin Infect Dis. 2013 Jul 9. [Epub ahead of print]


  681. Interleukin-28B genetic variations and spontaneous clearance of hepatitis C antibody-positive blood donors in China
    Liu Y, Ma H, Chen S, Wang J, Liu G, Xu M, Ke L, He M. Transfusion. 2013 Jun 19. doi: 10.1111/trf.12305. [Epub ahead of print]


  682. Analysis of Site Performance in Academic-based and Community-based Centers in the IDEAL Study
    Jou JH, Sulkowski MS, Noviello S, Long J, Pedicone LD, McHutchison JG, Muir AJ. J Clin Gastroenterol. 2013 Jun 19. [Epub ahead of print]


  683. Perceptions of drug users regarding Hepatitis C screening and care: a qualitative study
    Jordan AE, Masson CL, Mateu-Gelabert P, McKnight C, Pepper N, Bouche K, Guzman L, Kletter E, Seewald RM, Des-Jarlais DC, Sorensen JL, Perlman DC. Harm Reduct J. 2013 Jun 20;10:10. doi: 10.1186/1477-7517-10-10.


  684. Outbreak of hepatitis C virus infections at an outpatient hemodialysis facility: the importance of infection control competencies
    Rao AK, Luckman E, Wise ME, MacCannell T, Blythe D, Lin Y, Xia G, Drobeniuc J, Noble-Wang J, Arduino MJ, Thompson ND, Patel PR, Wilson LE. Nephrol Nurs J. 2013 Mar-Apr;40(2):101-10, 164; quiz 111.


  685. Half a Diagnosis: Gap in Confirming Infection among Hepatitis C Antibody-positive Patients
    McGibbon E, Bornschlegel K, Balter S. Am J Med. 2013 Aug;126(8):718-22. doi: 10.1016/j.amjmed.2013.01.031. Epub 2013 Jun 17.


  686. Evaluation of the significance of pretreatment liver biopsy and baseline mental health disorder diagnosis on hepatitis C treatment completion rates at a veterans affairs medical center
    Kluck J, O'Flynn RM, Kaplan DE, Chang KM. Hepat Res Treat. 2013;2013:653976. doi: 10.1155/2013/653976. Epub 2013 May 16.


  687. Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: A population and clonal analysis
    Barnard RJ, McHale CM, Newhard W, Cheney CA, Graham DJ, Himmelberger AL, Strizki J, Hwang PM, Rivera AA, Reeves JD, Nickle D, Dinubile MJ, Hazuda DJ, Mobashery N. Virology. 2013 Sep 1;443(2):278-84. doi: 10.1016/j.virol.2013.05.013. Epub 2013 Jun 10.


  688. Comparative Analysis of T-Cell Depletion Method for Clinical Immunotherapy-Anti-Hepatitis C Effects of Natural Killer Cells Via Interferon-? Production
    Ohira M, Nishida S, Matsuura T, Muraoka I, Tryphonopoulos P, Fan J, Tekin A, Selvaggi G, Levi D, Ruiz P, Ricordi C, Ohdan H, Tzakis AG. http://www.ncbi.nlm.nih.gov/pubmed/23769105#


  689. Socioeconomic status in HCV infected patients - risk and prognosis
    Omland LH, Osler M, Jepsen P, Krarup H, Weis N, Christensen PB, Roed C, Sørensen HT, Obel N. Clin Epidemiol. 2013 May 31;5:163-72. doi: 10.2147/CLEP.S43926. Print 2013.


  690. Acceptability of Psychotherapy, Pharmacotherapy, and Self-Directed Therapies in Australians Living with Chronic Hepatitis C
    Stewart BJ, Turnbull D, Mikocka-Walus AA, Harley HA, Andrews JM. http://www.ncbi.nlm.nih.gov/pubmed/23756631#


  691. IL-4 -590C/T Polymorphism and Susceptibility to Liver Disease: A Meta-Analysis and Meta-Regression
    Zheng Z, Li X, Li Z, Ma XC. DNA Cell Biol. 2013 Aug;32(8):443-50. doi: 10.1089/dna.2013.2020. Epub 2013 Jun 15.


  692. Comparative analysis of viral protein interaction networks in Hepatitis B Virus and Hepatitis C Virus infected HCC
    Yuan W, Huang T, Yu J, Zeng L, Lian B, He Q, Li Y, Zhang X, Zhou F, Xie L.


  693. Absence of activating killer immunoglobulin-like receptor genes combined with hepatitis C viral genotype is predictive of hepatocellular carcinoma
    Littera R, Zamboni F, Tondolo V, Fantola G, Chessa L, Orrù N, Sanna M, Valentini D, Cappai L, Mulargia M, Caocci G, Arras M, Floris A, Orrù S, La Nasa G, Carcassi C. Hum Immunol. 2013 Jun 10. pii: S0198-8859(13)00148-1. doi: 10.1016/j.humimm.2013.05.007. [Epub ahead of print]


  694. Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres
    Cazzagon N, Trevisani F, Maddalo G, Giacomin A, Vanin V, Pozzan C, Del Poggio P, Rapaccini G, Di Nolfo AM, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Foschi FG, Cabibbo G, Felder M, Ciccarese F, Missale G, Svegliati Baroni G, Morisco F, Pecorelli A, Farinati F; for the ITA.LI.CA Group. Liver Int. 2013 May 9. doi: 10.1111/liv.12208. [Epub ahead of print]


  695. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection
    Abe H, Aida Y, Ishiguro H, Yoshizawa K, Seki N, Miyazaki T, Itagaki M, Sutoh S, Ika M, Kato K, Shimada N, Tsubota A, Aizawa Y. J Med Virol. 2013 Sep;85(9):1523-33. doi: 10.1002/jmv.23626. Epub 2013 Jun 17.


  696. Donor notification and counseling - Experience and challenges
    Kaur G, Kaur P, Basu S, Kaur R, Sharma S. Transfus Apher Sci. 2013 Jun 12. pii: S1473-0502(13)00164-X. doi: 10.1016/j.transci.2013.05.005. [Epub ahead of print]


  697. Direct-Acting Antiviral-Associated Dermatitis During Chronic Hepatitis C Virus Treatment
    Biesbroeck LK, Scott JD, Taraska C, Moore E, Falsey RR, Shinohara MM. Am J Clin Dermatol. 2013 Jun 18. [Epub ahead of print]


  698. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial
    Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY, Wenning L, Sklar P, Wahl J, Greaves W; P05411 study investigators. Lancet Infect Dis. 2013 Jul;13(7):597-605. doi: 10.1016/S1473-3099(13)70149-X. Epub 2013 Jun 12.


  699. The AASLD clinical practice guidelines: A critical review of scientific evidence and evolving recommendations
    Koh C, Zhao X, Samala N, Sakiani S, Liang TJ, Talwalkar JA. Hepatology. 2013 Jun 14. doi: 10.1002/hep.26578. [Epub ahead of print]


  700. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics
    Lawitz E, Sulkowski M, Jacobson I, Kraft WK, Maliakkal B, Al-Ibrahim M, Gordon SC, Kwo P, Rockstroh JK, Panorchan P, Miller M, Caro L, Barnard R, Hwang PM, Gress J, Quirk E, Mobashery N. Antiviral Res. 2013 Jun 7;99(3):214-220. doi: 10.1016/j.antiviral.2013.05.015. [Epub ahead of print]


  701. Therapeutic DNA Vaccination Using In Vivo Electroporation Followed by Standard of Care Therapy in Patients With Genotype 1 Chronic Hepatitis C
    Weiland O, Ahlén G, Diepolder H, Jung MC, Levander S, Fons M, Mathiesen I, Sardesai NY, Vahlne A, Frelin L, Sällberg M. Mol Ther. 2013 Jun 11. doi: 10.1038/mt.2013.119. [Epub ahead of print]


  702. Global confluence of infectious and non-communicable diseases - The case of type 2 diabetes
    Magee MJ, Narayan KM. Prev Med. 2013 Jun 6. pii: S0091-7435(13)00190-4. doi: 10.1016/j.ypmed.2013.05.027. [Epub ahead of print]


  703. Somatic hypermutations confer rheumatoid factor activity in hepatitis C virus-associated mixed cryoglobulinemia
    Charles ED, Orloff MI, Nishiuchi E, Marukian S, Rice CM, Dustin LB. Arthritis Rheum. 2013 Jun 10. doi: 10.1002/art.38041. [Epub ahead of print]


  704. Hepatitis C therapy at home: a hospital and home care partnership
    Jack K, Barnett J, Holiday A, Heard G, Thomson B. Br J Nurs. 2013 May 9-22;22(9):518-23


  705. Outcome After Liver Transplantation for Cirrhosis Due to Alcohol and Hepatitis C: Comparison to Alcoholic Cirrhosis and Hepatitis C Cirrhosis
    Singal AK, Hmoud BS, Guturu P, Kuo YF. J Clin Gastroenterol. 2013 Jun 6. [Epub ahead of print]


  706. Efficacy and Safety of Pegylated Interferon Alfa-2b and Ribavirin Combination Therapy Versus Pegylated Interferon Monotherapy in Hemodialysis Patients: A Comparison of 2 Sequentially Treated Cohorts
    Tseng PL, Chen TC, Chien YS, Hung CH, Yen YH, Chang KC, Tsai MC, Lin MT, Lee CT, Shen CH, Hu TH. Am J Kidney Dis. 2013 Jun 5. pii: S0272-6386(13)00782-8. doi: 10.1053/j.ajkd.2013.03.037. [Epub ahead of print]


  707. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C
    Squadrito G, Cacciola I, Alibrandi A, Pollicino T, Raimondo G. J Hepatol. 2013 Jun 7. pii: S0168-8278(13)00376-0. doi: 10.1016/j.jhep.2013.05.043. [Epub ahead of print]


  708. Depression and Fatigue in Chronic Hepatitis C Patients with and Without HIV Co-Infection
    Tavakkoli M, Ferrando SJ, Rabkin J, Marks K, Talal AH. Psychosomatics. 2013 Jun 4. pii: S0033-3182(13)00047-9. doi: 10.1016/j.psym.2013.02.009. [Epub ahead of print]


  709. Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practice
    Niederau C, Mauss S, Böker K, Lutz T, Heyne R, Moog G, John C, Witthöft T, Alshuth U, Hüppe D. Eur J Gastroenterol Hepatol. 2013 Jun 11. [Epub ahead of print]


  710. Altered functionality of anti-bacterial antibodies in patients with chronic hepatitis C virus infection
    Lamontagne A, Long RE, Comunale MA, Hafner J, Rodemich-Betesh L, Wang M, Marrero J, Di Bisceglie AM, Block T, Mehta A. PLoS One. 2013 Jun 4;8(6):e64992. doi: 10.1371/journal.pone.0064992. Print 2013.


  711. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
    Bartenschlager R, Lohmann V, Penin F. Nat Rev Microbiol. 2013 Jul;11(7):482-96. doi: 10.1038/nrmicro3046. Epub 2013 Jun 10.


  712. Increasing Hepatitis C Prevalence and Associated Risk Behaviors among Incarcerated Young Adults
    McNamara BC, Losikoff PT, Huguenin L, Macalino GE, Rich JD, Gregory SH. J Urban Health. 2013 May 31. [Epub ahead of print]


  713. A multicentre survey of hepatitis C awareness in a high-risk population
    Kanaan T, Liu A, Leroi M, Nanan R. J Paediatr Child Health. 2013 Jun 7. doi: 10.1111/jpc.12259. [Epub ahead of print]


  714. Sofosbuvir and ABT-450: Terminator of hepatitis C virus?
    Zeng QL, Zhang JY, Zhang Z, Wang LF, Wang FS. World J Gastroenterol. 2013 Jun 7;19(21):3199-206. doi: 10.3748/wjg.v19.i21.3199.


  715. The impact of infectious diseases consultation on oncology practice
    Granwehr BP, Kontoyiannis DP. Curr Opin Oncol. 2013 Jul;25(4):353-9. doi: 10.1097/CCO.0b013e3283622c32.


  716. Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients
    Tamaki N, Kurosaki M, Matsuda S, Nakata T, Muraoka M, Suzuki Y, Yasui Y, Suzuki S, Hosokawa T, Nishimura T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Matsunaga K, Taki K, Asahina Y, Izumi N. Hepatol Res. 2013 Jun 6. doi: 10.1111/hepr.12179. [Epub ahead of print]


  717. Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation
    Ponziani FR, Annicchiarico EB, Siciliano M, D'Aversa F, Pompili M, Gasbarrini A. World J Gastroenterol. 2013 Jun 7;19(21):3255-62. doi: 10.3748/wjg.v19.i21.3255.


  718. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end
    Heim MH. Nat Rev Immunol. 2013 Jun 7;13(7):535-42. doi: 10.1038/nri3463. Epub 2013 Jun 7.


  719. Therapy of chronic hepatitis C with PEG-IFN ?-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses
    Fabris P, Carlotto A, Bianco TD, Malfatti F, Tramarin A, Miotti MA, Baldo V, Floreani A, Giordani MT, Grasso A. Eur J Gastroenterol Hepatol. 2013 Jun 19. [Epub ahead of print]


  720. Editorial: killing two birds with one stone: screening for chronic hepatitis C at the time of colonoscopy in the baby boomer cohort
    Torres DM, Harrison SA. Am J Gastroenterol. 2013 Jun;108(6):990-2. doi: 10.1038/ajg.2013.54.


  721. Autoantibody profile in individuals with chronic hepatitis C
    Marconcini ML, Fayad L, Shiozawa MB, Dantas-Correa EB, Lucca Schiavon Ld, Narciso-Schiavon JL. Rev Soc Bras Med Trop. 2013;46(2). pii: S0037-86822013000200147. doi: 10.1590/0037-8682-0039-2013.


  722. A multicentre survey of hepatitis C awareness in a high-risk population
    Kanaan T, Liu A, Leroi M, Nanan R. J Paediatr Child Health. 2013 Jun 7. doi: 10.1111/jpc.12259. [Epub ahead of print]


  723. Sofosbuvir and ABT-450: Terminator of hepatitis C virus?
    Zeng QL, Zhang JY, Zhang Z, Wang LF, Wang FS. World J Gastroenterol. 2013 Jun 7;19(21):3199-206. doi: 10.3748/wjg.v19.i21.3199.


  724. The impact of infectious diseases consultation on oncology practice
    Granwehr BP, Kontoyiannis DP. Curr Opin Oncol. 2013 Jul;25(4):353-9. doi: 10.1097/CCO.0b013e3283622c32.


  725. Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients
    Tamaki N, Kurosaki M, Matsuda S, Nakata T, Muraoka M, Suzuki Y, Yasui Y, Suzuki S, Hosokawa T, Nishimura T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Matsunaga K, Taki K, Asahina Y, Izumi N. Hepatol Res. 2013 Jun 6. doi: 10.1111/hepr.12179. [Epub ahead of print]


  726. Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation
    Ponziani FR, Annicchiarico EB, Siciliano M, D'Aversa F, Pompili M, Gasbarrini A. World J Gastroenterol. 2013 Jun 7;19(21):3255-62. doi: 10.3748/wjg.v19.i21.3255.


  727. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end
    Heim MH. Nat Rev Immunol. 2013 Jun 7;13(7):535-42. doi: 10.1038/nri3463. Epub 2013 Jun 7.


  728. Therapy of chronic hepatitis C with PEG-IFN ?-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses
    Fabris P, Carlotto A, Bianco TD, Malfatti F, Tramarin A, Miotti MA, Baldo V, Floreani A, Giordani MT, Grasso A. Eur J Gastroenterol Hepatol. 2013 Jun 19. [Epub ahead of print]


  729. Editorial: killing two birds with one stone: screening for chronic hepatitis C at the time of colonoscopy in the baby boomer cohort
    Torres DM, Harrison SA. Am J Gastroenterol. 2013 Jun;108(6):990-2. doi: 10.1038/ajg.2013.54.


  730. Autoantibody profile in individuals with chronic hepatitis C
    Marconcini ML, Fayad L, Shiozawa MB, Dantas-Correa EB, Lucca Schiavon Ld, Narciso-Schiavon JL. Rev Soc Bras Med Trop. 2013;46(2). pii: S0037-86822013000200147. doi: 10.1590/0037-8682-0039-2013.


  731. Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients
    Petta S, Grimaudo S, Marco VD, Scazzone C, Macaluso FS, Cammà C, Cabibi D, Pipitone R, Craxì A. J Viral Hepat. 2013 Jul;20(7):486-93. doi: 10.1111/jvh.12072. Epub 2013 Mar 25.


  732. Genetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development
    Lange CM, Miki D, Ochi H, Nischalke HD, Bojunga J, Bibert S, Morikawa K, Gouttenoire J, Cerny A, Dufour JF, Gorgievski-Hrisoho M, Heim MH, Malinverni R, Müllhaupt B, Negro F, Semela D, Kutalik Z, Müller T, Spengler U, Berg T, Chayama K, Moradpour D, Bochud PY; Hiroshima Liver Study Group; Swiss Hepatitis C Cohort Study Group. PLoS One. 2013 May 29;8(5):e64053. doi: 10.1371/journal.pone.0064053. Print 2013.


  733. Role of T cell immunity in hepatitis C virus infections
    Claassen MA, Janssen HL, Boonstra A. Curr Opin Virol. 2013 Jun 1. pii: S1879-6257(13)00066-7. doi: 10.1016/j.coviro.2013.05.006. [Epub ahead of print]


  734. Impact of oral silymarin on virus- and non-virus-specific T-cell responses in chronic hepatitis C infection
    Adeyemo O, Doi H, Rajender Reddy K, Kaplan DE. J Viral Hepat. 2013 Jul;20(7):453-62. doi: 10.1111/jvh.12050. Epub 2013 Apr 12.


  735. Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies
    Pedersen J, Carlsen TH, Prentoe J, Ramirez S, Jensen TB, Forns X, Alter H, Foung SK, Law M, Gottwein J, Weis N, Bukh J. Hepatology. 2013 May 31. doi: 10.1002/hep.26524. [Epub ahead of print]


  736. Influence of antiviral therapy in the long-term outcome of recurrent hepatitis C virus infection following liver transplantation
    García-Reyne A, Lumbreras C, Fernández I, Colina F, Abradelo M, Magan P, San-Juan R, Manrique A, López-Medrano F, Fuertes A, Lizasoain M, Moreno E, Aguado JM. Transpl Infect Dis. 2013 Jun 3. doi: 10.1111/tid.12097. [Epub ahead of print]


  737. Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection
    Seto WK, Tsang OT, Liu K, Chan JM, Wong DK, Fung J, Lai CL, Yuen MF. J Viral Hepat. 2013 Jul;20(7):470-7. doi: 10.1111/jvh.12047. Epub 2013 Apr 12.


  738. Project ECHO: Replicating a Novel Model to Enhance Access to Hepatitis C Care in a Community Health Center
    Khatri K, Haddad M, Anderson D. J Health Care Poor Underserved. 2013;24(2):850-8. doi: 10.1353/hpu.2013.0093.


  739. Elimination of Hepatitis C Virus Infection Among People Who Inject Drugs Through Treatment as Prevention: Feasibility and Future Requirements
    Grebely J, Matthews GV, Lloyd AR, Dore GJ. Clin Infect Dis. 2013 Jun 27. [Epub ahead of print]


  740. Dermatological side-effects of telaprevir-based triple therapy for chronic hepatitis C in phase III trials in Japan
    Torii H, Sueki H, Kumada H, Sakurai Y, Aoki K, Yamada I, Ohtsuki M. J Dermatol. 2013 Jun 5. doi: 10.1111/1346-8138.12199. [Epub ahead of print]


  741. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C
    Shah N, Pierce T, Kowdley KV. Expert Opin Investig Drugs. 2013 Jun 4. [Epub ahead of print]


  742. Cost-Effectiveness Analysis of Direct-Acting Antiviral Therapy for Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Infection in the Veterans Health Administration
    Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB. Clin Gastroenterol Hepatol. 2013 May 22. pii: S1542-3565(13)00705-2. doi: 10.1016/j.cgh.2013.05.014. [Epub ahead of print]


  743. Drug-Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors
    Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Clin Pharmacokinet. 2013 May 24. [Epub ahead of print]


  744. SOCS-1 Promoter Methylation and Treatment Response in Chronic Hepatitis C Patients Receiving Pegylated-Interferon/Ribavirin
    Tseng KC, Chou JL, Huang HB, Tseng CW, Wu SF, Chan MW. J Clin Immunol. 2013 May 24. [Epub ahead of print]


  745. Side effects of antiviral therapy in hepatitis C virus infection-sarcoidosis - case report
    Teodor D, Teodor A, Grigore L, Jug?nariu G, Dorob?? CM, Miftode E, Azoic?i D. Rev Med Chir Soc Med Nat Iasi. 2012 Oct-Dec;116(4):1039-43.


  746. Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy
    Trimoulet P, Pinson P, Papuchon J, Foucher J, Vergniol J, Chermak F, Wittkop L, Castaing N, Merrouche W, Reigadas S, Molimard M, Kann M, Fleury H, de Lédinghen V. Antivir Ther. 2013 May 23. doi: 10.3851/IMP2632. [Epub ahead of print]


  747. Current and future disease progression of the chronic HCV population in the United States
    Zalesak M, Francis K, Gedeon A, Gillis J, Hvidsten K, Kidder P, Li H, Martyn D, Orne L, Smith A, Kwong A. PLoS One. 2013 May 21;8(5):e63959. doi: 10.1371/journal.pone.0063959. Print 2013.


  748. Association Between a Polymorphism in Cannabinoid Receptor 2 and Severe Necroinflammation in Patients With Chronic Hepatitis C
    Coppola N, Zampino R, Bellini G, Macera M, Marrone A, Pisaturo M, Boemio A, Nobili B, Pasquale G, Maione S, Adinolfi LE, Perrone L, Sagnelli E, Del Giudice EM, Rossi F. Clin Gastroenterol Hepatol. 2013 May 21. pii: S1542-3565(13)00687-3. doi: 10.1016/j.cgh.2013.05.008. [Epub ahead of print]


  749. Osteopontin: Versatile modulator of liver diseases
    Nagoshi S. Hepatol Res. 2013 May 22. doi: 10.1111/hepr.12166. [Epub ahead of print]


  750. Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection
    Fusfeld L, Aggarwal J, Dougher C, Vera-Llonch M, Bubb S, Donepudi M, Goss TF. BMC Infect Dis. 2013 May 23;13(1):234. [Epub ahead of print]


  751. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: A longitudinal analysis
    Noureddin M, Wright EC, Alter H, Clark S, Thomas E, Chen R, Zhao X, Conry-Cantilena C, Kleiner D, Liang TJ, Ghany MG. Hepatology. 2013 May 23. doi: 10.1002/hep.26506. [Epub ahead of print]


  752. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C
    Cammà C, Petta S, Cabibbo G, Ruggeri M, Enea M, Bruno R, Capursi V, Gasbarrini A, Alberti A, Craxì A; WEF Study Group. J Hepatol. 2013 May 23. pii: S0168-8278(13)00350-4. doi: 10.1016/j.jhep.2013.05.019. [Epub ahead of print]


  753. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy
    Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; The Kyushu University Liver Disease Study (KULDS) Group. J Hepatol. 2013 May 23. pii: S0168-8278(13)00348-6. doi: 10.1016/j.jhep.2013.05.017. [Epub ahead of print]


  754. Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV: A Randomized Trial
    Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, Gharakhanian S, McCallister S, Henshaw J, Girard PM, Adiwijaya B, Garg V, Rubin RA, Adda N, Soriano V. Ann Intern Med. 2013 May 17. doi: 10.7326/0003-4819-159-2-201307160-00654. [Epub ahead of print]


  755. Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: A comparison of two real-time PCR assays
    Ogawa E, Furusyo N, Murata M, Toyoda K, Eiraku K, Shimizu M, Harada Y, Mitsumoto F, Takayama K, Okada K, Kainuma M, Hayashi J. Antiviral Res. 2013 May 14;99(2):119-124. doi: 10.1016/j.antiviral.2013.05.002. [Epub ahead of print]


  756. Sustained virological response: A milestone in the treatment of chronic hepatitis C
    Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, Loperto I, Gentile I, Auriemma F, Caporaso N. World J Gastroenterol. 2013 May 14;19(18):2793-8. doi: 10.3748/wjg.v19.i18.2793.


  757. Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons ?-2a and ?-2b, plus ribavirin
    Dogan UB, Akin MS, Yalaki S. Eur J Gastroenterol Hepatol. 2013 May 15. [Epub ahead of print]


  758. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation
    Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, Yataco ML, Satyanarayana R, Rosser BG, Vargas HE, Charlton MR, Keaveny AP. Liver Transpl. 2013 Jul;19(7):690-700. doi: 10.1002/lt.23669. Epub 2013 Jun 3.


  759. Precise evaluation of liver histology by computerized morphometry shows that steatosis influences liver stiffness measured by Transient Elastography is a Useful Clinical Tool to Detect Minimal Hepatic Encephalopathy in a Cohort of Compensated Cirrhotic Patients in chronic hepatitis C
    Boursier J, de Ledinghen V, Sturm N, Amrani L, Bacq Y, Sandrini J, Le Bail B, Chaigneau J, Zarski JP, Gallois Y, Leroy V, Al Hamany Z, Oberti F, Fouchard-Hubert I, Dib N, Bertrais S, Rousselet MC, Calès P; Multicentre group ANRS HC EP23 FIBROSTAR. J Gastroenterol. 2013 May 17. [Epub ahead of print]


  760. Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1
    Oze T, Hiramatsu N, Yakushijin T, Miyazaki M, Iio S, Oshita M, Hagiwara H, Mita E, Inui Y, Hijioka T, Inada M, Tamura S, Yoshihara H, Inoue A, Imai Y, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, Kasahara A, Hayashi N, Takehara T. J Gastroenterol. 2013 May 21. [Epub ahead of print]


  761. IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection
    Sato M, Kato N, Tateishi R, Muroyama R, Kowatari N, Li W, Goto K, Otsuka M, Shiina S, Yoshida H, Omata M, Koike K. J Gastroenterol. 2013 May 22. [Epub ahead of print]


  762. Genetic analysis of interferon induced thyroiditis (IIT): Evidence for a key role for MHC and apoptosis related genes and pathways
    Hasham A, Zhang W, Lotay V, Haggerty S, Stefan M, Concepcion E, Dieterich DT, Tomer Y. J Autoimmun. 2013 May 15. pii: S0896-8411(13)00049-8. doi: 10.1016/j.jaut.2013.04.002. [Epub ahead of print]


  763. Prevalence of Hepatitis C Virus Infection in Alcoholic Patients: Cohort Study and Systematic Review
    Novo-Veleiro I, Calle CD, Domínguez-Quibén S, Pastor I, Marcos M, Laso FJ. Alcohol Alcohol. 2013 May 19. [Epub ahead of print]


  764. Donor risk index for african american liver transplant recipients with hepatitis C virus
    Shores NJ, Dodge JL, Feng S, Terrault NA. Hepatology. 2013 May 20. doi: 10.1002/hep.26478. [Epub ahead of print]


  765. Ever closer to a prophylactic vaccine for HCV
    Swadling L, Klenerman P, Barnes E. Expert Opin Biol Ther. 2013 May 7. [Epub ahead of print]


  766. Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir
    Benito JM, Sánchez-Parra C, Maida I, Aguilera A, Rallón NI, Rick F, Labarga P, Fernández-Montero JV, Barreiro P, Soriano V. Antivir Ther. 2013 May 3. doi: 10.3851/IMP2614. [Epub ahead of print]


  767. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes
    De Meyer S, Ghys A, Foster GR, Beumont M, Van Baelen B, Lin TI, Dierynck I, Ceulemans H, Picchio G. J Viral Hepat. 2013 Jun;20(6):395-403. doi: 10.1111/jvh.12046. Epub 2013 Jan 10.


  768. Hepatitis C antiviral treatment outcomes are comparable between clinical trial participants and recipients of standard-of-care therapy: an analysis of trial effect.
    Kelly EM, Cooper CL. Eur J Gastroenterol Hepatol. 2013 May 4. [Epub ahead of print]


  769. Synthesis and evaluation of a new phosphorylated ribavirin prodrug
    Dong SD, Lin CC, Schroeder M. Antiviral Res. 2013 Apr 24;99(1):18-26. doi: 10.1016/j.antiviral.2013.04.014. [Epub ahead of print]


  770. Impact of sustained virologic response on quality of life in chronic HVC carriers
    Daltro-Oliveira R, Morais-de-Jesus M, Pettersen KM, Paraná R, Quarantini LC.


  771. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a
    Palanisamy N, Danielsson A, Kokkula C, Yin H, Bondeson K, Wesslén L, Duberg AS, Lennerstrand J. Antiviral Res. 2013 May 3;99(1):12-17. doi: 10.1016/j.antiviral.2013.04.018. [Epub ahead of print]


  772. The association of non-O blood group and severity of liver fibrosis in patients with chronic hepatitis C infection
    Shavakhi A, Hajalikhani M, Minakari M, Norian A, Riahi R, Azarnia M, Liaghat L. J Res Med Sci. 2012 May;17(5):466-9.


  773. Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach
    Laouénan C, Guedj J, Mentré F. BMC Med Res Methodol. 2013 Apr 25;13:60. doi: 10.1186/1471-2288-13-60.


  774. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors
    Harris M, Rhodes T. Harm Reduct J. 2013 May 7;10(1):7. [Epub ahead of print]


  775. IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis
    Rangnekar AS, Fontana RJ. J Viral Hepat. 2013 Jun;20(6):377-84. doi: 10.1111/jvh.12039. Epub 2013 Jan 7.


  776. Response of hepatitis C virus to long-term passage in the presence of interferon-?. Multiple mutations and a common phenotype
    Perales C, Beach NM, Gallego I, Soria ME, Quer J, Esteban JI, Rice C, Domingo E, Sheldon J. J Virol. 2013 May 1. [Epub ahead of print]


  777. Increasing Hepatitis C Knowledge Among Homeless Adults: Results of a Community-Based, Interdisciplinary Intervention
    Tyler D, Nyamathi A, Stein JA, Koniak-Griffin D, Hodge F, Gelberg L. J Behav Health Serv Res. 2013 Apr 25. [Epub ahead of print]


  778. A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C-Associated Liver Cirrhosis
    Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, Verbaan H, Stål P, Carlsson T, Norrgren H, Ekbom A, Granath F, Hultcrantz R. Clin Infect Dis. 2013 May 14. [Epub ahead of print]


  779. Poor response to hepatitis C treatment in elderly patients
    Silva I, Carvalho Filho R, Feldner AC, Zaros I, Silva AE, Ferraz ML. Ann Hepatol. 2013 May-Jun;12(3):392-8.


  780. Vital signs: evaluation of hepatitis C virus infection testing and reporting - eight u.s. Sites, 2005-2011
    Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2013 May 10;62(18):357-61.


  781. Maintenance of Th1 HCV-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment
    Flynn JK, Dore GJ, Hellard M, Yeung B, Rawlinson WD, White PA, Kaldor JM, Lloyd AR, Ffrench RA; ATAHC Study Group. J Gastroenterol Hepatol. 2013 May 10. doi: 10.1111/jgh.12265. [Epub ahead of print]


  782. Testing for HCV infection: an update of guidance for clinicians and laboratorians
    Centers for Disease Control and Prevention (CDC).


  783. Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C
    Stasi C, Arena U, Zignego AL, Corti G, Monti M, Triboli E, Pellegrini E, Renzo S, Leoncini L, Marra F, Laffi G, Milani S, Pinzani M. Dig Liver Dis. 2013 May 6. pii: S1590-8658(13)00143-6. doi: 10.1016/j.dld.2013.03.023. [Epub ahead of print]


  784. The impact of nutritional supplementation on quality of life in patients infected with hepatitis C virus
    Boulhosa RS, Oliveira LP, Jesus RP, Cavalcante LN, Lemaire DC, Vinhas L, Lyra LG, Lyra AC. J Hum Nutr Diet. 2013 May 9. doi: 10.1111/jhn.12087. [Epub ahead of print]


  785. Education and counseling of pregnant patients with chronic hepatitis B: pespectives from obstetricians and perinatal nurses in santa clara county, california.
    Yang EJ, Cheung CM, So SK, Chang ET, Chao SD. Asian Pac J Cancer Prev. 2013;14(3):1707-13.


  786. Efficacy and Tolerability of Peginterferon ? -2a and Peginterferon ? -2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials
    Yang Z, Zhuang L, Yang L, Chen X. Gastroenterol Res Pract. 2013;2013:739029. doi: 10.1155/2013/739029. Epub 2013 Apr 11.


  787. Development of oleanane-type triterpenes as a new class of HCV entry inhibitors
    Yu F, Wang Q, Zhang Z, Peng Y, Qiu Y, Shi Y, Zheng Y, Xiao S, Wang H, Huang X, Zhu L, Chen K, Zhao C, Zhang C, Yu M, Sun D, Zhang L, Zhou D. J Med Chem. 2013 Jun 13;56(11):4300-19. doi: 10.1021/jm301910a. Epub 2013 May 28.


  788. Estimating the prevalence of hepatitis C infection in New York City using surveillance data
    Balter S, Stark JH, Kennedy J, Bornschlegel K, Konty K. Epidemiol Infect. 2013 May 9:1-8. [Epub ahead of print]


  789. Neutralizing Antibodies in Patients with Chronic Hepatitis C, Genotype 1, against a Panel of Genotype 1 Culture Viruses: Lack of Correlation to Treatment Outcome
    Pedersen J, Jensen TB, Carlsen TH, Schønning K, Christensen PB, Laursen AL, Krarup H, Bukh J, Weis N. PLoS One. 2013 May 7;8(5):e62674. doi: 10.1371/journal.pone.0062674. Print 2013.


  790. Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors
    Londoño MC, Crespo G, Forns X. Curr Opin Organ Transplant. 2013 Jun;18(3):271-8. doi: 10.1097/MOT.0b013e3283614aca.


  791. Pathogenic Role of Iron Deposition in Reticuloendothelial Cells during the Development of Chronic Hepatitis C
    Mitsuyoshi H, Yasui K, Yamaguchi K, Minami M, Okanoue T, Itoh Y. Int J Hepatol. 2013;2013:686420. doi: 10.1155/2013/686420. Epub 2013 Apr 4.


  792. Injecting practices in sexual partnerships: Hepatitis C transmission potentials in a 'risk equivalence' framework
    Harris M, Rhodes T. Drug Alcohol Depend. 2013 May 7. pii: S0376-8716(13)00141-5. doi: 10.1016/j.drugalcdep.2013.04.012. [Epub ahead of print]


  793. Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma
    Lange CM, Bibert S, Dufour JF, Cellerai C, Cerny A, Heim MH, Kaiser L, Malinverni R, Müllhaupt B, Negro F, Semela D, Moradpour D, Kutalik Z, Bochud PY; Swiss Hepatitis C Cohort Study Group. J Hepatol. 2013 May 8. pii: S0168-8278(13)00287-0. doi: 10.1016/j.jhep.2013.04.032. [Epub ahead of print]


  794. Amiodarone inhibits the entry and assembly steps of Hepatitis C virus life cycle
    Cheng YL, Lan KH, Lee WP, Tseng SH, Hung LR, Lin HC, Lee FY, Lee SD, Lan KH. Clin Sci (Lond). 2013 May 9. [Epub ahead of print]


  795. IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis
    Rangnekar AS, Fontana RJ. J Viral Hepat. 2013 Jun;20(6):377-84. doi: 10.1111/jvh.12039. Epub 2013 Jan 7


  796. Response of hepatitis C virus to long-term passage in the presence of interferon-?. Multiple mutations and a common phenotype
    Perales C, Beach NM, Gallego I, Soria ME, Quer J, Esteban JI, Rice C, Domingo E, Sheldon J. J Virol. 2013 May 1. [Epub ahead of print]


  797. Increasing Hepatitis C Knowledge Among Homeless Adults: Results of a Community-Based, Interdisciplinary Intervention
    Tyler D, Nyamathi A, Stein JA, Koniak-Griffin D, Hodge F, Gelberg L. J Behav Health Serv Res. 2013 Apr 25. [Epub ahead of print]


  798. A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C-Associated Liver Cirrhosis
    Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, Verbaan H, Stål P, Carlsson T, Norrgren H, Ekbom A, Granath F, Hultcrantz R. Clin Infect Dis. 2013 May 14. [Epub ahead of print]


  799. Poor response to hepatitis C treatment in elderly patients
    Silva I, Carvalho Filho R, Feldner AC, Zaros I, Silva AE, Ferraz ML. Ann Hepatol. 2013 May-Jun;12(3):392-8.


  800. A Small Percentage of Patients with Hepatitis C Receive Triple Therapy with Boceprevir or Telaprevir
    Chen EY, Sclair SN, Czul F, Apica B, Dubin P, Martin P, Lee WM. Clin Gastroenterol Hepatol. 2013 Apr 16. pii: S1542-3565(13)00482-5. doi: 10.1016/j.cgh.2013.03.032. [Epub ahead of print]


  801. High tumor necrosis factor-?/interleukin-10 ratio is associated with hepatocellular carcinoma in patients with chronic hepatitis C
    Aroucha DC, do Carmo RF, Moura P, Silva JL, Vasconcelos LR, Cavalcanti MS, Muniz MT, Aroucha ML, Siqueira ER, Cahú GG, Pereira LM, Coêlho MR. Cytokine. 2013 Jun;62(3):421-5. doi: 10.1016/j.cyto.2013.03.024. Epub 2013 Apr 16.


  802. Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: A systematic review and meta-analysis
    Zhu Q, Li N, Han Q, Zhang P, Yang C, Zeng X, Chen Y, Lv Y, Liu X, Liu Z. Antiviral Res. 2013 Jun;98(3):373-9. doi: 10.1016/j.antiviral.2013.04.009. Epub 2013 Apr 16.


  803. Sofosbuvir for previously untreated chronic hepatitis C infection
    Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. N Engl J Med. 2013 May 16;368(20):1878-87. doi: 10.1056/NEJMoa1214853. Epub 2013 Apr 23.


  804. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options
    Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR; POSITRON Study; FUSION Study. N Engl J Med. 2013 May 16;368(20):1867-77. doi: 10.1056/NEJMoa1214854. Epub 2013 Apr 23.


  805. aProspective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8900 high-risk patients
    Izzo F, Piccirillo M, Albino V, Palaia R, Belli A, Granata V, Setola S, Fusco R, Petrillo A, Orlando R, Tosone G, Scordino F, Curley SA. HPB (Oxford). 2013 Apr 22. doi: 10.1111/hpb.12080. [Epub ahead of print]


  806. Treatment of chronic hepatitis C in end stage renal disease: experience at a tertiary care centre
    Duseja A, Choudhary NS, Gupta S, Dhiman RK, Chawla Y, Sakhuja V. Trop Gastroenterol. 2012 Jul-Sep;33(3):189-92.


  807. Hepatic triglyceride lipase plays an essential role in changing the lipid metabolism in genotype 1b hepatitis C virus replicon cells and hepatitis C patients
    Shinohara Y, Imajo K, Yoneda M, Tomeno W, Ogawa Y, Fujita K, Kirikoshi H, Takahashi J, Funakoshi K, Ikeda M, Kato N, Nakajima A, Saito S. Hepatol Res. 2013 Jan 14. doi: 10.1111/hepr.12072. [Epub ahead of print]


  808. The missing mass of morality: A new fitpack design for hepatitis C prevention in sexual partnerships
    Fraser S. Int J Drug Policy. 2013 May;24(3):212-9. doi: 10.1016/j.drugpo.2013.03.009. Epub 2013 Apr 18.


  809. Peg-IFN?/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24
    Saadoun D, Resche Rigon M, Thibault V, Longuet M, Pol S, Blanc F, Pialoux G, Karras A, Bazin-Karra D, Cazorla C, Vittecoq D, Musset L, Decaux O, Ziza JM, Lambotte O, Cacoub P. Ann Rheum Dis. 2013 Apr 20. [Epub ahead of print]


  810. Peg-IFN?/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24
    Saadoun D, Resche Rigon M, Thibault V, Longuet M, Pol S, Blanc F, Pialoux G, Karras A, Bazin-Karra D, Cazorla C, Vittecoq D, Musset L, Decaux O, Ziza JM, Lambotte O, Cacoub P. Ann Rheum Dis. 2013 Apr 20. [Epub ahead of print]


  811. Hepatitis C virus core antigen assay: can we think beyond convention in resource limited settings?
    Chakravarti A, Chauhan MS, Dogra G, Banerjee S. Braz J Infect Dis. 2013 May-Jun;17(3):369-74. doi: 10.1016/j.bjid.2012.10.028. Epub 2013 Apr 18.


  812. Oral supplementation with branched-chain amino acid granules prevents hepatocarcinogenesis in patients with hepatitis C-related cirrhosis: A propensity score analysis
    Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Niinomi T, Ito T, Hasegawa R, Ando Y, Yamamoto K, Tanaka T. Hepatol Res. 2013 Mar 29. doi: 10.1111/hepr.12120. [Epub ahead of print]


  813. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening
    Hahné SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar M. BMC Infect Dis. 2013 Apr 18;13(1):181. [Epub ahead of print]


  814. Impact of new therapeutics for hepatitis C virus infection in incarcerated populations
    Spaulding AS, Kim AY, Harzke AJ, Sullivan JC, Linas BP, Brewer A, Dickert J, McGovern BH, Strick LB, Trestman R, Ferguson WJ. Top Antivir Med. 2013 Feb-Mar;21(1):27-35.


  815. Missed opportunities for hepatitis C testing in opioid treatment programs
    Frimpong JA. Am J Public Health. 2013 Jun;103(6):1028-30. doi: 10.2105/AJPH.2012.301129. Epub 2013 Apr 18.


  816. Noninvasive Serum Fibrosis Markers for Screening and Staging Chronic Hepatitis C Virus Patients in a Large US Cohort
    Holmberg SD, Lu M, Rupp LB, Lamerato LE, Moorman AC, Vijayadeva V, Boscarino JA, Henkle EM, Gordon SC; for the Chronic Hepatitis Cohort Study (CHeCS) Investigators. Clin Infect Dis. 2013 May 8. [Epub ahead of print]


  817. Evaluating the Role of Macrocycles in the Susceptibility of Hepatitis C Virus NS3/4A Protease Inhibitors to Drug Resistance
    Ali A, Aydin C, Gildemeister R, Romano KP, Cao H, Ozen A, Soumana D, Newton A, Petropoulos CJ, Huang W, Schiffer CA. ACS Chem Biol. 2013 May 1. [Epub ahead of print]


  818. Hepatitis C virus: virology and life cycle
    Kim CW, Chang KM. Clin Mol Hepatol. 2013 Mar;19(1):17-25. doi: 10.3350/cmh.2013.19.1.17. Epub 2013 Mar 25.


  819. Hepatitis C virus targets the interferon-? JAK/STAT pathway by promoting proteasomal degradation in immune cells and hepatocytes
    Stevenson NJ, Bourke NM, Ryan EJ, Binder M, Fanning L, Johnston JA, Hegarty JE, Long A, O'Farrelly C. FEBS Lett. 2013 May 21;587(10):1571-8. doi: 10.1016/j.febslet.2013.03.041. Epub 2013 Apr 12.


  820. The hidden epidemic of hepatitis C virus infection in the United States: occult transmission and burden of disease
    Ward JW. Top Antivir Med. 2013 Feb-Mar;21(1):15-9.


  821. Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: Meta-analysis of clinical studies
    Fabrizi F, Dixit V, Messa P. J Med Virol. 2013 Jun;85(6):1019-27. doi: 10.1002/jmv.23562.


  822. Mutual Antagonism between Circadian Protein Period 2 and Hepatitis C Virus Replication in Hepatocytes
    Benegiamo G, Mazzoccoli G, Cappello F, Rappa F, Scibetta N, Oben J, Greco A, Williams R, Andriulli A, Vinciguerra M, Pazienza V. PLoS One. 2013 Apr 8;8(4):e60527. doi: 10.1371/journal.pone.0060527. Print 2013.


  823. CCR5-?32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection
    Suppiah V, Armstrong NJ, O'Connor KS, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M, Dore GJ, Irving WL, Powell E, Nattermann J, Mueller T, Riordan S, Stewart GJ, George J, Booth DR, Ahlenstiel G; and the International Hepatitis C Genetics Consortium (IHCGC), Michalk M, Malik B, McClure P, Smith S, Sheridan D, Snape E, Fragomeli V, Norris R, How-Chow D, Jonsson JR, Barrie H, Stelzer-Braid S, Fletcher S, Applegate T, Grebely J, Matthews G, Bharadwaj M, Smedile A. Genes Immun. 2013 Apr 18. doi: 10.1038/gene.2013.15. [Epub ahead of print]


  824. Presentation, Outcomes, and Response to Therapy Among Patients with Acute Exacerbation of Chronic Hepatitis C
    Sagnelli E, Pisaturo M, Stanzione M, Messina V, Alessio L, Sagnelli C, Starace M, Pasquale G, Coppola N. Clin Gastroenterol Hepatol. 2013 Apr 13. pii: S1542-3565(13)00466-7. doi: 10.1016/j.cgh.2013.03.025. [Epub ahead of print]


  825. Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials
    Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J, Tigges AM, Ghys A, Dorrian J, Adda N, Martin EC, Beumont M, Jacobson IM, Sherman KE, Zeuzem S, Picchio G, Kieffer TL. Clin Infect Dis. 2013 May 7. [Epub ahead of print]


  826. T cell receptor variable ? gene repertoire in liver and peripheral blood lymphocytes of chronically hepatitis C virus-infected patients with and without mixed cryoglobulinaemia
    Russi S, Lauletta G, Serviddio G, Sansonno S, Conteduca V, Sansonno L, De Re V, Sansonno D. Clin Exp Immunol. 2013 May;172(2):254-62. doi: 10.1111/cei.12035.


  827. Emerging Therapeutic Targets for Hepatitis C Virus Infection
    Jesudian AB, de Jong YP, Jacobson IM. Clin Gastroenterol Hepatol. 2013 Apr 11. pii: S1542-3565(13)00457-6. doi: 10.1016/j.cgh.2013.04.003. [Epub ahead of print]


  828. Syndecan-1 Serves as the Major Receptor for Attachment of Hepatitis C Virus to the surface of hepatocytes
    Shi Q, Jiang J, Luo G. J Virol. 2013 Apr 10. [Epub ahead of print]


  829. Psychological, lifestyle and social predictors of hepatitis C treatment response: a systematic review
    Sublette VA, Douglas MW, McCaffery K, George J, Perry KN. Liver Int. 2013 Feb 18. doi: 10.1111/liv.12138. [Epub ahead of print]


  830. Validation of a solid-phase electrochemical array for genotyping hepatitis C virus
    Sam SS, Steinmetz HB, Tsongalis GJ, Tafe LJ, Lefferts JA. Exp Mol Pathol. 2013 Apr 11;95(1):18-22. doi: 10.1016/j.yexmp.2013.04.001. [Epub ahead of print]


  831. Treatment of hepatitis C virus infection in the future
    Kanda T, Yokosuka O, Omata M. Clin Transl Med. 2013 Apr 11;2(1):9. doi: 10.1186/2001-1326-2-9.


  832. Hepatitis C Virus Core Protein Down-Regulates p21(Waf1/Cip1) and Inhibits Curcumin-Induced Apoptosis through MicroRNA-345 Targeting in Human Hepatoma Cells
    Shiu TY, Huang SM, Shih YL, Chu HC, Chang WK, Hsieh TY. PLoS One. 2013;8(4):e61089. doi: 10.1371/journal.pone.0061089. Epub 2013 Apr 8.


  833. Meta-analysis: pegylated interferon ?-2a achieves higher early virological responses than ?-2b in chronic hepatitis C
    Romero-Gómez M, Planas R, Ampuero J, Solà R, García-Samaniego J, Diago M, Crespo J, Calleja JL, Turnes J. Aliment Pharmacol Ther. 2013 Jun;37(11):1065-73. doi: 10.1111/apt.12314. Epub 2013 Apr 14.


  834. Sustained Hyperresponsiveness of Dendritic Cells is Associated with Spontaneous Resolution of Acute Hepatitis C
    Pelletier S, Bédard N, Said E, Ancuta P, Bruneau J, Shoukry NH. J Virol. 2013 Apr 10. [Epub ahead of print]


  835. Risk factors for recurrence after curative resection of hepatitis C-related hepatocellular carcinoma in patients without postoperative interferon therapy
    Yamashita YI, Shirabe K, Toshima T, Tsuijita E, Takeishi K, Harimoto N, Ikegami T, Yoshizumi T, Ikeda T, Soejima Y, Maehara Y. Hepatol Res. 2013 Mar 27. doi: 10.1111/hepr.12091. [Epub ahead of print]


  836. Hepatitis C virus therapy update 2013
    Casey LC, Lee WM. Curr Opin Gastroenterol. 2013 May;29(3):243-9. doi: 10.1097/MOG.0b013e32835ff972.


  837. Telaprevir-related dermatitis
    Roujeau JC, Mockenhaupt M, Tahan SR, Henshaw J, Martin EC, Harding M, van Baelen B, Bengtsson L, Singhal P, Kauffman RS, Stern RS. JAMA Dermatol. 2013 Feb;149(2):152-8.


  838. In vitro detection of hepatitis C virus in platelets from uninfected individuals exposed to the virus
    Padovani JL, Corvino SM, Drexler JF, Silva GF, Pardini MI, Grotto RM. Rev Soc Bras Med Trop. 2013 Apr 2:0. [Epub ahead of print]


  839. The role of natural killer cells in hepatitis C infection
    Howell J, Visvanathan K. Antivir Ther. 2013 Apr 4. doi: 10.3851/IMP2565. [Epub ahead of print]


  840. Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin
    Huang CF, Yeh ML, Hsieh MH, Hsieh MY, Lin ZY, Chen SC, Wang LY, Huang JF, Juo SH, Lin YC, Dai CY, Chuang WL, Yu ML. J Gastroenterol Hepatol. 2013 Apr 5. doi: 10.1111/jgh.12211. [Epub ahead of print]


  841. Interferon-lambda polymorphisms and hepatitis C virus clearance revisited
    Lupberger J, Felmlee DJ, Baumert TF. Hepatology. 2013 Apr 8. doi: 10.1002/hep.26443. [Epub ahead of print]


  842. IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients
    Jiménez-Sousa MA, Berenguer J, Rallón N, Guzmán-Fulgencio M, López JC, Soriano V, Fernández-Rodríguez A, Cosín J, Restrepo C, García-Álvarez M, Miralles P, Benito JM, Resino S. J Viral Hepat. 2013 May;20(5):358-66. doi: 10.1111/jvh.12041. Epub 2012 Dec 20.


  843. Faldaprevir (BI 201335), BI 207127 and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results
    Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Müllhaupt B, Gane E, Schuchmann M, Lohse AW, Pol S, Bronowicki JP, Roberts S, Arasteh K, Zoulim F, Heim M, Stern JO, Nehmiz G, Kukolj G, Böcher WO, Mensa FJ. Antivir Ther. 2013 Apr 4. doi: 10.3851/IMP2567. [Epub ahead of print]


  844. Hepatocyte destruction with enhanced collagen synthesis: characteristic feature of chronic hepatitis C patients on haemodialysis
    Ue M, Ikebe N, Munekage K, Ochi T, Hirose A, Kataoka H, Fujimoto S, Kikuchi K, Okuhara Y, Ono M, Saibara T. J Viral Hepat. 2013 May;20(5):350-7. doi: 10.1111/jvh.12031. Epub 2012 Dec 11.


  845. The role of the hepatitis viruses in cholangiocarcinoma
    Ralphs S, Khan SA. J Viral Hepat. 2013 May;20(5):297-305. doi: 10.1111/jvh.12093.


  846. Cancer biomarker profiling in patients with chronic hepatitis C virus, liver cirrhosis and hepatocellular carcinoma
    Costantini S, Capone F, Maio P, Guerriero E, Colonna G, Izzo F, Castello G. Oncol Rep. 2013 Jun;29(6):2163-8. doi: 10.3892/or.2013.2378. Epub 2013 Apr 3.


  847. ?-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C
    Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nakagawa M, Kakinuma S, Watanabe M, Izumi N. Hepatology. 2013 Apr 8. doi: 10.1002/hep.26442. [Epub ahead of print]


  848. Telaprevir: Clinical Pharmacokinetics, Pharmacodynamics, and Drug-Drug Interactions
    Kiang TK, Wilby KJ, Ensom MH. Clin Pharmacokinet. 2013 Apr 4. [Epub ahead of print]


  849. Hepatitis C virus adaptation to T-cell immune pressure
    Plauzolles A, Lucas M, Gaudieri S. ScientificWorldJournal. 2013;2013:673240. doi: 10.1155/2013/673240. Epub 2013 Mar 11.


  850. Hepatitis C and recurrent treatment-resistant acute ischemic stroke
    Saxsena A, Tarsia J, Dunn C, Aysenne A, Shah B, Moore DF. Proc (Bayl Univ Med Cent). 2013 Apr;26(2):182-4.


  851. HCV RNA viral load assessments in the era of direct-acting antivirals
    Cobb B, Pockros PJ, Vilchez RA, Vierling JM. Am J Gastroenterol. 2013 Apr;108(4):471-5. doi: 10.1038/ajg.2012.248.


  852. Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review
    Modabbernia A, Poustchi H, Malekzadeh R. Hepat Mon. 2013 Jan;13(1):e8340. doi: 10.5812/hepatmon.8340. Epub 2013 Jan 7.


  853. Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response
    Neukam K, Barreiro P, Rivero-Juárez A, Caruz A, Mira JA, Camacho A, Macías J, Rivero A, Soriano V, Pineda JA. J Infect. 2013 Mar 28. pii: S0163-4453(13)00066-2. doi: 10.1016/j.jinf.2013.03.010. [Epub ahead of print]


  854. Survival after surgery for hepatocellular carcinoma in relation to presence or absence of viral infection
    Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T. Am J Surg. 2013 Mar 30. pii: S0002-9610(13)00132-3. doi: 10.1016/j.amjsurg.2012.08.011. [Epub ahead of print]


  855. Genome-wide analysis of host mRNA translation during hepatitis C virus infection
    Colman H, Le Berre-Scoul C, Hernandez C, Pierredon S, Bihouée A, Houlgatte R, Vagner S, Rosenberg AR, Féray C. J Virol. 2013 Apr 3. [Epub ahead of print]


  856. Management of the Extrahepatic Symptoms of Chronic Hepatitis C: Feasibility of a Randomized Controlled Trial of Exercise
    McKenna O, Cunningham C, Gissane C, Blake C. Am J Phys Med Rehabil. 2013 Apr 2. [Epub ahead of print]


  857. Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study
    Nishiguchi S, Enomoto H, Aizawa N, Nishikawa H, Osaki Y, Tsuda Y, Higuchi K, Okazaki K, Seki T, Kim SR, Hongo Y, Jyomura H, Nishida N, Kudo M. J Gastroenterol. 2013 Mar 30. [Epub ahead of print]


  858. Systematic review: Asian patients with chronic hepatitis C infection
    Nguyen LH, Nguyen MH. Aliment Pharmacol Ther. 2013 May;37(10):921-36. doi: 10.1111/apt.12300. Epub 2013 Apr 5.


  859. Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review
    Bota S, Sporea I, Sirli R, Popescu A, Neghin? AM, D?nil? M, Str?in M. World J Hepatol. 2013 Mar 27;5(3):120-6. doi: 10.4254/wjh.v5.i3.120.


  860. SIGMA-1 RECEPTOR REGULATES EARLY STEPS OF VIRAL RNA REPLICATION AT THE ONSET OF HEPATITIS C VIRUS INFECTION
    Friesland M, Mingorance L, Chung J, Chisari FV, Gastaminza P. J Virol. 2013 Mar 27. [Epub ahead of print]


  861. Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States
    Liu S, Cipriano LE, Holodniy M, Goldhaber-Fiebert JD. PLoS One. 2013;8(3):e58975. doi: 10.1371/journal.pone.0058975. Epub 2013 Mar 22.


  862. Treatment of HCV infection by targeting microRNA
    Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR. N Engl J Med. 2013 May 2;368(18):1685-94. doi: 10.1056/NEJMoa1209026. Epub 2013 Mar 27.


  863. Development and evaluation of an internet and personal health record training program for low-income patients with HIV or hepatitis C
    McInnes DK, Solomon JL, Shimada SL, Petrakis BA, Bokhour BG, Asch SM, Nazi KM, Houston TK, Gifford AL. Med Care. 2013 Mar;51(3 Suppl 1):S62-6. doi: 10.1097/MLR.0b013e31827808bf.


  864. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management
    Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S. J Hepatol. 2013 Mar 27. pii: S0168-8278(13)00197-9. doi: 10.1016/j.jhep.2013.03.018. [Epub ahead of print]


  865. Role of Interleukin-28B Polymorphism as a Predictor of Sustained Virological Response in Patients with Chronic Hepatitis C Treated with Triple Therapy: A Systematic Review and Meta-Analysis
    Bota S, Sporea I, Sirli R, Neghin? AM, Popescu A, Str?in M. Clin Drug Investig. 2013 May;33(5):325-31. doi: 10.1007/s40261-013-0074-0.


  866. Combination therapy of natural human interferon-beta and ribavirin for chronic hepatitis C patients with injection drug use
    Morikawa H, Kozuka R, Fujii H, Iwai S, Enomoto M, Tamori A, Saito S, Kawada N. Hepatol Res. 2013 Mar 27. doi: 10.1111/hepr.12066. [Epub ahead of print]


  867. Ischemic colitis with type I interferons used in the treatment of hepatitis C and multiple sclerosis: an evaluation from the food and drug administration adverse event reporting system and review of the literature
    Salk A, Stobaugh DJ, Deepak P, Ehrenpreis ED. Ann Pharmacother. 2013 Apr;47(4):537-42. doi: 10.1345/aph.1R526. Epub 2013 Mar 27.


  868. Telaprevir: Changing the standard of care of chronic hepatitis C
    Rajani AK, Ravindra BK, Dkhar SA. J Postgrad Med. 2013 Jan-Mar;59(1):42-7. doi: 10.4103/0022-3859.109493.


  869. Progesterone suppresses interferon signaling by repressing TLR-7 and MxA expression in peripheral blood mononuclear cells of patients infected with hepatitis C virus
    Tayel SS, Helmy AA, Ahmed R, Esmat G, Hamdi N, Abdelaziz AI. Arch Virol. 2013 Mar 23. [Epub ahead of print]


  870. Incident Hepatitis C Virus Infection in Men Who Have Sex With Men: A Prospective Cohort Analysis, 1984-2011
    Witt MD, Seaberg EC, Darilay A, Young S, Badri S, Rinaldo CR, Jacobson LP, Detels R, Thio CL. Clin Infect Dis. 2013 Apr 22. [Epub ahead of print]


  871. Prediction of efficacy to pegylated interferon-?-2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks
    Wada Y, Tamai H, Uno A, Kawashima A, Shingaki N, Mori Y, Moribata K, Miyata K, Higashi K, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M. Hepatol Res. 2013 Feb 25. doi: 10.1111/hepr.12101. [Epub ahead of print]


  872. Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients
    Huang CF, Dai CY, Yeh ML, Huang JF, Huang CI, Hsieh MY, Lin ZY, Chen SC, Wang LY, Juo SH, Chuang WL, Lin YC, Yu ML. PLoS One. 2013;8(3):e58882. doi: 10.1371/journal.pone.0058882. Epub 2013 Mar 19.


  873. The Diagnostic Accuracy of Fibroscan for Cirrhosis is Influenced by Liver Morphometry in HCV Patients with a Sustained Virological Response
    D'Ambrosio R, Aghemo A, Fraquelli M, Grazia Rumi M, Francesca Donato M, Paradis V, Bedossa P, Colombo M. J Hepatol. 2013 Mar 22. pii: S0168-8278(13)00191-8. doi: 10.1016/j.jhep.2013.03.013. [Epub ahead of print]


  874. Pharmacokinetic Evaluation of the Interaction Between the HCV Protease Inhibitor Boceprevir and the HMG-CoA Reductase Inhibitors Atorvastatin and Pravastatin
    Hulskotte E, Feng HP, Xuan F, Gupta S, van Zutven M, O'Mara E, Wagner J, Butterton J. Antimicrob Agents Chemother. 2013 Mar 25. [Epub ahead of print]


  875. Patterns of Interferon-alpha Induced Thyroid Dysfunction Vary with Ethnicity, Sex, Smoking Status and Pre-Treatment TSH in an International Cohort of Patients Treated for Hepatitis C
    Mammen JS, Ghazarian SR, Rosen A, Ladenson PW. Thyroid. 2013 Mar 21. [Epub ahead of print]


  876. A health technology assessment of Transient Elastography is a Useful Clinical Tool to Detect Minimal Hepatic Encephalopathy in a Cohort of Compensated Cirrhotic Patients in adult liver disease
    Steadman R, Myers RP, Leggett L, Lorenzetti D, Noseworthy T, Rose S, Sutherland L, Clement F. Can J Gastroenterol. 2013 Mar;27(3):149-58.


  877. A novel strategy to inhibit the reproduction and translation of hepatitis C virus
    Duan A, Ning L, Li C, Hou Y, Yang N, Sun L, Li G. Sci China Life Sci. 2013 Apr;56(4):293-7. doi: 10.1007/s11427-013-4468-2. Epub 2013 Mar 20.


  878. Hepatitis C virus-induced mitochondrial dysfunctions
    Brault C, Levy PL, Bartosch B. Viruses. 2013 Mar 21;5(3):954-80. doi: 10.3390/v5030954.


  879. Spontaneous clearance and treatment of acute hepatitis C infection in HIV-positive men with 48 weeks of interferon-alpha and ribavirin
    Webster DP, Wojcikiewicz T, Keller M, Castelnovo D, Mistry H, Gilleece Y, Tibble J, Fisher M. Int J STD AIDS. 2013 Mar 20. [Epub ahead of print]


  880. Simultaneous detection of hepatitis c virus antigen and antibodies in dried blood spots
    Brandão CP, Marques BL, Marques VA, Villela-Nogueira CA, Do Ó KM, de Paula MT, Lewis-Ximenez LL, Lampe E, Sá Ferreira JA, Villar LM. J Clin Virol. 2013 Mar 18. pii: S1386-6532(13)00075-9. doi: 10.1016/j.jcv.2013.02.014. [Epub ahead of print]


  881. Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model
    Rong L, Guedj J, Dahari H, Coffield DJ Jr, Levi M, Smith P, Perelson AS. PLoS Comput Biol. 2013 Mar;9(3):e1002959. doi: 10.1371/journal.pcbi.1002959. Epub 2013 Mar 14.


  882. Serum aspartate aminotransferase levels and previous histopathological findings enable reduction of protocol liver biopsies after liver transplantation for hepatitis C
    Tanaka T, Therapondos G, Selzner N, Renner EL, Lilly LB. Can J Gastroenterol. 2013 Mar;27(3):131-6.


  883. Management of Hepatitis C Virus Infection in Heavy Drinkers
    Costentin CE, Trabut JB, Mallet V, Darbeda S, Thépot V, Nalpas B, Badin de Montjoye B, Lavielle B, Vallet-Pichard A, Sogni P, Pol S. Alcohol Alcohol. 2013 Mar 21. [Epub ahead of print]


  884. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial
    Deterding K, Grüner N, Buggisch P, Wiegand J, Galle PR, Spengler U, Hinrichsen H, Berg T, Potthoff A, Malek N, Großhennig A, Koch A, Diepolder H, Lüth S, Feyerabend S, Jung MC, Rogalska-Taranta M, Schlaphoff V, Cornberg M, Manns MP, Wedemeyer H; for The Hep-Net Acute HCV-III Study Group. Lancet Infect Dis. 2013 Mar 21. pii: S1473-3099(13)70059-8. doi: 10.1016/S1473-3099(13)70059-8. [Epub ahead of print]


  885. Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection
    Tsan YT, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC. J Clin Oncol. 2013 Mar 18. [Epub ahead of print]


  886. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir
    McPhee F, Hernandez D, Yu F, Ueland J, Monikowski A, Carifa A, Falk P, Wang C, Fridell R, Eley T, Zhou N, Gardiner D. Hepatology. 2013 Mar 15. doi: 10.1002/hep.26388. [Epub ahead of print]


  887. The incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta-analysis
    Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, Hagan H, Rich JD, van den Bergh BJ, Degenhardt L. Hepatology. 2013 Mar 15. doi: 10.1002/hep.26387. [Epub ahead of print]


  888. Recurrent hepatitis C and non-alcoholic fatty liver disease in transplanted patients: a review
    Testino G, Sumberaz A, Leone S, Borro P. Minerva Med. 2013 Apr;104(2):225-32.


  889. Pretransplant serum hepatitis C virus RNA levels predict response to antiviral treatment after living donor liver transplantation
    Ueda Y, Kaido T, Ogura Y, Ogawa K, Yoshizawa A, Hata K, Fujimoto Y, Miyagawa-Hayashino A, Haga H, Marusawa H, Teramukai S, Uemoto S, Chiba T. PLoS One. 2013;8(3):e58380. doi: 10.1371/journal.pone.0058380. Epub 2013 Mar 7.


  890. Sustained Virological Response following Chronic Hepatitis C treatment is associated with improvement in Insulin Resistance (Insulin Resistance in Hepatitis C)
    Chan CH, Hansen RD, Gilliver RS, Jones BE. Intern Med J. 2013 Mar 19. doi: 10.1111/imj.12136. [Epub ahead of print]


  891. Prevalence and predictors of hepatitis B virus co-infection in a united states cohort of hepatitis C virus-infected patients
    Tyson GL, Kramer JR, Duan Z, Davila JA, Richardson PA, El-Serag HB. Hepatology. 2013 Mar 16. doi: 10.1002/hep.26400. [Epub ahead of print]


  892. Liver fibrosis staging through a stepwise analysis of non-invasive markers (FibroSteps) in patients with chronic hepatitis C infection
    El-Kamary SS, Mohamed MM, El-Raziky M, Shardell MD, Shaker OG, Elakel WA, Esmat G. Liver Int. 2013 Feb 15. doi: 10.1111/liv.12139. [Epub ahead of print]


  893. Birth Cohort Screening for Chronic Hepatitis During Colonoscopy Appointments
    Sears DM, Cohen DC, Ackerman K, Ma JE, Song J. Am J Gastroenterol. 2013 Mar 19. doi: 10.1038/ajg.2013.50. [Epub ahead of print]


  894. Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know
    Kim YH, Kim do Y. Oncology. 2013;84 Suppl 1:34-9. doi: 10.1159/000345887. Epub 2013 Feb 20.


  895. Hepatitis C virus vaccines - Progress and perspectives
    Fauvelle C, Lepiller Q, Felmlee DJ, Fofana I, Habersetzer F, Stoll-Keller F, Baumert TF, Fafi-Kremer S. Microb Pathog. 2013 Mar 7. pii: S0882-4010(13)00025-9. doi: 10.1016/j.micpath.2013.02.005. [Epub ahead of print]


  896. Transient Elastography is a Useful Clinical Tool to Detect Minimal Hepatic Encephalopathy in a Cohort of Compensated Cirrhotic Patients in hepatitis C virus-infected patients with beta-thalassemia for assessment of fibrosis
    Poustchi H, Eslami M, Ostovaneh MR, Modabbernia A, Saeedian FS, Taslimi S, George J, Malekzadeh R, Zamani F. Hepatol Res. 2013 Feb 7. doi: 10.1111/hepr.12088. [Epub ahead of print]


  897. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
    Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A. Lancet Infect Dis. 2013 Mar 14. pii: S1473-3099(13)70033-1. doi: 10.1016/S1473-3099(13)70033-1. [Epub ahead of print]


  898. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
    Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, Demicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Lancet. 2013 Mar 14. pii: S0140-6736(13)60247-0. doi: 10.1016/S0140-6736(13)60247-0. [Epub ahead of print]


  899. A Comparison of Modified Directly Observed Therapy to Standard Care for Chronic Hepatitis C
    Cioe PA, Stein MD, Promrat K, Friedmann PD. J Community Health. 2013 Mar 8. [Epub ahead of print]


  900. IL-28B (IFN-?3) and IFN-? synergistically inhibit HCV replication
    Shindo H, Maekawa S, Komase K, Miura M, Kadokura M, Sueki R, Komatsu N, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. J Viral Hepat. 2013 Apr;20(4):281-9. doi: 10.1111/j.1365-2893.2012.01649.x. Epub 2012 Aug 7.


  901. Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study
    Piluso A, Giannini C, Fognani E, Gragnani L, Caini P, Monti M, Petrarca A, Ranieri J, Urraro T, Triboli E, Laffi G, Zignego AL. J Viral Hepat. 2013 Apr;20(4):e107-14. doi: 10.1111/jvh.12017. Epub 2012 Dec 4.


  902. 'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype-3a infection and do not predict sustained virological response after 24 weeks of therapy
    Bucci C, von Delft A, Cristian A, Flemming VM, Harrison A, Halliday J, Collier J, Manganis C, Klenerman P, Irving W, Barnes E. J Gen Virol. 2013 Mar 13. [Epub ahead of print]


  903. Impairment of health-related quality of life in patients with chronic hepatitis C is associated with insulin resistance
    Kuwashiro T, Mizuta T, Kawaguchi Y, Iwane S, Takahashi H, Oza N, Oeda S, Isoda H, Eguchi Y, Ozaki I, Anzai K, Fujimoto K. J Gastroenterol. 2013 Mar 16. [Epub ahead of print]


  904. Hepatitis C infection and hepatocellular carcinoma in liver transplantation: a 20-year experience
    Dumitra S, Alabbad SI, Barkun JS, Dumitra TC, Coutsinos D, Metrakos PP, Hassanain M, Paraskevas S, Chaudhury P, Tchervenkov JI. HPB (Oxford). 2013 Mar 14. doi: 10.1111/hpb.12041. [Epub ahead of print]


  905. Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification
    Ross RS, Stambouli O, Grüner N, Marcus U, Cai W, Zhang W, Zimmermann R, Roggendorf M. Virol J. 2013 Mar 5;10:72. doi: 10.1186/1743-422X-10-72.


  906. Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know
    Kim YH, Kim do Y. Oncology. 2013;84 Suppl 1:34-9. doi: 10.1159/000345887. Epub 2013 Feb 20.


  907. Hepatitis C virus vaccines - Progress and perspectives
    Fauvelle C, Lepiller Q, Felmlee DJ, Fofana I, Habersetzer F, Stoll-Keller F, Baumert TF, Fafi-Kremer S. Microb Pathog. 2013 Mar 7. pii: S0882-4010(13)00025-9. doi: 10.1016/j.micpath.2013.02.005. [Epub ahead of print]


  908. Transient Elastography is a Useful Clinical Tool to Detect Minimal Hepatic Encephalopathy in a Cohort of Compensated Cirrhotic Patients in hepatitis C virus-infected patients with beta-thalassemia for assessment of fibrosis
    Poustchi H, Eslami M, Ostovaneh MR, Modabbernia A, Saeedian FS, Taslimi S, George J, Malekzadeh R, Zamani F. Hepatol Res. 2013 Feb 7. doi: 10.1111/hepr.12088. [Epub ahead of print]


  909. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
    Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A. Lancet Infect Dis. 2013 Mar 14. pii: S1473-3099(13)70033-1. doi: 10.1016/S1473-3099(13)70033-1. [Epub ahead of print]


  910. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
    Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, Demicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Lancet. 2013 Mar 14. pii: S0140-6736(13)60247-0. doi: 10.1016/S0140-6736(13)60247-0. [Epub ahead of print]


  911. A Comparison of Modified Directly Observed Therapy to Standard Care for Chronic Hepatitis C
    Cioe PA, Stein MD, Promrat K, Friedmann PD. J Community Health. 2013 Mar 8. [Epub ahead of print]


  912. IL-28B (IFN-?3) and IFN-? synergistically inhibit HCV replication
    Shindo H, Maekawa S, Komase K, Miura M, Kadokura M, Sueki R, Komatsu N, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. J Viral Hepat. 2013 Apr;20(4):281-9. doi: 10.1111/j.1365-2893.2012.01649.x. Epub 2012 Aug 7.


  913. Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study
    Piluso A, Giannini C, Fognani E, Gragnani L, Caini P, Monti M, Petrarca A, Ranieri J, Urraro T, Triboli E, Laffi G, Zignego AL. J Viral Hepat. 2013 Apr;20(4):e107-14. doi: 10.1111/jvh.12017. Epub 2012 Dec 4.


  914. 'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype-3a infection and do not predict sustained virological response after 24 weeks of therapy
    Bucci C, von Delft A, Cristian A, Flemming VM, Harrison A, Halliday J, Collier J, Manganis C, Klenerman P, Irving W, Barnes E. J Gen Virol. 2013 Mar 13. [Epub ahead of print]


  915. Impairment of health-related quality of life in patients with chronic hepatitis C is associated with insulin resistance
    Kuwashiro T, Mizuta T, Kawaguchi Y, Iwane S, Takahashi H, Oza N, Oeda S, Isoda H, Eguchi Y, Ozaki I, Anzai K, Fujimoto K. J Gastroenterol. 2013 Mar 16. [Epub ahead of print]


  916. Hepatitis C infection and hepatocellular carcinoma in liver transplantation: a 20-year experience
    Dumitra S, Alabbad SI, Barkun JS, Dumitra TC, Coutsinos D, Metrakos PP, Hassanain M, Paraskevas S, Chaudhury P, Tchervenkov JI. HPB (Oxford). 2013 Mar 14. doi: 10.1111/hpb.12041. [Epub ahead of print]


  917. Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification
    Ross RS, Stambouli O, Grüner N, Marcus U, Cai W, Zhang W, Zimmermann R, Roggendorf M. Virol J. 2013 Mar 5;10:72. doi: 10.1186/1743-422X-10-72.


  918. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. Preventive Services Task Force
    Cottrell EB, Chou R, Wasson N, Rahman B, Guise JM. Ann Intern Med. 2013 Jan 15;158(2):109-13.


  919. Diabetes and Infections-Hepatitis C: Is There Type 2 Diabetes Excess in Hepatitis C Infection?
    Naing C, Mak JW, Wai N, Maung M. Curr Diab Rep. 2013 Mar 7. [Epub ahead of print]


  920. Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients
    Macías J, Rivero A, Cifuentes C, Camacho A, Neukam K, Rivero-Juárez A, Mira JA, Torre-Cisneros J, Gómez-Mateos J, Pineda JA. Enferm Infecc Microbiol Clin. 2013 Feb 28. pii: S0213-005X(12)00443-0. doi: 10.1016/j.eimc.2012.12.004. [Epub ahead of print]


  921. The predictive value of steatosis in hepatitis C virus infection
    Adinolfi LE, Restivo L, Marrone A. Expert Rev Gastroenterol Hepatol. 2013 Mar;7(3):205-13. doi: 10.1586/egh.13.7.


  922. The Hepatitis C Self-Management Program: Sustainability of Primary Outcomes at 1 Year
    Groessl EJ, Ho SB, Asch SM, Stepnowsky CJ, Laurent D, Gifford AL. Health Educ Behav. 2013 Feb 27. [Epub ahead of print]


  923. Perspectives of a self-selected sample of former patients on the long-term health outcomes of interferon-based hepatitis C treatments: an exploratory study
    Hopwood M.


  924. The origin of hepatitis C virus
    Simmonds P. Curr Top Microbiol Immunol. 2013;369:1-15. doi: 10.1007/978-3-642-27340-7_1.


  925. A high MELD score, combined with the presence of hepatitis C, is associated with a poor prognosis in living donor liver transplantation
    Ikegami T, Shirabe K, Yoshiya S, Yoshizumi T, Yamashita YI, Harimoto N, Toshima T, Uchiyama H, Soejima Y, Maehara Y. Surg Today. 2013 Feb 23. [Epub ahead of print]


  926. Antiviral Activity of Boceprevir Monotherapy in Treatment-Naive Subjects With Chronic Hepatitis C Genotype 2/3
    Silva MO, Treitel M, Graham DJ, Curry S, Frontera MJ, McMonagle P, Gupta S, Hughes E, Chase R, Lahser F, Barnard RJ, Howe AY, Howe JA. J Hepatol. 2013 Feb 27. pii: S0168-8278(13)00140-2. doi: 10.1016/j.jhep.2013.02.018. [Epub ahead of print]


  927. Profile of alisporivir and its potential in the treatment of hepatitis C
    Gallay PA, Lin K. Drug Des Devel Ther. 2013;7:105-15. doi: 10.2147/DDDT.S30946. Epub 2013 Feb 15.


  928. Risk of Pancreatic Cancer in Relation to ABO Blood Group and Hepatitis C Virus Infection in Korea: A Case-Control Study
    Woo SM, Joo J, Lee WJ, Park SJ, Han SS, Kim TH, Koh YH, Kim HB, Hong EK. J Korean Med Sci. 2013 Feb;28(2):247-51. doi: 10.3346/jkms.2013.28.2.247. Epub 2013 Jan 29.


  929. Therapy for HCV Infection Increases Survival of Patients with Pre-Treatment Anemia
    Mohanty A, Erqou S, McGinnis KA, Vanasse G, Freiberg MS, Sherman KE, Butt AA. Clin Gastroenterol Hepatol. 2013 Jan 31. pii: S1542-3565(13)00166-3. doi: 10.1016/j.cgh.2013.01.023. [Epub ahead of print]


  930. A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots
    Shepherd SJ, Kean J, Hutchinson SJ, Cameron SO, Goldberg DJ, Carman WF, Gunson RN, Aitken C. J Clin Virol. 2013 Jan 28. pii: S1386-6532(13)00005-X. doi: 10.1016/j.jcv.2013.01.002. [Epub ahead of print]


  931. High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C
    Petta S, Handberg A, Marchesini G, Cammà C, Di Marco V, Cabibi D, Macaluso FS, Craxì A. J Viral Hepat. 2013 Mar;20(3):174-82. doi: 10.1111/j.1365-2893.2012.01641.x. Epub 2012 Jul 9.


  932. Serum fibrinogen alpha C-chain 5.9 kDa fragment (FIC 5.9) as a biomarker for early detection of hepatic fibrosis related to hepatitis C virus
    Sogawa K, Noda K, Umemura H, Seimiya M, Kuga T, Tomonaga T, Nishimura M, Kanai F, Imazeki F, Takizawa H, Yoneda M, Nakajima A, Tsutsumi M, Yokosuka O, Nomura F. Proteomics Clin Appl. 2013 Feb 4. doi: 10.1002/prca.201200094. [Epub ahead of print]


  933. The Association of IL28B Polymorphism and Graft Survival in Patients with Hepatitis C Undergoing Liver Transplantation
    Allam SR, Krüger B, Mehrotra A, Schiano T, Schröppel B, Murphy B. PLoS One. 2013;8(1):e54854. doi: 10.1371/journal.pone.0054854. Epub 2013 Jan 30.


  934. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors
    Hernandez D, Zhou N, Ueland J, Monikowski A, McPhee F. J Clin Virol. 2013 Feb 2. pii: S1386-6532(13)00007-3. doi: 10.1016/j.jcv.2012.12.020. [Epub ahead of print]


  935. Frequency of Thyroid Dysfunctions during Interferon Alpha Treatment of Single and Combination Therapy in Hepatitis C Virus-Infected Patients: A Systematic Review Based Analysis
    Nair Kesavachandran C, Haamann F, Nienhaus A. PLoS One. 2013;8(2):e55364. doi: 10.1371/journal.pone.0055364. Epub 2013 Feb 1.


  936. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting
    Maasoumy B, Port K, Markova AA, Serrano BC, Rogalska-Taranta M, Sollik L, Mix C, Kirschner J, Manns MP, Wedemeyer H, Cornberg M. PLoS One. 2013;8(2):e55285. doi: 10.1371/journal.pone.0055285. Epub 2013 Feb 1.


  937. A Survey of Hepatitis C Treatment Clinical Practice Patterns Using the Newly Approved Protease Inhibitors
    Chen EY, Lee WM, Hynan LS, Singal AG. J Clin Gastroenterol. 2013 Mar 6. [Epub ahead of print]


  938. The Efficacy and Safety of Telaprevir-based Regimens for Treating Chronic Hepatitis C Virus Genotype 1 Infection: A Meta-analysis of Randomized Trials
    Yang D, Liang HJ, Li D, Wei X, Ma L, Jia Z. Intern Med. 2013;52(6):653-60. Epub 2013 Mar 15.


  939. New therapeutic strategies in HCV: second-generation protease inhibitors
    Clark VC, Peter JA, Nelson DR. Liver Int. 2013 Feb;33 Suppl 1:80-4. doi: 10.1111/liv.12061.


  940. Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin
    Yi NJ, Choi JY, Suh KS, Cho JY, Baik M, Hong G, Lee KW, Kim W, Kim YJ, Yoon JH, Lee HS, Kim DG. J Gastroenterol. 2013 Mar 6. [Epub ahead of print]


  941. Equal efficacy between the two types of peginterferon on HCV: A matter of relapse?
    Brochot E, Nguyen-Khac E, Duverlie G. Antiviral Res. 2013 Feb 16;98(1):1-3. doi: 10.1016/j.antiviral.2013.02.006. [Epub ahead of print]


  942. Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C
    Younossi ZM, Zheng L, Stepanova M, Venkatesan C, Mir HM. Aliment Pharmacol Ther. 2013 Apr;37(7):703-9. doi: 10.1111/apt.12265. Epub 2013 Feb 24.


  943. The impact of timing and prioritisation on the cost-effectiveness of birth-cohort testing and treatment for hepatitis C virus in the U.S
    McEwan P, Ward T, Yuan Y, Kim R, L'italien G. Hepatology. 2013 Feb 6. doi: 10.1002/hep.26304. [Epub ahead of print]


  944. Testing for hepatitis B infection in prospective chemotherapy patients: A retrospective study
    Wang Y, Luo XM, Yang D, Zhang J, Zhuo HY, Zhang J, Jiang Y. World J Gastroenterol. 2013 Feb 14;19(6):923-30. doi: 10.3748/wjg.v19.i6.923.


  945. Recurrent hepatitis C virus infection post liver transplantation: impact of choice of calcineurin inhibitor
    Duvoux C, Firpi R, Grazi GL, Levy G, Renner E, Villamil F. Transpl Int. 2013 Feb 18. doi: 10.1111/tri.12065. [Epub ahead of print]


  946. Physical, social, and psychological consequences of treatment for hepatitis C : a community-based evaluation of patient-reported outcomes
    Manos MM, Ho CK, Murphy RC, Shvachko VA. Patient. 2013;6(1):23-34. doi: 10.1007/s40271-013-0005-4.


  947. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
    Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, Layden TJ, Uprichard SL, Perelson AS. Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3991-6. doi: 10.1073/pnas.1203110110. Epub 2013 Feb 19.


  948. Intrafamilial transmission of hepatitis C virus
    Indolfi G, Nesi A, Resti M. J Med Virol. 2013 Apr;85(4):608-14. doi: 10.1002/jmv.23522.


  949. Future therapies for chronic hepatitis C
    Dabbouseh NM, Jensen DM. Nat Rev Gastroenterol Hepatol. 2013 Feb 19. doi: 10.1038/nrgastro.2013.17. [Epub ahead of print]


  950. HIV and Hepatitis C Virus: Special Concerns for Patients With Cirrhosis.
    Curry MP. J Infect Dis. 2013 Mar;207 Suppl 1:S40-4. doi: 10.1093/infdis/jis763.


  951. Treatment Outcomes of Treatment-Naïve Hepatitis C Patients Co-Infected with HIV: A Systematic Review and Meta-Analysis of Observational Cohorts
    Davies A, Singh KP, Shubber Z, Ducros P, Mills EJ, Cooke G, Ford N. PLoS One. 2013;8(2):e55373. doi: 10.1371/journal.pone.0055373. Epub 2013 Feb 5.


  952. Association of Interleukin 28B genotype and hepatocellular carcinoma recurrence in patients with chronic hepatitis C
    Hodo Y, Honda M, Tanaka A, Nomura Y, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Sakai A, Sasaki M, Nakanuma Y, Moriyama M, Kaneko S. Clin Cancer Res. 2013 Feb 20. [Epub ahead of print]


  953. Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients
    Joshi D, Carey I, Agarwal K. Aliment Pharmacol Ther. 2013 Apr;37(7):659-71. doi: 10.1111/apt.12260. Epub 2013 Feb 21.


  954. Pegylated Interferon-?2a and Ribavirin versus Pegylated Interferon-?2b and Ribavirin in Chronic Hepatitis C : A Meta-Analysis
    Flori N, Funakoshi N, Duny Y, Valats JC, Bismuth M, Christophorou D, Daurès JP, Blanc P. Drugs. 2013 Mar;73(3):263-77. doi: 10.1007/s40265-013-0027-1.


  955. Hepatitis C virus in pregnancy
    Prasad MR, Honegger JR. Am J Perinatol. 2013 Feb;30(2):149-60. doi: 10.1055/s-0033-1334459. Epub 2013 Feb 6.


  956. Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-?2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 Trial
    Ogert RA, Howe JA, Vierling JM, Kwo PY, Lawitz EJ, McCone J, Schiff ER, Pound D, Davis MN, Gordon SC, Ravendhran N, Rossaro L, Jacobson IM, Ralston R, Chaudhri E, Qiu P, Pedicone LD, Brass CA, Albrecht JK, Barnard RJ, Hazuda DJ, Howe AY. Antivir Ther. 2013 Feb 12. doi: 10.3851/IMP2549. [Epub ahead of print]


  957. Vitamin D deficiency and vitamin D therapy in chronic hepatitis C
    Ladero JM, Torrejón MJ, Sánchez-Pobre P, Suárez A, Cuenca F, de la Orden V, Devesa MJ, Rodrigo M, Estrada V, López-Alonso G, Agúndez JA. Ann Hepatol. 2013 Mar;12(2):199-204.


  958. Highlights of the 2012 American Association for the Study of Liver Diseases meeting
    Osborn MK. r Med. 2012 Dec;20(5):180-4.


  959. Adherence and completion in hepatitis C management: a systematic review
    Redulla R, Dudley-Brown S. Gastroenterol Nurs. 2013 Jan;36(1):53-8. doi: 10.1097/SGA.0b013e318281634e.


  960. Management of hepatitis C virus infection: the basics
    Naggie S. Top Antivir Med. 2012 Dec;20(5):154-61.


  961. Hepatitis C virus vaccines in the era of new direct-acting antivirals
    Shi C, Ploss A. Expert Rev Gastroenterol Hepatol. 2013 Feb;7(2):171-85. doi: 10.1586/egh.12.72.


  962. Pegylated interferon monotherapy in patients with chronic hepatitis C with low viremia and its relationship to mutations in the NS5A region and the single nucleotide polymorphism of interleukin-28B
    Hayashi K, Katano Y, Masuda H, Ishizu Y, Kuzuya T, Honda T, Ishigami M, Itoh A, Hirooka Y, Nakano I, Ishikawa T, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H. Hepatol Res. 2012 Oct 18. doi: 10.1111/hepr.12005. [Epub ahead of print]


  963. The ratio of insulin-like growth factor-I/insulin-like growth factor-binding protein-3 in sera of patients with hepatitis C virus-related chronic liver disease as a predictive marker of insulin resistance
    Himoto T, Tani J, Miyoshi H, Yoneyama H, Mori H, Inukai M, Masugata H, Goda F, Senda S, Haba R, Masaki T. Nutr Res. 2013 Jan;33(1):27-33. doi: 10.1016/j.nutres.2012.11.007. Epub 2012 Dec 20.


  964. Telaprevir Versus Boceprevir in Chronic Hepatitis C: A Meta-Analysis of Data From Phase II and III Trials
    Sitole M, Silva M, Spooner L, Comee MK, Malloy M. Clin Ther. 2013 Feb;35(2):190-7. doi: 10.1016/j.clinthera.2012.12.017. Epub 2013 Jan 29.


  965. Safety and Effectiveness of a Nurse-Led Outreach Program for Assessment and Treatment of Chronic Hepatitis C in the Custodial Setting
    Lloyd AR, Clegg J, Lange J, Stevenson A, Post JJ, Lloyd D, Rudge G, Boonwaat L, Forrest G, Douglas J, Monkley D. Clin Infect Dis. 2013 Jan 29. [Epub ahead of print]


  966. Closing in on the Target: Sustained Virologic Response in Hepatitis C Virus Genotype 1 Infection Response-Guided Therapy
    Lontok E, Mani N, Harrington PR, Miller V. Clin Infect Dis. 2013 Feb 12. [Epub ahead of print]


  967. Review of drug interactions with telaprevir and antiretrovirals
    van Heeswijk RP, Beumont M, Kauffman RS, Garg V. Antivir Ther. 2013 Jan 23. doi: 10.3851/IMP2527. [Epub ahead of print]


  968. Influence of healthcare-associated factors on the efficacy of hepatitis C therapy
    Daw MA, Dau AA, Agnan MM. ScientificWorldJournal. 2012;2012:580216. doi: 10.1100/2012/580216. Epub 2012 Dec 27.


  969. Host genetic variants in the pathogenesis of hepatitis C
    Rau M, Baur K, Geier A. Viruses. 2012 Dec;4(12):3281-302.


  970. Polymorphisms near Interleukin 28B Gene Are Not Associated with Hepatitis B Virus Clearance, Hepatitis B e Antigen Clearance and Hepatocellular Carcinoma Occurrence
    Lee DH, Cho Y, Seo JY, Kwon JH, Cho EJ, Jang ES, Kwak MS, Cheong JY, Cho SW, Lee JH, Yu SJ, Yoon JH, Lee HS, Kim CY, Shin HD, Kim YJ. Intervirology. 2013 Jan 22. [Epub ahead of print]


  971. Neurocognitive Deficits Associated With the Hepatitis C Virus Among Incarcerated Men
    Umaki TM, Denney RL. Clin Neuropsychol. 2013 Jan 24. [Epub ahead of print]


  972. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma
    Arzumanyan A, Reis HM, Feitelson MA. Nat Rev Cancer. 2012 Dec 21;13(2):123-35. doi: 10.1038/nrc3449.


  973. Recurrent hepatitis C virus after transplant and the importance of plasma cells on biopsy
    Kallwitz ER. World J Gastroenterol. 2013 Jan 14;19(2):158-60. doi: 10.3748/wjg.v19.i2.158.


  974. Economic burden and current managed care challenges associated with hepatitis c
    Mathis AS. Am J Manag Care. 2012 Dec;18(14 Suppl):s350-9


  975. Interventions to Improve Patient Adherence to Hepatitis C Treatment: Comparative Effectiveness [Internet]
    Sun X, Patnode CD, Williams C, Senger CA, Kapka TJ, Whitlock EP.


  976. A Review of standard and newer treatment strategies in hepatitis c
    Tran TT. Am J Manag Care. 2012 Dec;18(14 Suppl):s340-9.


  977. Telaprevir for genotype 1 chronic hepatitis C: a systematic review and meta-analysis
    Gu L, Chen Q, Xie J, Yan Y, Wu G, Tan J, Liang B, Chen W, Wu P, Su L, Tang N. Pharmazie. 2012 Dec;67(12):963-72.


  978. Serum Apoptosis Markers Related to Liver Damage in Chronic Hepatitis C: sFas as a Marker of Advanced Fibrosis in Children and Adults While M30 of Severe Steatosis Only in Children
    Valva P, Casciato P, Lezama C, Galoppo M, Gadano A, Galdame O, Galoppo MC, Mullen E, De Matteo E, Preciado MV. PLoS One. 2013;8(1):e53519. doi: 10.1371/journal.pone.0053519. Epub 2013 Jan 11.


  979. Overview of epidemiology, diagnosis, and disease progression associated with hepatitis c
    Tran TT. Am J Manag Care. 2012 Dec;18(14 Suppl):s335-9.


  980. Prognostic Gene-Expression Signature for Patients with Hepatitis C-Related Early-Stage Cirrhosis
    Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, Minguez B, Iavarone M, Friedman SL, Colombo M, Llovet JM, Golub TR. Gastroenterology. 2013 Jan 17. pii: S0016-5085(13)00078-4. doi: 10.1053/j.gastro.2013.01.021. [Epub ahead of print]


  981. Detection of Hepatocellular Carcinoma at Advanced Stages Among Patients in the HALT-C Trial: Where Did Surveillance Fail?
    Singal AG, Nehra M, Adams-Huet B, Yopp AC, Tiro JA, Marrero JA, Lok AS, Lee WM. Am J Gastroenterol. 2013 Jan 22. doi: 10.1038/ajg.2012.449. [Epub ahead of print]


  982. IL28B in the Era of Direct-acting Antivirals for Hepatitis C
    Muir AJ. J Clin Gastroenterol. 2013 Mar;47(3):222-7. doi: 10.1097/MCG.0b013e3182680221.


  983. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma
    Tanaka S, Miyanishi K, Kobune M, Kawano Y, Hoki T, Kubo T, Hayashi T, Sato T, Sato Y, Takimoto R, Kato J. J Gastroenterol. 2013 Jan 19. [Epub ahead of print]


  984. Spleen stiffness: Towards a non-invasive portal sphygmomanometer?
    Abraldes JG, Reverter E, Berzigotti A. Hepatology. 2013 Jan 21. doi: 10.1002/hep.26239. [Epub ahead of print]


  985. Performance of liver stiffness measurements by Transient Elastography is a Useful Clinical Tool to Detect Minimal Hepatic Encephalopathy in a Cohort of Compensated Cirrhotic Patients in chronic hepatitis
    Ferraioli G, Tinelli C, Bello BD, Zicchetti M, Lissandrin R, Filice G, Filice C, Above E, Barbarini G, Brunetti E, Calderon W, Gregorio MD, Gulminetti R, Lanzarini P, Ludovisi S, Maiocchi L, Malfitano A, Michelone G, Minoli L, Mondelli M, Novati S, Patruno SF, Perretti A, Poma G, Sacchi P, Zanaboni D, Zaramella M. World J Gastroenterol. 2013 Jan 7;19(1):49-56. doi: 10.3748/wjg.v19.i1.49.


  986. Hepatitis C virus core antigen test in monitoring of dialysis patients
    Li Cavoli G, Zagarrigo C, Schillaci O, Servillo F, Tralongo A, Coglitore M, Spadaro F, Scimeca C, Li Destri N, Rotolo U. Hepat Res Treat. 2012;2012:832021. doi: 10.1155/2012/832021. Epub 2012 Dec 4.


  987. Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices
    Di Marco V, Calvaruso V, Grimaudo S, Ferraro D, Pipitone RM, Di Stefano R, Craxì A. J Viral Hepat. 2013 Feb;20(2):113-21. doi: 10.1111/j.1365-2893.2012.01637.x. Epub 2012 Jul 25.


  988. Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4
    Domagalski K, Paw?owska M, Tretyn A, Halota W, Pilarczyk M, Smukalska E, Linkowska K, Grzybowski T. Eur J Clin Microbiol Infect Dis. 2013 Jan 13. [Epub ahead of print]


  989. Portal Vein Thrombosis in Patients with End Stage Liver Disease Awaiting Liver Transplantation: Outcome of Anticoagulation
    Werner KT, Sando S, Carey EJ, Vargas HE, Byrne TJ, Douglas DD, Harrison ME, Rakela J, Aqel BA. Dig Dis Sci. 2013 Jan 12. [Epub ahead of print]


  990. Treatment of hepatitis C: how will we use viral kinetics, response-guided therapy?
    Pawlotsky JM. Curr Gastroenterol Rep. 2013 Feb;15(2):309. doi: 10.1007/s11894-012-0309-x.


  991. Association of tattooing and hepatitis C virus infection: A multicenter case-control study
    Carney K, Dhalla S, Aytaman A, Tenner CT, Francois F. Hepatology. 2013 Jan 12. doi: 10.1002/hep.26245. [Epub ahead of print]


  992. Efficacy and safety of rituximab in the treatment of vasculitic leg ulcers associated with hepatitis C virus infection
    Bonilla-Abadía F, Echeverri AF, Izquierdo JH, Cañas F, Cañas CA. Case Report Rheumatol. 2012;2012:923897. doi: 10.1155/2012/923897. Epub 2012 Dec 16.


  993. Hepatitis C virus core antigen test in monitoring of dialysis patients
    Li Cavoli G, Zagarrigo C, Schillaci O, Servillo F, Tralongo A, Coglitore M, Spadaro F, Scimeca C, Li Destri N, Rotolo U. Hepat Res Treat. 2012;2012:832021. doi: 10.1155/2012/832021. Epub 2012 Dec 4.


  994. Optimal treatment with telaprevir for chronic HCV infection
    Jesudian AB, Jacobson IM. Liver Int. 2013 Feb;33 Suppl 1:3-13. doi: 10.1111/liv.12079.


  995. Hepatitis C virus diversity and hepatic steatosis
    Roingeard P. J Viral Hepat. 2013 Feb;20(2):77-84. doi: 10.1111/jvh.12035. Epub 2012 Nov 29.


  996. How to optimize HCV therapy in genotype 1 patients: management of side-effects
    Chopra A, Klein PL, Drinnan T, Lee SS. Liver Int. 2013 Feb;33 Suppl 1:30-4. doi: 10.1111/liv.12080.


  997. Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting
    Seidenberg A, Rosemann T, Senn O. BMC Infect Dis. 2013 Jan 8;13(1):9. doi: 10.1186/1471-2334-13-9.


  998. Occult hepatitis B virus infection in patients with chronic hepatitis C treated with antiviral therapy
    Caviglia GP, Abate ML, Manzini P, Danielle F, Ciancio A, Rosso C, Olivero A, Pellicano R, Touscoz GA, Smedile A, Rizzetto M. Hepat Mon. 2012 Nov;12(11):e7292. doi: 10.5812/hepatmon.7292. Epub 2012 Nov 30.


  999. Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C
    Kraus MR, Schäfer A, Teuber G, Porst H, Paul K, Wollschläger S, Keicher C, Scheurlen M. Hepatology. 2013 Jan 8. doi: 10.1002/hep.26229. [Epub ahead of print]


  1000. Current management and perspectives for HCV recurrence after liver transplantation
    Coilly A, Roche B, Samuel D. Liver Int. 2013 Feb;33 Suppl 1:56-62. doi: 10.1111/liv.12062.


  1001. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C
    Jimenez-Sousa MA, Fernandez-Rodriguez A, Guzman-Fulgencio M, Garcia-Alvarez M, Resino S. BMC Med. 2013 Jan 8;11(1):6. [Epub ahead of print]


  1002. IL-21R gene polymorphisms and serum IL-21 levels predict virological response to interferon-based therapy in Asian chronic hepatitis C patients
    Hsu CS, Hsu SJ, Liu WL, Liu CH, Chen CL, Liu CJ, Chen PJ, Chen DS, Kao JH. Antivir Ther. 2013 Jan 7. doi: 10.3851/IMP2502. [Epub ahead of print]


  1003. Interferon free therapy with direct acting antivirals for HCV
    Asselah T, Marcellin P. Liver Int. 2013 Feb;33 Suppl 1:93-104. doi: 10.1111/liv.12076.


  1004. HCV therapy in HIV-infected patients
    Sulkowski MS. Liver Int. 2013 Feb;33 Suppl 1:63-7. doi: 10.1111/liv.12082.


  1005. How to optimize HCV therapy in genotype 4 patients
    Esmat G, El Kassas M, Hassany M, Gamil ME, El Raziky M. Liver Int. 2013 Feb;33 Suppl 1:41-5. doi: 10.1111/liv.12059.


  1006. How to optimize HCV therapy in genotype 2 patients
    Grassi E, Aghemo A. Liver Int. 2013 Feb;33 Suppl 1:35-40. doi: 10.1111/liv.12056.


  1007. How to optimize HCV therapy in genotype 1 patients: predictors of response
    Petta S, Craxì A. Liver Int. 2013 Feb;33 Suppl 1:23-9. doi: 10.1111/liv.12053.


  1008. How to optimize HCV therapy in genotype 1 patients with cirrhosis
    Bourlière M, Wendt A, Fontaine H, Hézode C, Pol S, Bronowicki JP. Liver Int. 2013 Feb;33 Suppl 1:46-55. doi: 10.1111/liv.12067.


  1009. Best strategies for global HCV eradication
    Hagan LM, Schinazi RF. Liver Int. 2013 Feb;33 Suppl 1:68-79. doi: 10.1111/liv.12063.


  1010. Optimal treatment with boceprevir for chronic HCV infection
    Maasoumy B, Manns MP. Liver Int. 2013 Feb;33 Suppl 1:14-22. doi: 10.1111/liv.12070.


  1011. Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C
    Shlomai A, Halfon P, Goldiner I, Zelber-Sagi S, Halpern Z, Oren R, Bruck R. J Viral Hepat. 2013 Feb;20(2):95-102. doi: 10.1111/j.1365-2893.2012.01628.x. Epub 2012 Aug 3.


  1012. Hepatitis C treatment - better outcomes through partner support
    Chapman F, McManus A. Australas Med J. 2012;5(11):585-8. doi: 10.4066/AMJ.2012.1442. Epub 2012 Nov 30.


  1013. Chronic hepatitis C virus (HCV) disease burden and cost in the United States
    Razavi H, El Khoury A, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R. Hepatology. 2012 Dec 22. doi: 10.1002/hep.26218. [Epub ahead of print]


  1014. Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis
    Kong Y, Wang X, Shang Y, Schroder PM, Liang W, Ling X, Guo Z, He X. PLoS One. 2012;7(12):e52158. doi: 10.1371/journal.pone.0052158. Epub 2012 Dec 20.


  1015. Effects of IL-28B gene polymorphism on response to peginterferon plus ribavirin combination therapy for genotype 2 chronic hepatitis C
    Shimoyama Y, Nozaki A, Morimoto M, Moriya S, Kondo M, Fukuda H, Numata K, Miyajima E, Oba MS, Taguri M, Morita S, Maeda S, Tanaka K. Hepatol Res. 2012 Dec 5. doi: 10.1111/hepr.12037. [Epub ahead of print]


  1016. Risk factors for and incidence of acute hepatitis C after the achievement of blood supply safety in Italy: Results from the national surveillance system
    Spada E, Mele A, Mariano A, Zuccaro O, Tosti ME; on behalf of SEIEVA collaborating group. J Med Virol. 2012 Dec 28. doi: 10.1002/jmv.23485. [Epub ahead of print]


  1017. Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin
    Yu ML, Liu CH, Huang CF, Tseng TC, Huang JF, Dai CY, Lin ZY, Chen SC, Wang LY, Juo SH, Chuang WL, Kao JH. PLoS One. 2012;7(12):e52048. doi: 10.1371/journal.pone.0052048. Epub 2012 Dec 21.


  1018. Polymorphisms of the core, NS3 and NS5A proteins of hepatitis C 1 virus genotype 1b associate with development of hepatocellular carcinoma
    El-Shamy A, Shindo M, Shoji I, Deng L, Okuno T, Hotta H. Hepatology. 2012 Dec 24. doi: 10.1002/hep.26205. [Epub ahead of print]


  1019. Introduction of an automated system for the diagnosis and quantification of hepatitis B and hepatitis C viruses
    Cabezas-Fernandez M, Cabeza-Barrera M. Source Open Virol J. 2012;6:122-34. doi: 10.2174/1874357901206010122. Epub 2012 Nov 30.


  1020. Low Oxygen Tension Enhances Hepatitis C Virus Replication
    Vassilaki N, Kalliampakou KI, Kotta-Loizou I, Befani C, Liakos P, Simos G, Mentis AF, Kalliaropoulos A, Doumba PP, Smirlis D, Foka P, Bauhofer O, Poenisch M, Windisch MP, Lee ME, Koskinas J, Bartenschlager R, Mavromara P. J Virol. 2012 Dec 26. [Epub ahead of print]


  1021. Serum RANTES level influences the response to pegylated interferon and ribavirin therapy in chronic hepatitis C
    Komase K, Maekawa S, Miura M, Sueki R, Kadokura M, Shindo H, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. Hepatol Res. 2012 Nov 29. doi: 10.1111/hepr.12032. [Epub ahead of print]


  1022. Predictors of Psychopathological Outcome During Peg-Interferon and Ribavirin Therapy in Patients with Chronic HCV-Correlated Hepatitis
    Dell'osso B, Prati G, Palazzo MC, Rumi MG, Cavallaro F, Aghemo A, Colombo M, Altamura AC. J Interferon Cytokine Res. 2013 Jan;33(1):9-14. doi: 10.1089/jir.2012.0060. Epub 2012 Dec 31.


  1023. Combination treatment with HCV protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a and 3a virus
    Gottwein JM, Jensen SB, Li YP, Ghanem L, Scheel TK, Serre SB, Mikkelsen L, Bukh J. Antimicrob Agents Chemother. 2012 Dec 28. [Epub ahead of print]


  1024. Update on the treatment of patients with non-genotype 1 HCV infection
    Mangia A, Mottola L, Piazzolla V. Clin Infect Dis. 2012 Dec 27. [Epub ahead of print]


  1025. Combinations of Interferon Lambda with Direct-Acting Antiviral Agents are Highly Efficient in Suppressing Hepatitis C Virus Replication
    Friborg J, Levine S, Chen C, Sheaffer AK, Chaniewski S, McPhee F. Antimicrob Agents Chemother. 2012 Dec 28. [Epub ahead of print]


  1026. Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: A 16-week prospective study
    Loftis JM, Patterson AL, Wilhelm CJ, McNett H, Morasco BJ, Huckans M, Morgan T, Saperstein S, Asghar A, Hauser P. J Psychosom Res. 2013 Jan;74(1):57-63. doi: 10.1016/j.jpsychores.2012.10.012. Epub 2012 Nov 21.


  1027. Remission of HCV-associated glomerulonephritis with pegylated ifn and ribavirin therapy after liver transplantation: case report and literature review
    Donato MF, Fabrizi F, Fogazzi GB, Cresseri D, Passerini P, Martin P, Messa P. Int J Artif Organs. 2013 Jan 2:0. doi: 10.5301/ijao.5000166. [Epub ahead of print]


  1028. New targets for treatment against HCV infection
    Pan Q, van der Laan LJ. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):505-15. doi: 10.1016/j.bpg.2012.10.002.


  1029. Vitamin A deficiency is associated with HCV chronic infection and with unresponsiveness to interferon based antiviral therapy
    Bitetto D, Bortolotti N, Falleti E, Vescovo S, Fabris C, Fattovich G, Cussigh A, Cmet S, Fornasiere E, Ceriani E, Pirisi M, Toniutto P. Hepatology. 2012 Dec 5. doi: 10.1002/hep.26186. [Epub ahead of print]


  1030. Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations
    North CS, Hong BA, Adewuyi SA, Pollio DE, Jain MK, Devereaux R, Quartey NA, Ashitey S, Lee WM, Lisker-Melman M. Gen Hosp Psychiatry. 2012 Dec 6. pii: S0163-8343(12)00336-2. doi: 10.1016/j.genhosppsych.2012.11.002. [Epub ahead of print]


  1031. The role of resistance in HCV treatment
    Vermehren J, Sarrazin C. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):487-503. doi: 10.1016/j.bpg.2012.09.011.


  1032. Hepatitis C virus and natural compounds: a new antiviral approach?
    Calland N, Dubuisson J, Rouillé Y, Séron K. Viruses. 2012 Oct 17;4(10):2197-217. doi: 10.3390/v4102197.


  1033. Genetic Variants of STAT-4 Affect the Development of Graft Fibrosis After Liver Transplantation for HCV-Induced Liver Disease
    Eurich D, Boas-Knoop S, Struecker B, Neuhaus R, Neuhaus P, Bahra M. Transplantation. 2013 Jan 15;95(1):203-8. doi: 10.1097/TP.0b013e318277e2f6.


  1034. Evaluation of a rapid on-site anti-HCV test as a screening tool for hepatitis C virus infection
    Kant J, Möller B, Heyne R, Herber A, Böhm S, Maier M, Liebert UG, Mössner J, Berg T, Wiegand J. Eur J Gastroenterol Hepatol. 2012 Dec 3. [Epub ahead of print]


  1035. Occupational Exposures and the Prevalence of Blood-Borne Pathogens in a Deployed Setting: Data from a US Military Trauma Center in Afghanistan
    Okulicz JF, Yun HC, Murray CK. Infect Control Hosp Epidemiol. 2013 Jan;34(1):74-9. doi: 10.1086/668784. Epub 2012 Nov 19.


  1036. Evaluation of the Liver Fibrosis Index calculated by using real-time tissue elastography for the non-invasive assessment of liver fibrosis in chronic liver diseases
    Tomeno W, Yoneda M, Imajo K, Suzuki K, Ogawa Y, Shinohara Y, Mawatari H, Fujita K, Shibata W, Kirikoshi H, Maeda S, Nakajima A, Saito S. Hepatol Res. 2012 Nov 12. doi: 10.1111/hepr.12023. [Epub ahead of print]


  1037. Project ECHO: a model for complex, chronic care in the Pacific Northwest region of the United States
    Scott JD, Unruh KT, Catlin MC, Merrill JO, Tauben DJ, Rosenblatt R, Buchwald D, Doorenbos A, Towle C, Ramers CB, Spacha DH. J Telemed Telecare. 2012;18(8):481-4. doi: 10.1258/jtt.2012.GTH113. Epub 2012 Dec 3.


  1038. Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers
    Bruggmann P. J Viral Hepat. 2012 Dec;19(12):829-35. doi: 10.1111/jvh.12008. Epub 2012 Oct 1.


  1039. Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Viral Response in Patients with Genotype 1 Chronic Hepatitis C
    Petta S, Rosso C, Leung R, Abate ML, Booth D, Salamone F, Gambino R, Rizzetto M, Caviglia P, Smedile A, Grimaudo S, Cammà C, Craxì A, George J, Bugianesi E. Clin Gastroenterol Hepatol. 2012 Dec 4. pii: S1542-3565(12)01422-X. doi: 10.1016/j.cgh.2012.11.022. [Epub ahead of print]


  1040. Second generation direct antivirals and the way to interferon-free regimens in chronic HCV
    Lewis H, Cunningham M, Foster G. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):471-85. doi: 10.1016/j.bpg.2012.09.008.


  1041. Neutralizing antibodies and pathogenesis of hepatitis C virus infection
    Fafi-Kremer S, Fauvelle C, Felmlee DJ, Zeisel MB, Lepiller Q, Fofana I, Heydmann L, Stoll-Keller F, Baumert TF. Viruses. 2012 Oct 9;4(10):2016-30. doi: 10.3390/v4102016.


  1042. Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
    Edward J. Gane, M.D., Catherine A. Stedman, M.B., Ch.B., Ph.D., Robert H. Hyland, D.Phil., Xiao Ding, Ph.D., Evguenia Svarovskaia, Ph.D., William T. Symonds, Pharm.D., Robert G. Hindes, M.D., and M. Michelle Berrey, M.D., M.P.H. N Engl J Med 2013; 368:34-44January 3, 2013DOI: 10.1056/NEJMoa1208953


  1043. Is there a benefit to a routine preoperative screening of infectivity for HIV, hepatitis B and C virus before elective orthopaedic operations?
    Weber P, Eberle J, Bogner JR, Schrimpf F, Jansson V, Huber-Wagner S. Infection. 2012 Dec 7. [Epub ahead of print]


  1044. Pathogenesis of hepatitis C during pregnancy and childhood
    Le Campion A, Larouche A, Fauteux-Daniel S, Soudeyns H. Viruses. 2012 Dec 6;4(12):3531-50. doi: 10.3390/v4123531.


  1045. Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
    Fred Poordad, M.D., Eric Lawitz, M.D., Kris V. Kowdley, M.D., Daniel E. Cohen, M.D., Thomas Podsadecki, M.D., Sara Siggelkow, R.N., Michele Heckaman, M.S., Lois Larsen, Ph.D., Rajeev Menon, Ph.D., Gennadiy Koev, Ph.D., Rakesh Tripathi, M.S., Tami Pilot-Matias, Ph.D., and Barry Bernstein, M.D. N Engl J Med 2013; 368:45-53January 3, 2013DOI: 10.1056/NEJMoa120880


  1046. Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers
    Ponziani FR, Milani A, Gasbarrini A, Zaccaria R, Viganò R, Iemmolo RM, Donato MF, Rendina M, Toniutto P, Pasulo L, Cescon M, Burra P, Miglioresi L, Merli M, Paolo DD, Fagiuoli S, Pompili M; on behalf of AISF RECOLT-C Group. Transpl Int. 2012 Dec 11. doi: 10.1111/tri.12027. [Epub ahead of print]


  1047. Viral hepatitis induces hepatocellular cancer: what can we learn from epidemiology comparing iran and worldwide findings?
    Smolle E, Zöhrer E, Bettermann K, Haybaeck J. Hepat Mon. 2012 Oct;12(10 HCC):e7879. doi: 10.5812/hepatmon.7879. Epub 2012 Oct 30.


  1048. Effects of triple-drug therapy with nitazoxanide, high-dose ribavirin and peginterferon-?-2a in patients with chronic hepatitis C
    Basu PP, Rayapudi K, Shah NJ, Krishnaswamy N, Brown RS. Hepatol Res. 2012 Dec 5. doi: 10.1111/hepr.12013. [Epub ahead of print]


  1049. IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4
    Antaki N, Bibert S, Kebbewar K, Asaad F, Baroudi O, Alideeb S, Hadad M, Abboud D, Sabah H, Bochud PY, Negro F. J Viral Hepat. 2013 Jan;20(1):59-64. doi: 10.1111/j.1365-2893.2012.01621.x. Epub 2012 May 24.


  1050. Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences
    Ng J, Wu J. Hepat Mon. 2012 Oct;12(10 HCC):e7635. doi: 10.5812/hepatmon.7635. Epub 2012 Oct 25.


  1051. Determinants of Hepatitis C Virus Treatment Completion and Efficacy in Drug Users Assessed by Meta-analysis
    Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Clin Infect Dis. 2012 Dec 27. [Epub ahead of print]


  1052. Therapy-induced clearance of HCV core antigen from plasma predicts an end of treatment viral response
    Tedder RS, Tuke P, Wallis N, Wright M, Nicholson L, Grant PR. J Viral Hepat. 2013 Jan;20(1):65-71. doi: 10.1111/j.1365-2893.2012.01630.x. Epub 2012 Jul 4.


  1053. Boceprevir and personalized medicine in hepatitis C virus infection
    Habersetzer F, Leboeuf C, Doffoël M, Baumert TF. Pharmgenomics Pers Med. 2012;5:125-37. doi: 10.2147/PGPM.S24259. Epub 2012 Sep 26.


  1054. Rapid hepatitis C virus divergence among chronically infected individuals
    Cruz-Rivera M, Carpio-Pedroza JC, Escobar-Gutiérrez A, Lozano D, Vergara-Castaneda A, Rivera-Osorio P, Martinez-Guarneros A, Chacon CA, Fonseca-Coronado S, Vaughan G. J Clin Microbiol. 2012 Dec 5. [Epub ahead of print]


  1055. Boceprevir: A recently approved protease inhibitor for hepatitis C virus infection
    Lam JT, Jacob S. Am J Health Syst Pharm. 2012 Dec 15;69(24):2135-9. doi: 10.2146/ajhp110500.


  1056. Relationship of ?-fetoprotein levels and development of hepatocellular carcinoma in hepatitis C patients with liver cirrhosis
    Taura N, Fukuda S, Ichikawa T, Miyaaki H, Shibata H, Honda T, Yamaguchi T, Kubota Y, Uchida S, Kamo Y, Yoshimura E, Isomoto H, Matsumoto T, Takeshima F, Tsutsumi T, Tsuruta S, Nakao K. Exp Ther Med. 2012 Dec;4(6):972-976. Epub 2012 Sep 17.


  1057. Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection
    Feld JJ. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):429-44. doi: 10.1016/j.bpg.2012.09.013.


  1058. Natural history of acute and chronic hepatitis C
    Maasoumy B, Wedemeyer H. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):401-12. doi: 10.1016/j.bpg.2012.09.009.


  1059. Interferon stimulated genes are associated with peginterferon plus ribavirin treatment response regardless IL28B alleles in HCV/HIV coinfected patients
    Rallon NI, Lopez-Fernandez LA, Garcia MI, Benguria A, Fiorante S, Soriano V, Benito JM. AIDS. 2012 Nov 28. [Epub ahead of print]


  1060. The role of viral and host genetics in natural history and treatment of chronic HCV infection
    Doyle JS, Hellard ME, Thompson AJ. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):413-27. doi: 10.1016/j.bpg.2012.09.004.


  1061. Baseline serum cholesterol is associated with a response to pegylated interferon alfa-2b and ribavirin therapy for chronic hepatitis C genotype 2
    Taura N, Ichikawa T, Miyaaki H, Kadokawa Y, Tsutsumi T, Tsuruta S, Kato Y, Inoue O, Kinoshita N, Ohba K, Kato H, Ohata K, Masuda J, Hamasaki K, Yatsuhashi H, Nakao K. Gastroenterol Res Pract. 2012;2012:317580. doi: 10.1155/2012/317580. Epub 2012 Nov 5.


  1062. Exploratory study on telaprevir given every 8?h at 500?mg or 750?mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients
    Suzuki F, Suzuki Y, Sezaki H, Akuta N, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Mineta R, Watahiki S, Kobayashi M, Nakayasu Y, Tsuda H, Aoki K, Yamada I, Kumada H. Hepatol Res. 2012 Nov 29. doi: 10.1111/hepr.12009. [Epub ahead of print]


  1063. A combined proteomics and computational approach provides a better understanding of HCV-induced liver disease
    Tripathi LP, Mizuguchi K. Expert Rev Proteomics. 2012 Oct;9(5):493-6. doi: 10.1586/epr.12.47.


  1064. Immunology of hepatitis C virus infections
    Spaan M, Janssen HL, Boonstra A. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):391-400. doi: 10.1016/j.bpg.2012.09.005.


  1065. The Impact of Hepatitis A Virus Infection on Hepatitis C Virus Infection: A Competitive Exclusion Hypothesis
    Amaku M, Coutinho FA, Chaib E, Massad E. Bull Math Biol. 2012 Nov 29. [Epub ahead of print]


  1066. HCV's days are numbered: next-generation direct-acting antivirals and host-targeting agents
    Calle Serrano B, Manns MP. Antivir Ther. 2012;17(6 Pt B):1133-46. doi: 10.3851/IMP2425. Epub 2012 Oct 5.


  1067. Response guided therapy in patients with chronic hepatitis C - Yesterday, today and tomorrow
    Ferenci P. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):463-9. doi: 10.1016/j.bpg.2012.09.002.


  1068. Hepatitis C infection among men who have sex with men, san francisco, 2011
    Raymond HF, Chu P, Nieves-Rivera I, Louie B, McFarland W, Pandori M. Sex Transm Dis. 2012 Dec;39(12):985-6. doi: 10.1097/OLQ.0b013e3182716e59.


  1069. Interferon Gamma With Peg-Interferon ? 2a and Ribavirin in Non Responder Patients With Chronic Hepatitis C (ANRS HC16 GAMMATRI)
    Couzigou P, Pérusat S, Bourlière M, Trimoulet P, Poynard T, Leroy V, Marcellin P, Foucher J, Bronowicki JP, Chêne G; the ANRS HC16 GAMMATRI trial Group. J Gastroenterol Hepatol. 2012 Nov 28. doi: 10.1111/jgh.12060. [Epub ahead of print]


  1070. Characteristics of elderly hepatitis C virus-associated hepatocellular carcinoma patients
    Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T, Tanaka J. J Gastroenterol Hepatol. 2012 Nov 28. doi: 10.1111/jgh.12057. [Epub ahead of print]


  1071. Virology of hepatitis C virus infection
    Chevaliez S, Pawlotsky JM. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):381-9. doi: 10.1016/j.bpg.2012.09.006.


  1072. Telaprevir-Related Dermatitis
    Roujeau JC, Mockenhaupt M, Tahan SR, Henshaw J, Martin EC, Harding M, van Baelen B, Bengtsson L, Singhal P, Kauffman RS, Stern RS. Arch Dermatol. 2012 Nov 19:1-7. doi: 10.1001/jamadermatol.2013.938. [Epub ahead of print]


  1073. Telaprevir to Boceprevir Switch Highlights Lack of Cross-Reactivity
    Carlson A, Gregorich Z, Striker R. Clin Infect Dis. 2012 Dec 7. [Epub ahead of print]


  1074. Sexual transmission of HCV among monogamous heterosexual couples: The HCV partners study
    Terrault NA, Dodge JL, Murphy EL, Tavis JE, Kiss A, Levin TR, Gish R, Busch M, Reingold AL, Alter MJ. Hepatology. 2012 Nov 23. doi: 10.1002/hep.26164. [Epub ahead of print]


  1075. Natural killer cells in hepatitis C virus infection
    Bozzano F, Marras F, Biassoni R, Maria AD. Expert Rev Clin Immunol. 2012 Nov;8(8):775-88. doi: 10.1586/eci.12.71.


  1076. None of the Six SNPs of IL28B Could Predict Treatment Responses in Genotype 2 Chronic HCV Infected Patients by Propensity Score Matching Analysis
    Jeng WJ, Lin CY, Chen JY, Huang CW, Huang CH, Sheen IS. PLoS One. 2012;7(11):e48217. doi: 10.1371/journal.pone.0048217. Epub 2012 Nov 16.


  1077. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to hepatitis C virus seroprevalence
    Hanafiah KM, Groeger J, Flaxman AD, Wiersma ST. Hepatology. 2012 Nov 21. doi: 10.1002/hep.26141. [Epub ahead of print]


  1078. Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation
    Du Y, Su T, Ding Y, Cao G. Hepat Mon. 2012 Oct;12(10 HCC):e6031. doi: 10.5812/hepatmon.6031. Epub 2012 Oct 20.


  1079. The science of direct-acting antiviral and host-targeted agent therapy
    Pawlotsky JM. Antivir Ther. 2012;17(6 Pt B):1109-17. doi: 10.3851/IMP2423. Epub 2012 Oct 5.


  1080. Public health issues of hepatitis C virus infection
    Papatheodoridis G, Hatzakis A. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):371-80. doi: 10.1016/j.bpg.2012.09.012.


 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Live CME Meetings
Telewebs
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2015 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.